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GENOME-WIDE ANGIOTENSIN II REGULATED MIRNA EXPRESSION
PROFILING: A SMOOTH MUSCLE-SPECIFIC MIRNA SIGNATURE

JACQUELINE R. KEMP

ABSTRACT

Renin-angiotensin system (RAS) activation and phenotypic modulation of
vascular smooth muscle cells (VSMCs) are common characteristics associated with
human diseases, such as pulmonary hypertension, atherosclerosis and stroke. While
elevation of the RAS hormone product, angiotensin II (AngII) is a well-established risk in
these diseases; the mechanism of activation of RAS and modulation of VSMC phenotype
by AngII is vague, suggesting that novel global regulators may mediate the risk by AngII.
MicroRNAs (miRNAs) represent one such class of potential global regulators. MiRNAs
are small (~22 nt), endogenous, non-coding RNAs that act as post-transcriptional
regulators of physiological processes.

MiRNAs primarily function by binding to

complementary target sites in the 3’-untranslated regions (3’-UTR) of mRNAs, causing
translational repression and/or mRNA destabilization.

To elucidate the global miRNA expression profile following chronic Angiotensin
II Type 1 Receptor (AT1R) activation by AngII, we performed microarray analysis in 23
biological and technical replicates derived from humans, rats and mice. We

viii

pharmacologically distinguished the AT1R-regulated miRNA profiles by comparing
technical replicates treated with the specific AT1R-blocker, losartan and biological
replicates following chronic AT2R activation by AngII. Thirty-two miRNAs are AngIIregulated universally. Most other miRNAs are regulated in a treatment- or speciesspecific manner. A few miRNAs are unique to specific cell types.

We have previously shown that a single miRNA can have multiple targets,
potentially providing simultaneous regulation of the genes involved in a physiological
pathway and accounting for a complex phenotype, such as human heart failure (JBC 284:
27487-27499). In the current study, we explored the extent to which AngII/AT1Rregulated miRNAs contribute to maintenance of RAS homeostasis and phenotypic
modulation of VSMCs. A distinct AngII-regulated miRNA expression pattern emerged in
the human and rat VSM cell lines in the profiling experiment, which was validated in our
independent samples. Of the 17 miRNAs comprising the VSMC expression pattern, we
selected miR-483 as a representative candidate for further study because of its location
within the genome and its ability to potentially target multiple components of RAS. In
addition, we show evidence that suggests muscle cell-specific expression of miR-483.
We incorporated a miR-483 expression cassette into two distinct cell lines as a means to
determine post-transcriptional inhibition of specific RAS component gene expression.
The functionality of miR-483, in terms of modulating the cellular phenotype, was
assessed in a wound-healing assay. Overall, miR-483 regulates both RAS and AngIIactivated migration; specifically in VSMCs. Our results further suggest that following
inhibition of several AT1R-activated kinases, the AngII-regulated MEK1 kinase signaling

ix

cascade most effectively mediates the steady state pool of miRNAs, which includes
downregulation of mir-483. In this context, JAK2 inhibition is somewhat effective. This
results in activation of RAS and switching of the VSMC phenotype associated with
pathological states in vivo, such as hypertension. Further insight into these mechanisms
will be valuable for a greater understanding of AngII biology.

In the context of

determining the full capacity of RAS as an intrinsic regulatory system, AngII-regulated
miRNAs will likely have a strong influence on cardiovascular disease.
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CHAPTER I
INTRODUCTION

1.1 The Renin-Angiotensin System (RAS)

1.1.1

The Circulating Axis of RAS
The Renin-Angiotensin System (RAS) has been a key target for the management

of cardiac and vascular abnormalities since its discovery and has been found to be
increasingly complex. RAS is an elaborate endocrine system that globally regulates
numerous

physiological

processes,

such

as

blood

pressure

maintenance,

electrolyte/volume homeostasis, vascular tone, facilitation of catecholamine release (e.g.,
epinephrine and norepinephrine) from the brain and aldosterone release from the adrenal
gland. Increasing evidence has pointed to a role for Angiotensin II (AngII), the major
bioactive product of RAS, in disease states (Aplin et al., 2008, Taubman, 2003, Forbes,
2011). AngII has the capability to induce numerous intracellular signaling events that can
ultimately lead to global gene expression changes and pathological conditions, including
hypertension, heart failure (HF), renal and inflammatory diseases (Teerlink, 1996).
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The classical, circulating axis of RAS is activated in response to decreased plasma
sodium and fluid volume, resulting in the secretion of renin from the juxtaglomerular
cells of the kidney. The enzyme renin releases the N-terminal decapeptide angiotensin I
(Ang I) from a liver-produced serpin, angiotensinogen (AGT), by proteolytic cleavage.
Angiotensin converting enzyme-1 (ACE-1), abundant in the endothelial lumen of the
pulmonary microvasculature, hydrolyzes the C-terminal dipeptide to produce the
octapeptide hormone, AngII (Figure 1.1) (Lavoie and Sigmund, 2003, Teerlink, 1996).
AngII then interacts with specific receptors on the plasma membrane to elicit a cellular
response. The physiological importance of AngII cannot be overstated. The biological
result of circulating AngII is widespread and diverse, giving the system an endocrine
characteristic.

Notably, AngII is also formed by an alternative pathway, in which

chymase, a serine protease highly expressed in the heart, vasculature, and kidney in
humans, is capable of local AngII production from its precursor Ang I (Forbes, 2011).

AngII has a short half-life in circulation; therefore, the peptide hormone is readily
cleaved by amino- and carboxy- peptidases, resulting in production of additional
angiotensin peptides (e.g., Ang III, Ang3-8, Ang IV, Ang1-7) (Figure 1.2) (Forbes, 2011).
Each of the angiotensin metabolites exerts biological effects, some of which are distinct
from the functions of AngII (Lavoie and Sigmund, 2003).

Figure 1.1. The classical circulating axis of RAS. Decreased blood pressure stimulates
the release of renin from the kidney. Renin cleaves angiotensinogen to produce Ang I,
which is in turn cleaved by ACE-1 to produce AngII. AngII is the major bioactive
product of RAS, regulating blood pressure through vasoconstriction and stimulation of
aldosterone and vasopressin release. AngII is capable of giving rise to pathological
conditions such as cardiac and vascular hypertrophy and end-organ damage.
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Figure 1.2. Additional RAS components. The peptide hormone, AngII can be readily
cleaved, resulting in the production of additional angiotensin peptides (shown in red).
The angiotensin peptides exert distinct biological effects. Adapted from (Hunyady and
Catt, 2006).
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For example, a homolog of ACE-1, ACE-2, was discovered and shown to degrade AngII,
yielding Ang1-7 and leading to activation of a second major axis of RAS, the ACE2/Ang1-7/Ang1-7 Receptor axis (Zhang et al., 2010, Santos et al., 2003). This axis has
been proposed to have a vasoprotective role in pathophysiology of the cardiovascular,
renal, pulmonary, and central nervous systems and is considered counter-regulatory to the
classical circulating axis (Zhang et al., 2010, Santos et al., 2003). Furthermore, a protein
has recently been discovered, which binds and activates renin in tissues, the renin
receptor. The physiological role of these new RAS components is not completely
resolved, but they may exert considerable impact on local AngII generation and effect
mediation in tissues (Bader et al., 2001).

1.1.2

Role of G-Protein Coupled Receptors (GPCRs) in Mediating RAS Effects
AngII affects various cell systems by binding to seven-transmembrane, cell

surface, GPCRs (Mehta and Griendling, 2007). GPCRs constitute a vast integral
membrane protein family that encompasses a wide-range of functions; therefore, they are
divided into classes, of which the rhodopsin-like family accounts for nearly 85% of the
GPCR genes (Rosenbaum et al., 2009). The AngII receptors are included within the
rhodopsin-like family and are a member of the subgroup of peptide receptors. The
characteristic feature of the rhodopsin family is the presence of conserved amino acid
sequences that suggest common structural features and activation mechanisms.

GPCRs are the largest family of cell surface receptors, having a major role in
signal transduction.

They mediate responses to extracellular ligands by binding,
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facilitating a conformational change in the receptor, and activating intracellular
heterotrimeric G-proteins (Karnik et al., 2003, Rosenbaum et al., 2009). The GPCR
activates the intracellular G-protein by facilitating the exchange of bound GDP for GTP.
In so doing, the G-protein’s α subunit, together with the GTP, can dissociate from the β
and γ subunits to elicit activation of effectors such as adenylyl cyclase and
phospholipases, which in turn changes the levels of intracellular second messengers, such
as calcium and cAMP (Figure 1.3) (Pierce et al., 2002). In addition to the canonical
signaling events initiated by G-protein signaling, studies have also shown alternative
signaling pathways that are related to diverse functions of these receptors. GPCRs, for
example, can also signal in a G-protein-independent manner, which leads to activation of
mitogen activated protein kinases (MAPKs) (Miura et al., 2004). Numerous G proteins
exist, including Gαs, Gαi/o, Gαq/11, and Gα12/13. Each of these G proteins causes distinct
functional consequences within the cell, due to the varying subunits present (Karnik et
al., 2003, Rosenbaum et al., 2009).

A common feature of GPCRs is that they exhibit a degree of basal activity in the
absence of an agonist, which can be reduced in the presence of an inverse agonist.
Agonists are ligands that fully activate the receptor beyond the basal level. Conversely,
antagonists compete with other ligands without affecting the basal activity (Kobilka,
2007). GPCRs transmit extracellular signals across the cell membrane as a response to a
wide variety of ligands, including hormones, ions, neurotransmitters, proteins/peptides,
fatty acids, small molecules, and physical stimuli such as light, smell, taste, and

6

mechanical stretch (Rosenbaum et al., 2009). Thus, GPCRs are extremely relevant in cell
signaling, pharmacology, physiology, and pathophysiology.

Due to their involvement in many biological functions, GPCRs are also extremely
important in drug discovery. Nearly 50% of all modern human therapeutics is targeted to
only a few GPCRs. Understanding the full capacity of GPCR signaling in physiology and
pathophysiology is a critical aspect of receptor biology.

7

Figure 1.3. Prototypical GPCR activation. Upon activation of a GPCR, the GDP of the
G-protein is exchanged with GTP, resulting in dissociation of the α and βγ subunits of the
heterotrimeric protein. The dissociated subunits further activate intracellular downstream
effectors, which in turn alter the levels of second messengers.
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1.1.3

AngII-induced Pleiotropic Signaling Events: The AngII Receptors
AngII functions as a master regulator of cardiovascular and renal system

homeostasis. As its name implies, the net effect of AngII action is a potent constriction of
vessels in most vascular beds (Aplin et al., 2008, Taubman, 2003, Touyz and Schiffrin,
2000). In recent years, AngII has been shown to play a pivotal role in mediating cell
proliferation and/or apoptosis and fibrosis through activation of intracellular signaling
molecules in a variety of cell types, including cardiac myocytes, fibroblasts, renal
mesangial and epithelial cells, endothelial cells (ECs), and vascular smooth muscle cells
(VSMCs) (Bell and Madri, 1990, Kim and Iwao, 2000, Lijnen and Petrov, 1999, Ohtsu et
al., 2006).

AngII elicits many diverse physiological effects in various tissues due to 1) its
ability to bind to different receptor subtypes; 2) receptor coupling to distinct second
messenger pathways; and 3) tissue specificity of the receptor subtypes (Berk, 2003).
Cellular responses to AngII are dependent on two pharmacologically distinct GPCR
subtypes, the Angiotensin II Type 1 Receptor (AT1R) and the Angiotensin II Type 2
Receptor (AT2R), both of which have similar affinity for the agonist, AngII (Aplin et al.,
2008, de Gasparo et al., 2000, Hunyady and Catt, 2006, Miura and Karnik, 1999).

1.1.3.1 The AT2R
The AT2 receptor subtype shares approximately 34% sequence homology with the
AT1R, but unlike its RAS counterpart, the precise role of the AT2R is debatable. The
gene for the AT2R is located on the X chromosome within exon 3 of the AGTR2 gene
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and is approximately 50 Kb. While the signaling mechanisms induced by activation of
the AT2R remain poorly understood, it is known that the type 2 receptor is abundantly
expressed in the developing fetus, owing to a role in physiological development. The
AT2R is expressed at low levels in the normal adult cardiovascular system, but it may
increase in density in tissues under pathological conditions, in which inflammation and
tissue remodeling occur (e.g., myocardial infarction, hypertension, atherosclerosis,
diabetes mellitus, neointima formation after vascular injury) (Lemarie and Schiffrin,
2010, Booz and Baker, 1996).

The proposed increase in AT2R expression during

pathology can be viewed as fetal gene-reactivation, which is a prominent feature of the
disease state of the cardiovascular system (Paul et al., 2006).

Many studies have suggested that the AT2R is constitutively active and does not
require binding of AngII to induce intracellular signaling cascades. For example, Miura
and Karnik found that overexpression of the AT2R alone determined whether cultured
fibroblasts, epithelial, or VSMCs underwent apoptosis in the absence of AngII (Miura
and Karnik, 2000).

The AT2R has been implicated in cardiovascular disease as a

beneficial moiety due to its proposed vasodilatory role, ability to inhibit cell growth,
induce apoptosis, and inhibit activation of mitogen activated protein kinases (MAPKs) –
functions that appear to counterbalance the actions of the AT1R (Table I.I) (Miura et al.,
2010, Berk, 2003). Three main events have been described for the function of the AT2R
in signal transduction: 1) phosphatase activation causing protein dephosphorylation; 2)
activation of the bradykinin/nitric oxide/cGMP pathway; and 3) stimulation of
phospholipase A2 and release of arachidonic acid (Blume et al., 2001, Matsubara, 1998).
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The AT2R-selective antagonists, PD123319 and PD123177, are capable of inhibiting
these signaling events by displacing the receptor’s agonist (Gallinat et al., 2000, Verdonk
et al., 2012).
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Table I.I. Differential effects of AngII stimulation of the AT1 and AT2 receptors.
Adapted from (Silverstein and Ram, 2005).

AT1 Receptor Stimulation
Increased vasoconstriction
Increased cardiac contractility and hypertrophy
Increased vascular smooth muscle proliferation
Increased extracellular matrix production
Increased tubular sodium reabsorption
Increased synthesis and secretion of aldosterone
Increased secretion of vasopressin
Increased noradrenergic activity
Cell growth and proliferation
AT2 Receptor Stimulation
Regulation of:
Cell growth and proliferation
Cell differentiation
Extracellular matrix composition
Left-ventricular remodeling
Fetal tissue development
Apoptosis
Vasodilation
Antiproliferation
Increased neuronal regeneration
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1.1.3.2 Significance of the AT1R
The human AT1R (hAT1R) is ubiquitously expressed in the cardiovascular system
and mediates the major cardiovascular effects of AngII (Dinh et al., 2001) (de Gasparo et
al., 2000). The gene for the hAT1R (AGTR1) is approximately 50 Kb in size and located
within exon 5 on chromosome 3 in the genome (de Gasparo et al., 2000, Elton and
Martin, 2007). A prototypical GPCR, the AT1R has been characterized by molecular
cloning, mutagenesis, and molecular pharmacology studies to be functionally activated
upon high-affinity AngII binding and shown to rapidly undergo desensitization and
internalization (Elton and Martin, 2007).

Under normal conditions, AngII activated AT1R generates acute responses by
coupling to the Gq-PLC pathway, leading to production of the second messengers,
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Production of IP3 and DAG
leads to Ca2+ mobilization and activation of protein kinase C (PKC), respectively (Mehta
and Griendling, 2007, Hunyady and Catt, 2006). AT1R activation is associated with a
rapid increase in tyrosine phosphorylation of various signaling molecules (Yin et al.,
2003). Phosphorylation leads to induction of growth-promoting signals such as mitogenactivated

protein

kinase

(MAPK)/extracellular

signal-related

kinase

(ERK),

phosphatidylinositol 3-kinase/Akt, and JAK-STAT signaling (Saito and Berk, 2002).
These cytoplasmic signaling cascades ultimately propagate to the nucleus upon chronic
AT1R activation. In the nucleus, gene expression is either induced or repressed by
distinct transcription factors (e.g., NFAT, MEF2, GATA, and STAT), following binding
to response elements in the promoters of genes (Figure 1.4) (Hunyady and Catt, 2006,
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Saito and Berk, 2002, Friddle et al., 2000). Additionally, Gβγ, through interaction with
histones and transcription factors, modulates transcription in response to AT1R activation
in cells (Bhatnagar et al., 2013). The pleiotropic signaling events that occur in response to
AngII and result in changes in gene expression of a set of AngII responsive genes are
ultimately responsible for phenotypic modulation of target cells (Hunyady and Catt,
2006).
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Figure 1.4. Major AT1R signal transduction pathways. Binding of AngII to the AT1R
activates the Gq-coupled signaling pathway, leading to activation of PLC, which results
in mobilization of Ca2+. AT1R activation leads to phosphorylation of multiple signaling
pathways and induction of growth-promoting signals.
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1.1.4

Consequences of AT1R Signal Transduction: Tissue RAS Over Activity
In addition to systemic RAS, the components of RAS with the exception of renin

are also expressed at variable levels throughout tissues, including the brain, heart,
vasculature, pancreas, adipocytes and kidneys, allowing for local production of AngII
peptides (Bader et al., 2001, Paul et al., 2006). Tissue RAS regulates long-term and
chronic responses to locally produced AngII in these tissues, thus, implicating AngII in
the progression of development and growth, regulation of metabolic pathways, learning
and memory. Importantly, tissue RAS primarily functions independently of circulating
RAS; therefore, it has a critical role in pathophysiological conditions, acting as a
paracrine or autocrine system (Bader et al., 2001, Nakashima et al., 2006).

These

conditions include inflammation, oxidative stress, hypertension, thrombosis, end-stage
renal disease, coronary artery disease, cardiovascular hypertrophy and HF (Figure 1.6)
(Daugherty and Cassis, 2004, Margulies et al., 2009, Mehta and Griendling, 2007). As a
result, fine control mechanisms regulating the effectiveness of tissue RAS is a major
research frontier.
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Figure 1.5. Effects of tissue RAS over activity. The components of RAS are expressed
at variable levels through many major tissue types. This leads to local production of
AngII and progression of pathophysiological conditions.
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Genomic and proteomic advances have established that GPCRs regulate global
gene expression programs, leading to processes such as differentiation, proliferation, and
apoptosis in a variety of cell types (Karnik et al., 2003, Rosenbaum et al., 2009). Two
main cell types directly and adversely affected by an increase in local AngII action are
VSMCs and ECs due to the high density of AT1 receptors present within these cells.
Ultimately, tissue RAS contributes to the maintenance of cardiovascular homeostasis by
the impact on vessel function mediated through the AT1R. Extensive research into the
precise signal transduction mechanisms that are critical for modulation of EC and VSMC
phenotype and function are important to fully characterize the molecular effects of AngII.
In particular, animal models as well as cellular studies have sought to examine the effects
of AngII as a mediator of the development of vascular diseases.

Cardiac fibroblasts and myocytes are additional cell types that express AT1
receptors. AngII was found to exhibit growth-promoting effects in the heart more than
30 years ago. Furthermore, in the heart, these effects were thought to be most relevant by
inducing hypertrophy and fibrosis (Bader and Ganten, 2008). The results of animal
studies, including the angiotensin type 1 receptor gene (Agtr1)-null mice (Oliverio et al.,
1998), tissue targeted AT1R transgenic (TG) mice (Paradis, 2000), and gain of function
AT1R mutant knock-in mice (Billet et al., 2007), indicate that the AT1R mediates
hypertrophic and proliferative effects of AngII. The AT1R is an AngII-activated growth
promoter in tissues and indeed overexpression of AT1R correlates with a higher risk for
cardiac hypertrophy, vascular thickening and ultimately tissue fibrosis. A hallmark of
pathogenesis of human cardiovascular disease (CVD) is the overexpression of the AT1R
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and most CVDs respond favorably to therapy with AT1R-selective drugs (Aplin et al.,
2008).

It has become increasingly clear that tissue RAS is not an isolated entity, but can
interact with circulating RAS as well as other peptide systems on multiple levels. In
response to either systemically or locally generated AngII, the AT1R mediates the
contractile response of VSMCs by PLC-dependent mechanisms leading to an increase in
intracellular calcium. It also functions indirectly, by stimulating the synthesis of other
vasoconstrictors. At the cellular level, the endothelium dysfunction that occurs in
response to AngII is primarily due to an increase in adhesion, migration, and proliferation
of ECs. In the presence of AngII, there is increased expression of the vasoconstrictor,
endothelin, which can act to potentiate the action of PDGF (Rossi et al., 1999).
Moreover, using an animal model overexpressing the AT1 receptor only in endothelial
cells, Ramchandran et al. demonstrated that AngII also acts as a vasodilator, when
interacting with the AT1R on these cells (Ramchandran et al., 2006). AngII promoted
tissue factor and initiator of coagulation expression, both of which could lead to a
coagulant property of AngII (Taubman, 2003, Touyz and Schiffrin, 2000).

The global mRNA expression regulated by the AT1R (transcriptome) is a
persistent response of AT1R signaling that is widely studied in both physiological and
pathological settings. That is, if the activity of the AT1R is not properly regulated, AngII
stimulus becomes chronic and can damage the tissue, as well as contribute to lasting
cardiovascular disorders. The long-term research aim in this area is to elucidate how
normal gene regulatory mechanisms are altered in response to over activity of the RAS in
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different pathological settings. Typical transcriptional regulatory mechanisms are
significantly altered in the experimental models. In a recent study, Yue et al. discovered
that chronic AT1R activation mediates gene expression through U-STAT3 by a
mechanism distinct from that of physiological regulator phospho-STAT3. This accounts
for a dual role of STAT3 in regulating physiological and pathological gene expression
programs (Yue et al., 2010).

Yue et al. discovered nuclear accumulation of

unphosphorylated STAT3 (U-STAT3) which activates “renegade” transcription of genes
such as osteopontin (OPN), connective tissue growth factor (CTGF), regulator of G
protein signaling 2 (RGS2), and alpha-1 skeletal muscle actin, leading to hypertrophy and
HF in mice (Yue et al., 2010). This study suggested that chronic AngII/AT1R signaling
might alter the structure and dynamics of chromatin in target cell nuclei, such that latent
regulatory sites on promoters of genes may be rendered potent for promoting
overexpression (Yue et al., 2010).

Ultimately, the physiological role of this local system is the maintenance of
homeostasis at the tissue level. The local generation of AngII has been demonstrated for
all tissues relevant for cardiovascular control (Bader and Ganten, 2008). Tissue RAS
plays an important role in conveying and amplifying the effects of circulating AngII,
thereby modulating cardiovascular parameters and mostly accelerating the pathogenesis
of cardiovascular diseases. Overall, tissue RAS forms the basis for the understanding of
the extraordinary therapeutic efficiency of drugs inhibiting the RAS.

1.1.5

Effectiveness of Drugs Targeting the RAS
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The RAS has been a therapeutic target for cardiovascular diseases for decades.
Drugs targeting significant components of circulating RAS, such as ACE inhibitors and
antagonists for the AT1 receptor can effectively lower blood pressure and RAS-induced
pathologies. Very recently, inhibitors of the enzyme renin were also approved for clinical
use (Staessen et al., 2006). The efficiency of these drugs is partially based on the fact that
they not only inhibit the classical RAS in the circulation, but also local RAS in tissues
(Bader and Ganten, 2008).

ACE inhibitors compete with Ang I binding, preventing AngII formation
mediated by ACE-1 in the circulation and tissues (Doulton et al., 2005). The beneficial
effects of these pharmacologically distinct agents extend to the nonhemodynamic
functions of RAS, which suggests that RAS blockade is an overall effective means for
organ protection, not merely for blood pressure reduction. These therapeutic agents have
been used in the treatment of renal, cardiovascular, and cerebrovascular diseases,
showing that RAS has a global biological effect within the body (Doulton et al., 2005,
Miura et al., 2011).

An additional treatment option for controlling RAS is the use of AT1R-selective
drugs (i.e., AT1R blockers [ARBs]), which halt or reverse the pathological vascular
remodeling and cardiac dysfunction that occur in response to over activity of AngII at the
molecular level (Aplin et al., 2008, Burnier, 2001, Miura et al., 2011). This suggests that
the AT1R contributes to phenotypic changes at the cellular level in vivo (de Gasparo et
al., 2000, Hunyady and Catt, 2006). ARBs, a widely used class of anti-hypertensive
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drugs, are well tolerated with fewer side effects than ACE inhibitors. Irrespective of
whether AngII is generated systemically or by non-ACE mediated pathways, ARBs
specifically block AngII binding to the AT1R, and thereby target AT1R-regulated gene
expression changes (Miura et al., 2011). Several ARBs available for the treatment of
RAS associated disorders are losartan and candesartan, for treatment of hypertension and
hypertrophy, irbesartan, for treatment of diabetic nephropathy, and valsartan, for
treatment of heart failure in people who cannot tolerate ACE inhibitors (Silverstein and
Ram, 2005).

1.2 Regulation and Characteristics of Vascular Smooth Muscle Cells

1.2.1

The Vascular Smooth Muscle Cell (VSMC) and Its Function
Lying within the tunica media of blood vessels, smooth muscle cells (SMCs) are

essential for accurate performance of the vasculature. By contraction and relaxation,
these specialized cells alter the luminal diameter, which allows blood vessels to maintain
a homeostatic blood pressure (Rensen et al., 2007). VSMCs are innervated primarily by
the sympathetic nervous system through adrenergic receptors. Activation of α-adrenergic
receptors causes vasoconstriction, while activation of β-adrenergic receptors causes
vasodilation. In addition, within seconds to minutes of binding to AT1Rs, AngII causes
Ca2+ mobilization from the sarcoplasmic reticulum and promotes the interaction of actin
and myosin filaments to allow for contraction of cells. Excessive vasoconstriction leads
to hypertension, whereas excessive vasodilation leads to hypotension. Notably, due to
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their function of carrying blood away from the heart to all other organs and tissues,
arteries have a great deal more smooth muscle than veins.

VSMCs perform additional functions, which become important during
physiological conditions, or following vascular injury. In these cases, VSMCs will
synthesize increased amounts of extracellular matrix (ECM) components and exhibit
increased rates of migration and proliferation. Due to these characteristics, VSMCs are a
prime candidate for both short-term regulation of vessel diameter, and also for long-term
adaptation, involving vessel remodeling and changes in cell number (Rensen et al., 2007,
Gabbiani et al., 1981).

1.2.2

Modulation of VSMC Phenotype
The different functions that VSMCs exert are translated into distinct

morphologies, expression of SMC-specific genes, and varying degrees of proliferative
and migratory potential (Rensen et al., 2007). When the prime function of a VSMC is
contraction, the cytoplasm is filled with myofilaments, and when it is repair (synthesis of
matrix and/or cell division), the morphology changes to fit the altered functional demand
(Figure 1.5). Contractile SMCs are elongated, spindle-shaped cells with many contractile
filaments throughout the cytoplasm of the cell. Synthetic SMCs exhibit cobblestone
morphology and contain a high number of organelles necessary for protein synthesis.

VSMCs undergo reversible phenotypic switching from a quiescent, contractile
phenotype, in which cells have a unique repertoire of filamentous proteins (e.g., α-
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smooth muscle actin and smooth muscle-myosin heavy chain), agonist-specific receptors
and signaling molecules necessary for contraction to a synthetic state where cells exhibit
poor contractibility, changes in lipid metabolism and high production of ECM
components (Bell and Madri, 1990). In general, synthetic SMCs exhibit higher migratory
potential and proliferative rates than contractile SMCs. SMCs with different phenotypes
typically express varying levels of marker proteins, rather than completely different
marker proteins (Table I.II.) (Rensen et al., 2007).
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Figure 1.6. Characteristics of contractile and synthetic SMCs. Contractile SMCs are
elongated, spindle-shaped cells, whereas synthetic SMCs are less elongated and have
cobblestone morphology. From (Rensen et al., 2007).
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Table I.II. Genes associated with a particular SMC phenotype.

Marker Protein
α1 integrin, β1 integrin, α7 integrin,
Myocardin, N-/T-cadherin
α-SMA, γ-SMA
Desmin
SM22α
ACLP, APEG-1, CRP-2
SM-calponin, h-caldesmon, meta-vinculin
SM-MHC, Smoothelin
CRBP-1, Smemb
PDGF-A, ICAM-1, MGP
I-caldesmon
OPN
Collagen I, Moesin, Collagenase IV,
Connexin43, MMP isoforms, Syndecan-1/-4
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Phenotype Specificity
C>S
C>S
C>S
C>S
C
C > S, C, C > S
C > S, C
S>C
S
S
S>C
S>C

Currently, two marker proteins that provide the best definition of a mature
contractile SMC phenotype are SM-MHC and smoothelin. In humans and rodents,
respectively, Smemb/non-muscle MHC isoform-B and CRBP-1 represent suitable
synthetic SMC markers, since these proteins are quickly and markedly upregulated in
proliferating SMCs (Rensen et al., 2007).

The remarkable ability of VSMCs to shuttle between phenotypes is not unique to
this cell type. However, modulation of the VSMC phenotype is the best example of this
physiological phenomenon due to the ability of the cell to constantly maintain its
contractile capability. This is because there are many intermediates between the two
extreme ends of VSMC morphology (i.e., synthetic and contractile states) that can occur.
When a fibroblast, for example, undergoes differentiation and switches to a
myofibroblast, the process is irreversible (Misra et al., 2010). That is, the myofibroblast
cannot switch back to a fibroblast or the synthetic phenotype.

AngII affects virtually all vascular cells (e.g., endothelial cells, SMCs, fibroblasts,
monocytes/macrophages, and cardiac myocytes), and thus, is critical in disease
development. Changes in the phenotype and morphology of these cells, variable gene
expression, and enhanced responsiveness to stimuli lead to vascular pathology.

1.2.3

AngII-mediated Vascular Damage
As a growth factor, AngII regulates VSMC survival, growth, and hypertrophy. In

particular, activation of RAS is a highly effective and selective stimulus for the
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differentiation of quiescent VSMCs into the metabolically active, proliferative and
migratory phenotype (Ohtsu et al., 2006, Touyz and Schiffrin, 2000, Bell and Madri,
1990). Evidence points to AngII being directly involved in pathological disease states,
which are related to VSMC growth and vessel wall integrity, such as hypertension,
atherosclerosis, diabetes, cardiac remodeling, asthma, aneurysm formation, and
inflammatory responses to vessel injury (Daugherty and Cassis, 2004, Kim and Iwao,
2000, Hunyady and Catt, 2006).

AT1 receptors are highly abundant in VSMCs. AngII is known to promote its
effects in VSMCs by acting directly through the AT1R, indirectly through the release of
other factors, and possibly through cross-talk with intracellular signaling pathways of
other growth factors (Touyz and Schiffrin, 2000).

Besides VSMC contraction, AT1R-mediated pathways also activate various
downstream proteins that further enhance growth, adhesion, and migration related
signaling. Upon induction of intracellular signaling cascades in VSMCs, AngII activates
the AT1R and consequently various protein kinases (e.g., receptor or non-receptor
tyrosine kinases). Cellular protein synthesis and metabolism, transport, volume regulation,
gene expression, and growth all depend on MAPKs (Mehta and Griendling, 2007). AngII
mediates cell survival via p38/MAPKAPK-2, and PDK 1/Akt. Cell growth and
hypertrophy are mediated by AngII-mediated MAP kinases (e.g., p38MAPK, ERK1/2
and JNK, and the JAK/STAT pathway), which all lead to changes in transcription of
cellular proteins. Epidermal growth factor receptor (EGFR), platelet derived growth
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factor receptor (PDGFR), c-Src, and FAK are additional protein kinases that can be
activated by AngII in VSMCs (Daugherty and Cassis, 2004, Taubman, 2003).

AngII is also known to generate intracellular reactive oxygen species (ROS) in
VSMCs via a NADH/NADPH oxidase-dependent means, where ROS play a role in
further activation and modulation of the above mentioned signaling cascades (Harrison et
al., 2003, Irani, 2000). ROS mediate signaling in pathways causing hypertension and
vessel inflammation. AngII promotes production of chemokines (IL-8, osteopontin,
MCP-1), cytokines (IL-6, IL-12, TNFα), adhesion molecules (ICAM-1, VCAM-1,
selectins, integrins), metalloproteinases, and growth factors (VEGF, TGFβ, PDGF,
CTGF), all of which contribute to cell migration and enhanced extracellular matrix
production, ultimately leading to inflammation, fibrosis and/or cell proliferation (RuizOrtega et al., 2001, Touyz and Schiffrin, 2000). In addition, early studies demonstrated
that AngII is capable of inducing the proto-oncogenes c-Fos, c-Jun, and c-Myc, which
encode transcription factors that act as cell growth and differentiation mediators
(Taubman, 2003). Overall, through increased activation of the factors mentioned above,
AngII mediates vascular damage (Daugherty and Cassis, 2004, Irani, 2000).

The effects that AngII has on the vasculature are similar to those events that it
modulates in cardiac myocytes, fibroblasts and renal epithelial cells; whereby, the
hormone induces changes in protein production and activation of various intracellular
signaling cascades (Kim and Iwao, 2000).
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Overall, these alterations lead to vessel

remodeling and ultimately, cardiovascular diseases (Kim and Iwao, 2000, Friddle et al.,
2000).

1.3 Characteristics of micro-RNAs (miRNAs)

1.3.1

MiRNA Discovery
In 1993 Victor Ambros, Rosalind Lee, and Rhonda Feinbaum reported that they

had discovered single-stranded non-protein-coding regulatory RNA molecules in the
model organism C. elegans (Lee et al., 1993) . Previous research revealed that the lin-4
gene was responsible for the repression of the protein LIN-14 during larval development
of the worm; however, the mechanism for control of LIN-14 remained unknown.
Ambros and colleagues found that lin-4, unexpectedly, did not encode a regulatory
protein, but gave rise to small RNA molecules, 22 and 61 nucleotides in length, which
were called lin-4S (short) and lin-4L (long). Sequence analysis showed that lin-4S was
part of lin-4L, in which lin-4L was predicted to form a stem-loop structure with lin-4S
contained in the 5’ arm. It was discovered that lin-4S was partially complementary to
several sequences in the 3'-untranslated region (3’-UTR) of the messenger RNA encoding
the LIN-14 protein (Lee et al., 1993); therefore, Ambros and colleagues hypothesized that
lin-4 could regulate LIN-14 through binding of lin-4S to the lin-14 transcript in a type of
antisense RNA mechanism. In 2000, the Ruvkun lab characterized another C. elegans
small RNA regulatory molecule, let-7. Let-7 was conserved in many species, including
vertebrates (Reinhart et al., 2000). These discoveries confirmed that a class of small
RNAs with conserved sequences and functions existed. These molecules are now known
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as microRNAs (miRNAs).

MiRNAs were not recognized as a distinct class of regulators with conserved
functions until the early 2000s. In 2006, Andrew Z. Fire and Craig C. Mello won the
Nobel Prize for their work on RNA interference (RNAi) in C. elegans, which describes
gene silencing by double-stranded RNA, (Fire et al., 1998) exactly what the Ambros and
Ruvkun labs observed.

RNAi is the activated product when double-stranded RNA

duplex molecules exist in the cell. The RNAi, forming specific protein complexes
activates biochemical machinery, which degrades those mRNA molecules that carry a
silencing code identical to that of the double-stranded RNA. When such mRNA
molecules disappear, the corresponding gene is silenced and no protein is made. RNAi is
used to regulate gene expression in the cells of humans as well as worms. Interestingly,
miRNAs can also form a double-stranded structure with RNAi, the translational silencing
complex to block protein synthesis, lowering the expression of that particular gene.

Since the first report, the miRNA field has grown tremendously, becoming an
integral component of how researchers view gene expression regulation.

To date,

miRNA research has revealed multiple roles in transcript degradation and translational
suppression and possible involvement in transcriptional and translational activation
(Vasudevan et al., 2007, Buchan and Parker, 2007). MiRNAs have been linked to posttranscriptional regulation of at least 60% of protein encoding genes, modulating virtually
all biological processes, including differentiation, proliferation, and organ development
(Bartel, 2009, Fabian et al., 2010).

More than one-thousand miRNAs have been
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annotated in human, rat and mouse genomes, of which expressed miRNAs are generally
found in a tissue specific manner (Lagos-Quintana et al., 2002).

1.3.2

Biogenesis and Function of miRNAs
Genes that encode for miRNAs are distributed across chromosomes either

individually, or in clusters, in which two or more miRNA genes are transcribed from
physically adjacent miRNA genes. Usually miRNA clusters consist of two or three
genes, however, larger miRNA clusters exist. For example, the miR-17-92 cluster is
found on human chromosome 13 and is composed of six miRNAs. This miRNA
cluster is involved in cellular processes, ranging from tumor formation to the
development of heart, lungs, and immune system (Zhang et al., 2012). Whether
expressed individually or in conjunction with additional miRNAs, these small, noncoding RNAs have a significant biological impact.

The majority of genes for animal miRNAs, positioned along intronic or intergenic
regions of the genome, are initially transcribed by RNA polymerase II and to a lesser
extent by RNA polymerase III into a several hundred-nucleotide long stem-loop primary
miRNA (pri-miRNA). Pri-miRNAs are enzymatically processed to be endogenous
regulators, first in the nucleus as ~70 nucleotide long precursor miRNA (pre-miR)
hairpins by the enzyme Drosha and its obligate partner DGCR8. DGCR8 recognizes the
double-stranded RNA and then associates with Drosha to form the “microprocessor”
complex. A single pri-miRNA may contain from one to six miRNA precursors. The premiRNA is shuttled into the cytosol via Exportin-5/Ran-GTP where it is further processed.

32

Cytoplasmic processing occurs by the RNase III enzyme Dicer complexed with different
RNA-binding/modifying proteins (e.g., TRBP). The activity of Dicer yields an imperfect
miRNA:miRNA* duplex. Generally, only one strand of the duplex is functional. Selected
on the basis of its thermodynamic instability, the single-stranded, guide RNA (miRNA)
of approximately 18-25 nucleotides will be incorporated into a ribonucleoprotein
complex. The complementary passenger strand (miRNA*) is typically degraded. The
core component of the ribonucleoprotein (miRNP) complex is a member of Argonaute
protein family (Ago1 to Ago4) (Figure 1.7) (Bartel, 2009, Shukla et al., 2011, Winter et
al., 2009, Bartel, 2004). The Ago protein will orient the mature miRNA with its target
mRNA, ultimately causing regulation of translation or stability of target mRNAs.

Mechanistically, miRNAs have a cis-acting regulatory function to posttranscriptionally modulate at least 60% of protein encoding genes (Bartel, 2009), with
which they form imperfect hybrids, with the target sites in the 3’-UTR of mRNAs
(Fabian et al., 2010). The miRNA-mRNA hybrids are directed to mRNA cleavage,
translational repression, or mRNA deadenylation. MiRNAs are capable of directing
cleavage of endogenous and artificial substrates, containing highly complementary
binding sequences; however, the majority of interactions between miRNA and mRNAs in
animals are only partially complementary, and thus, translational inhibition predominates
(Hutvagner and Zamore, 2002). It has been speculated that miRNAs suppress translation
by inhibiting the processes of initiation or elongation.
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Figure 1.7. Canonical pathway of miRNA biogenesis and modes of action. Canonical
miRNA maturation includes the production of the pri-miRNA by RNA polymerase II or
III and cleavage by the microprocessor complex Drosha–DGCR8 in the nucleus. The premiRNA hairpin is exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm,
Dicer and TRBP cleave the pre-miRNA to its mature length. The functional strand of the
mature miRNA is loaded with Ago2 proteins into the RISC, where it guides RISC to
silence target mRNAs through mRNA cleavage, translational repression or deadenylation,
whereas the passenger strand (black) is degraded. From (Fazi and Nervi, 2008).
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A single miRNA can regulate multiple mRNAs to varying degrees; in addition, a
single mRNA can be targeted by multiple miRNAs. A miRNA, miRNA cluster, or
members of a miRNA family tend to target multiple mRNA transcripts within common
cellular response pathways (e.g. proliferation, apoptosis, angiogenesis, or fibrosis).
Because of this function, miRNAs are considered to be essential for protein quality
control and homeostasis and when misregulated, can result in developmental defects and
disease (Bartel, 2009, Fabian et al., 2010).

1.3.3

MiRNAs in Human Health and Disease
An important distinction between disease and healthy states in tissue homeostasis

resides in the regulatory networks that distinguish these states. As the miRNA field grows,
there is increasing recognition that miRNA networks are often associated with tissue
dysfunction.

Because of their global function, miRNAs are vital regulators of

homeostatic protein levels and when deregulated, can alter developmental fate and
physiological processes (Shukla et al., 2011, Bartel, 2009). Many researchers have
reported links between altered miRNA homeostasis and pathological conditions, such as
cancer, psychiatric and neurological diseases, cardiovascular disease, and autoimmune
disease. MiRNA deficiencies or excesses have been correlated with a number of
clinically important diseases.

Dysregulation of miRNA expression in cancer has suggested that miRNAs can act
as oncogenes (“oncomiRs”), by decreasing expression of tumor-suppressor genes or as
tumor-suppressors, by targeting oncogenic mRNA for translational silencing (Esquela-
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Kerscher and Slack, 2006). Mirs-17-92 and miR-21 have been identified as oncomiRs
and are linked to regulators of the cell cycle to promote proliferation. (Nana-Sinkam and
Croce, 2011, Pandit et al., 2011). An example of a tumor suppressor miRNA is let-7.
When overexpressed, this miRNA has been shown to inhibit tumor development and
growth (Nana-Sinkam and Croce, 2011). To add to the complexity, the cell and tissue
context of miRNA expression can be critical to understanding the overall pathobiology of
cancer. For example, miR-31 seems to be pro-oncogenic in lung cancer, but protective in
breast cancer. In addition, an observed increase in miR-3 occurs in lung cancer cell lines
and knockdown reduces cellular growth and colony formation (Liu et al., 2011).

Specific and global alteration of miRNA expression profiles has been shown in
heart and kidney, two main organs that are pathophysiologically affected by AngII (Bhatt
et al., 2011, Elton et al., 2010, Ikeda and Pu, 2010, Scalbert and Bril, 2008, Small and
Olson, 2011). In the kidney, collagen production during diabetic nephropathy (miRs-192,
-216a, and -217), fibrosis, (miR-21, and miR families -29, and -200), acute kidney injury
(miRs-132, -362, -379, -668, and -687), polycystic kidney disease (miRs-15a and -17),
kidney cancer (miRs-210, -155, -185, -21, 483-3p, and -562), and hypertensive kidney
sclerosis (miRs-200a-b, -141, -429, -205, and -192) exhibit altered expression of
miRNAs (Li et al., 2010).

Regulation of cardiac structure and function by miRNAs can also have deleterious
implications. Recent studies have established essential roles for miRs in cardiac
development and cardiac health. For example, cardiac cell fate decisions (miR-1-2),
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hyperplasia (miR-1-2), hypertrophy (miR-1, -133, -21, -23a, -24, -195, -199a, 208, -214),
apoptosis (miR-1, -133), contraction (miR-208), electrical conductance (miR-1-2, -133, 208), and cardiomyocyte fibrosis (miR-21, -29) can be strongly modulated by miRNAs.
In addition, early studies implicate specific miRNAs as contributors to vascular disease
(e.g., miR-155, -143, -145, -21, 126) (Dorn, 2011, van Rooij et al., 2008).

In a previous study, we have shown an altered miRNA expression profile in
dilated cardiomyopathic human hearts. MiRs-1, -29b, -7, and -378 were downregulated in
end-stage dilated cardiomyopathy; whereas, miRs-214, -342, -125b, and -181b were
upregulated. The altered miRNAs target gene networks (e.g., NFκB) that account for
compensatory remodeling in human HF. These novel studies suggest that mRNA and
miRNA profiles, together, contribute to AT1R biology in health and disease (Naga Prasad
et al., 2009, Naga Prasad and Karnik, 2010). It is unknown, however, miRNAs that are
involved in AngII and ARB mediated vascular pathologies, which is a major drawback to
fully understanding the signaling pathways mediated by RAS.

1.3.4

Therapeutic Potential of miRNAs
It is well established that miRNAs act as negative regulators of gene expression

via various mechanisms. Because individual miRNA often regulate the expression of
multiple target genes with related functions, modulating the expression of a single
miRNA can, in theory, influence an entire gene network and thereby modify complex
disease phenotypes. Thus, molecules that alter the function or abundance of specific
miRNAs represent a new strategy for treating human disease.
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The molecular mechanism by which miRNAs regulate gene expression is still not
fully understood, nor is the complete repertoire of mRNAs targeted by each miRNA
known. However, continual advances in the field points to effective strategies for
modulating expression of miRNAs, allowing them to have therapeutic potential. MiRs155 (inflammation), -122 (Hepatitis C virus), -208 (cardiac remodeling), -21 (fibrosis, 92a (neoangiogenesis), -33 (metabolic disease), -103/107 (metabolism), -15 family
(cardiac regeneration and injury) are multiple examples of instances where controlling
expression of the miRNA would show therapeutic promise (van Rooij et al., 2012).

To understand the roles of miRNAs in biological systems, it is important to be
able to artificially increase or decrease their function or abundance.

Expression of

exogenous small RNAs in cells is possible through transient or stable transfection or viral
transduction of a pri-miRNA transgene, pre-miRNA, or mature miRNA/miRNA*.
MiRNAs can also be targeted for inhibition by using antisense oligonucleotides, which
will bind miRNAs and prevent them from interacting with mRNA target genes (i.e.,
antagomirs) (van Rooij et al., 2012).

Studies have examined various chemical

modifications of antagomirs to improve their in vitro and in vivo stability and to improve
their in vivo delivery. Modifications include, 2′-O-methoxyethyl, 2′-fluoro and 2′, 4′methylene (locked nucleic acids (LNAs)), which have greater affinity to bind and inhibit
miRNAs and are more resistant to degradation (Broderick and Zamore, 2011).
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Delivery of therapeutic miRNAs to its target tissue is a challenge. Anything with
a diameter larger than 5nm, including therapeutic RNAs, cannot cross the capillary
endothelium and will remain in circulation until filtered by the kidneys. Therefore, local
delivery increases its bioavailability in target tissues and minimizes uptake in non-target
tissues. Local delivery is, unfortunately, limited to the eye, skin, mucous membranes and
tumors. Alternatively, systemic delivery into the bloodstream is challenged by the
immune response of the body. In some cases, where direct delivery is not possible,
nucleic acids can be encapsulated in lipids, forming vesicles (e.g., PEGylated liposomes,
lipidoids and biodegradable polymers) and enhancing intracellular delivery (Broderick
and Zamore, 2011). The advantage of using lipid delivery is that these lipid particles can
be tailored to 1) enable fusion with the cytoplasmic, endosomal or nuclear membrane and
2) promote endosomal release once inside the cell.

In the anti-miRNA therapeutics field, numerous clinical trials are being actively
pursued, particularly for those miRNAs mentioned above. The pharmacokinetics (fate of
the drug in the body), pharmacodynamics (time course and nature of pharmacological
effects), and absorption, distribution, metabolism, and excretion of the delivered
antagomirs are critical aspects that are taken into account when moving from the bench to
a clinical trial. In addition, the toxicity of the agent must be addressed to determine the
most effective dose and dose regimen that is safe and free of unwanted side effects (van
Rooij et al., 2012).
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A significant drawback to miRNA-targeted therapies is the extreme potential for
off-target-effects. Although a miRNA might target related genes, the fact still remains
that a single miRNA can target many genes and the genes that are targeted are cell type–
dependent, meaning that many genes can be unintentionally turned off and cause
additional deleterious outcomes (van Rooij et al., 2012). There are a lot of unknowns
surrounding the mode of action of the different antagomirs; however, the interest
surrounding miRNAs as novel therapeutic entities is tremendous and the anticipated
success of these early forerunners will likely spur the search for additional miRNA
therapeutic targets.

1.3.5

Regulation of RAS Components by miRNAs
Variations in the genotype of many of the RAS components (e.g., AGT, ACE1,

AT1R) are associated with altered activity and function and may have significant clinical
implications (Pontremoli et al., 2000). For example, a wide range of known stimuli can
regulate AT1R expression at the transcriptional level (e.g., NO, peroxisome proliferatoractivated receptor (PPAR)-γ suppress receptor density, while IL-6, glucocorticoids, and
insulin-like growth factor cause upregulation) (Elton and Martin, 2007). In recent years,
several studies have investigated the ability of miRNAs to regulate AT1R expression and
expression of other GPCRs. From regulated expression of β2-adrenergic receptors by
let-7f to controlling AT1R density by various miRNAs binding to either the 3’UTR or a
region of the protein-coding portion of the gene, miRNAs have a powerful function in
controlling receptor expression, and thereby function within the cell (Wang et al., 2011,
Elton et al., 2010).
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Recently, it has been demonstrated that miR-155 regulates the expression of the
AT1R. In human lung fibroblasts, miR-155 translationally repressed the expression of
AT1R and the inhibition of miRNA expression by anti-miR-155 or by transforming
growth factor-β1 (TGF-β1) treatment substantially increased AT1R protein levels, which
may have a role in the treatment of blood pressure (Martin et al., 2007b, Martin et al.,
2007a). MiR-155 has been shown to interact with the silent polymorphism (+1166A/C)
of the human AT1R gene in ECs and VSMCs. Martin and colleagues showed that when
the +1166C-allele polymorphism is present in the 3’UTR of the gene, the ability of miR155 to interact with the cis-regulatory site is decreased, leading to translational repression
of the AT1R (Martin et al., 2007b). The same group showed, for the first time, that
miRNAs (i.e., miR-132) could also bind to sequence recognition sites harbored in the
coding region of the hAT1R mRNA and suppress its translation (Elton, 2008).
Furthermore, miR-802 in the GI tract specifically, has been shown to regulate AT1R
expression through binding to the 3’UTR of the AGTR1 gene. In the absence of this
miRNA, researchers observed increased hAT1R levels and AngII/AT1R signaling
(Sansom et al., 2010). MiRNAs have also been shown to regulate additional components
of RAS. Specifically, rats experiencing nonpathological left ventricular hypertrophy
induced by exercise had altered expression of specific miRNAs targeting RAS genes.
MiR-27a and -27b targeting ACE were increased and miR-143 targeting ACE2 was
decreased in the heart (Fernandes et al., 2011). Finally, Boettger et al. demonstrated that
miR-145, which is enriched in mouse VSMCs, targets mouse ACE1 mRNA, leading to
thinning of the arterial tunica media in the absence of the miRNA (Boettger et al., 2009).
The miR-145 deficient mice had a decrease in the number of contractile VSMCs and an
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increase in the number of proliferative VSMCs, which gave rise to a defect in AngIIinduced contractility and blood pressure maintenance (Elia et al., 2009). These examples
show the potent ability of small RNAs to have a widespread effect on overall AT1R
signal transduction and function through changing mRNA expression of RAS
components.

1.3.6

AngII Regulation of Small Ribonucleic Acids
Establishing AngII/AT1R activation as a broad cellular agonist has provided the

foundation to undertake further comprehensive analyses of AngII effects on gene
expression induction. Understanding the role of AngII regulated small ribonucleic acids
(RNAs) is an area of interest that will provide additional insight into the ability of AngII
to modulate physiological and pathological phenotypes.

GPCR regulated miRNA

(miRNome) expression, particularly AT1R regulated miRNA expression, is an area of
mounting interest to researchers. The consequence of an important regulatory system,
such as RAS, modulating miRNA gene expression has not been extensively studied, but
promises to have a significant impact on the field of AngII biology.

Specifically,

miRNAs that are involved in AngII and ARB mediated vascular pathologies are not
known, which is a major drawback to fully understanding the signaling pathways
mediated by RAS.

Recent work by Jeppesen and colleagues shows that cardiac fibroblasts and
HEK293N cells overexpressing the AT1R have a differential miRNA profile in response
to AngII/AT1R activation, compared to control cells (Jeppesen et al., 2011). In a Gq/11-
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dependent manner, miR-29b, -129-3p, -132, -132* and -212 were upregulated in their
system, suggesting a possible role for these miRNAs in AngII mediated cardiovascular
biology (Jeppesen et al., 2011). This study has shown that the AT1R is an ideal model
system for exploring the GPCR regulated miRNome. Additionally, researchers have
shown that circulating levels of vascular and inflammation-associated miRNAs are
significantly downregulated in patients with coronary artery disease, which is an
important aspect of AngII biology (Fichtlscherer et al., 2010). Determining the AT1R
regulated miRNome and its effect on the pleiotropic signaling events of the AngII/AT1R
interactions will introduce a distinct regulatory axis into RAS as a whole.

4.1 Significance of Current Work
In both physiological and pathological settings, if the activity of AngII as a broad
cellular agonist is not properly regulated, AngII stimulus becomes chronic and can
damage the tissue, as well as contribute to lasting cardiovascular disorders (Mehta and
Griendling, 2007). It’s well established that activation of the AT1R by AngII leads to an
increase in protein coding genes and protein expression. A novel are of research is the
pursuit of understanding the regulation of expression and processing of miRNAs, which
is stringently controlled within a cell. The role of miRNAs must be a critical aspect of
effectiveness of vital hormones such as AngII. The miRNAs may also be involved in
modulation of beneficial tissue response to treatment of cardiovascular pathologies using
blockade of RAS. This aspect of AngII biology has not been studied, but acquisition of
knowledge of AngII modulating miRNA gene expression promises to have a significant
impact on the field.
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Increasing evidence points to the realization that the AT1R-mediated gene
expression models in various tissues and disease states are incomplete without the
accompanying miRNA profile. In this study, we documented the global AngII-regulated
miRNA expression profile for various model systems of human, mouse and rat origin.
The biological and technical replicates included cardiac tissue, cardiac myocytes, VSMCs
and epithelial cells. Our goal was to observe the established equilibrium of the miRNA
pool that would persist following chronic AngII treatment in each model as a means to
ultimately observe a common AngII responsive miRNA signature. We pharmacologically
distinguished the AT1R-regulated miRNA profiles by comparing technical replicates
treated with the specific AT1R-blocker, losartan and biological replicates following
chronic AT2R activation by AngII. We observed 32 miRNAs that were universally
regulated by AngII. Most other miRNAs were regulated in a treatment- or speciesspecific manner. In addition, a few miRNAs were unique to specific cell types.

In the current study, we also explored the extent to which AngII/AT1R-regulated
miRNAs contribute to maintenance of RAS homeostasis and phenotypic modulation of
VSMCs, which are an important cell type that can be adversely affected by a local
increase in AngII action. The balance between VSMC phenotypes depends on the
expression of different intracellular proteins, secretion of cytokines and chemokines, and
deposition of ECM components (Figure 1.8) (Ruiz-Ortega et al., 2001, Daugherty and
Cassis, 2004, Touyz and Schiffrin, 2000). Understanding the role that miRNAs may play
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in the regulation of AngII-induced VSMC phenotypic alterations will be an important
aspect for determining the full capacity of AngII/AT1R activation on vascular diseases.
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Figure 1.8. Effects of AngII on VMSCs. It has been well established that upon
stimulation with AngII, the AT1R becomes activated leading to an increase in protein
coding genes and protein expression. Receptor activation ultimately manifests as a
specific VSMC phenotype due to a host of alterations, including changes in gene
expression, the secretion of cytokines and chemokines, and increased protein and ECM
synthesis. Whether the effect AngII has on VSMCs is mediated through miRNA
expression and regulation is unknown.
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A distinct AngII-regulated miRNA expression pattern emerged in the human and
rat VSM cell lines in the profiling experiment, which was validated in our independent
samples. Of the 17 miRNAs comprising the VSMC expression pattern, we selected miR483 as a representative candidate for further study because of its location within the
genome and its ability to potentially target multiple components of RAS. Overall, we
show evidence that indicates muscle cell-specific expression of miR-483 and regulation
of tissue RAS and AngII-mediated migration by miR-483; specifically in VSMCs. Our
results further suggest that the AngII-regulated MEK1 kinase signaling cascade most
effectively mediates the steady state pool of miRNAs, which includes downregulation of
mir-483. This results in activation of RAS and switching of the VSMC phenotype
associated with pathological states in vivo, such as hypertension.

Our findings are significant in the context of determining the full capacity of RAS
as an intrinsic regulatory system. AngII-regulated miRNAs will likely have a strong
influence on cardiovascular and renal disease states.

Further, understanding their

expression and regulation could be applied to other biological systems in which ligandinduced GPCR activation or inhibition induces changes in gene expression and formation
of pathologies.
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CHAPTER II
MATERIALS AND METHODS

2.1 Construction of Plasmids
The hemaglutinin (HA)-tagged AT1R gene was subcloned into the shuttle
expression vector, pcDNA3.1 (+) (Life Technologies, NY, USA), which contains unique
EcoR1 and Not1 restriction sites (Figure 2.1 A). An EcoR1 restriction site on the 5’ end
and a Not1 restriction site on the 3’ end flank the synthetic rat AT1R gene. HA-AT1R was
previously sequenced and cloned into the pMT3 expression vector; therefore, the gene
was removed for subcloning using the appropriate restriction enzymes. The digest was
fractionated on a 1% agarose gel and isolated by QIAquick Gel Extraction Kit (Cat. No.
28704; QIAGEN, Valencia, CA, USA). The insert was ligated into the pcDNA3.1 (+)
expression cassette (Figure 2.1 B). The HA-tagged AT2R gene was cloned into pcDNA
3.1 (+), previously.

Figure 2.1. Subcloning of HA-AT1R gene in pcDNA3.1 expression vector. A)
Schematic representation of pcDNA3.1 cloning vector. PCMV, cytomegalovirus promoter;
T7, promoter/priming site; EcoR1-Not1, cloning sites for expression, BGH pA,
polyadenylation sequence; SV40, origin of replication; SV40 pA, early polyadenylation
signal; NeoR, neomycin resistance gene; pUC, origin of replication; AmpR, ampicillin
resistance gene.

B) Schematic representation of subcloning HA-AT1R gene into

pcDNA3.1 (+) vector.
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Pre-miR-483 was designed to have a completely complementary hairpin sequence and to
be oriented in the 3’5’ direction to allow for optimal expression of miR-483-3p in
mammalian cells (Figure 2.2).

The 76-nucleotide sequence was synthesized and cloned into the expression
vector pRNA U-6.1/Hygro by GenScript (Figure 2.3 A) (GenScript, NJ, USA) ad
provided as mini-prep DNA. Upon receipt, the pRNA U6.1-miR483 construct was
transformed into competent FB10B cells. The plasmid was isolated using the GenElute
HP Plasmid Maxiprep Kit (Cat. No. NA0300; Sigma-Aldrich, MO, USA) (Figure 2.3 B).

The 3’-UTRs of human AGT, ACE-1, ACE-2, and AGTR2 were generated using
polymerase chain reaction (PCR) amplification and cloned into the psiCHECK™-2 dual
luciferase reporter expression vector, which contains unique Xho1 and Not1 restriction
sites (Figure 2.3 A) (Cat. No. C8021; Promega, WI, USA). Genomic DNA was isolated
from human kidney epithelial (HEK) cells using the DNeasy Blood and Tissue Kit (Cat.
No. 69506; QIAGEN) and served as the DNA template for each individual PCR reaction.
Sense and antisense primers were designed to be complementary to each 3’-UTR
sequence and harbor nucleotide changes to incorporate restriction sites specific for Xho1
and Not1 enzymes (Table II.I.).
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Figure 2.2. MiRNA insert for expression construct. The insert sequence was designed
for expression of miR-483-3p in mammalian cells. Magenta, BamHI restriction site; teal,
purine for transcription initiation; yellow, sense (miR-483-3p); green, loop; red, antisense
(mir-483-5p); purple, termination signal; aqua, HindIII restriction site.

MiR-483 Hairpin Nucleotide Sequence
GGATCCCGTCACTCCTCTCCTCCCGTCTTTTGATATCCGAAGACGGGAGGAGAGGAGTG
ATTTTTTCCAAAAGCTT
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Figure 2.3. MiR-483 in pRNA U6.1 expression vector. A) Schematic representation of
pRNA U6.1/Hygro cloning vector. U6, promoter; T7, primer; BamH1-HindIII, cloning
sites for expression; SV40, origin of replication; Hygromycin, resistance gene; pUC,
origin of replication; Ampicillin, resistance gene.
isolating plasmid DNA for transfection.
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B) Schematic representation of

The 3’-UTR of each gene was PCR amplified in the presence of FailSafe enzyme
(Cat. No. FS99060; Epicentre Biotechnologies, WI, USA) using 10pmol/µl of sense and
10pmol/µl antisense primer. The parameters used for the PCR reaction were an initial
denaturing step of 5 min at 95°C followed by 30 cycles of 94°C for 1 min, 55°C for 1
min, and 72°C for 1.5 min and then a final extension at 72°C for 10min. The PCR
products were fractionated on a 1% agarose gel and isolated using QIAquick Gel
Extraction Kit (QIAGEN), digested with Xho1 and Not1, and purified with QIAquick
PCR purification Kit (Cat. No. 28104; QIAGEN). The purified products were ligated into
psiCHECK-2 and transformed into competent FB10B cells. The plasmids were isolated
using the GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich) (Figure 2.3 B). The
sequence of each 3’-UTR construct was verified using automated DNA sequencing
(Figure 2.4).
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Table II.I. Primers used for 3’-UTR amplification. Green, G clamp; aqua, Xho1
restriction site; red, stop codon; magenta, Not1 restriction site.

Primer
AGT
sense
AGT
antisense
ACE-1
sense
ACE-1
antisense
ACE-2
sense
ACE-2
antisense
AGTR2
sense
AGTR2
antisense

Sequence (5’  3’)

bp

%GC

TM

GGGGCTCGAGTGAGGCCAGGGCCCCAGAACACAG

34

71

86

GGGGGCGGCCGCGGAGGCTTATTGTGGCAAGAC

33

70

87

GGGGCTCGAGTGAGGTGACCCGGCTGGGTCGGCC

34

77

89

GGGGGCGGCCGCGGGAGGGCAGGACCTTTAATTG

34

71

88

GGGGCTCGAGTAGAAAAATCTATGTTTTTCCTC

33

42

70

GGGGGCGGCCGCGAGTGTGTAAATCTAGCATTTATTG

37

54

81

GGGGCTCGAGTTACGTGAGAGCAAAATGCATG

32

53

77

GGGGGCGGCCGCCTTCCAATTAAAAATTTTATTTATATG

39

41

77
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Figure 2.4. Cloning of 3’-UTRs in psiCHECK-2 expression vector. A) Schematic
representation of psiCHECK-2 cloning vector. HSV-TK, promoter; hluc+, Firefly
luciferase gene; SV40, late poly (A) signal; AmpR, ampicillin resistance gene; SV40,
early enhancer/promoter; T7, promoter; hRluc, Renilla luciferase gene; Not1-Xho1,
cloning sites for expression; Synthetic poly (A). B) Schematic representation of
subcloning HA-AT1R gene into pcDNA3.1 (+) vector.

56

57

Figure 2.5. Nucleotide Sequences of 3’-UTRs. The 3’-UTR sequence of AGT, ACE-1,
ACE-2, and AGTR2 was verified by automated DNA sequencing. Aqua, Xho1
restriction site; red, stop codon; green, miR-483-3p native binding site; magenta, Not1
restriction site.

AGT 3’-UTR Nucleotide Sequence
CTCGAGTGAGGCCAGGGCCCCAGAACACAGTGCCTGGCAAGGCCTCTGCCCCTGGCCTT
TGAGGCAAAGGCCAGCAGCAGATAACAACCCCGGACAAATCAGCGATGTGTCACCCCCA
GTCTCCCACCTTTTCTTCTAATGAGTCGACTTTGAGCTGGAAAGCAGCCGTTTCTCCTT
GGTCTAAGTGTGCTGCATGGAGTGAGCAGTAGAAGCCTGCAGCGGCACAAATGCACCTC
CCAGTTTGCTGGGTTTATTTTAGAGAATGGGGGTGGGGAGGCAAGAACCAGTGTTTAGC
GCGGGACTACTGTTCCAAAAAGAATTCCAACCGACCAGCTTGTTTGTGAAACAAAAAAG
TGTTCCCTTTTCAAGTTGAGAACAAAAATTGGGTTTTAAAATTAAAGTATACATTTTTG
CATTGCCTTCGGTTTGTATTTAGTGTCTTGAATGTAAGAACATGACCTCCGTGTAGTGT
CTGTAATACCTTAGTTTTTTCCACAGATGCTTGTGATTTTTGAACAATACGTGAAAGAT
GCAAGCACCTGAATTTCTGTTTGAATGCGGAACCATAGCTGGTTATTTCTCCCTTGTGT
TAGTAATAAACGTCTTGCCACAATAAGCCTCCAAAAAAAAGCGGCCGC

ACE-1 3’-UTR Nucleotide Sequence
CTCGAGTGACCCGGCTGGGTCGGCCCTGCCCAAGGGCCTCCCACCAGAGACTGGGATGG
GAACACTGGTGGGCAGCTGAGGACACACCCCACACCCCAGCCCACCCTGCTCCTCCTGC
CCTGTCCCTGTCCCCCTCCCCTCCCAGTCCTCCAGACCACCAGCCGCCCCAGCCCCTTC
TCCCAGCACACGGCTGCCTGACACTGAGCCCCACCTCTCCAAGTCTCTCTGTGAATACA
ATTAAAGGTCCTGCCCTCCCGCGGCCGC

ACE-2 3’UTR Nucleotide Sequence
CTCGAGTAGAAAAATCTATGTTTTTCCTCTTGAGGTGATTTTGTTGTATGTAAATGTTA
ATTTCATGGTATAGAAAATATAAGATGATAAAGATATCATTAAATGTCAAAACTATGAC
TCTGTTCAGAAAAAAAATTGTCCAAAGACAACATGGCCAAGGAGAGAGCATCTTCATTG
ACATTGCTTTCAGTATTTATTTCTGTCTCTGGATTTGACTTCTGTTCTGTTTCTTAATA
AGGATTTTGTATTAGAGTATATTAGGGAAAGTGTGTATTTGGTCTCACAGGCTGTTCAG
GGATAATCTAAATGTAAATGTCTGTTGAATTTCTGAAGTTGAAAACAAGGATATATCAT
TGGAGCAAGTGTTGGATCTTGTATGGAATATGGATGGATCACTTGTAAGGACAGTGCCT
GGGAACTGGTGTAGCTGCAAGGATTGAGAATGGCATGCATTAGCTCACTTTCATTTAAT
CCATTGTCAAGGATGACATGCTTTCTTCACAGTAACTCAGTTCAAGTACTATGGTGATT
TGCCTACAGTGATGTTTGGAATCGATCATGCTTTCTTCAAGGTGACAGGTCTAAAGAGA
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GAAGAATCCAGGGAACAGGTAGAGGACATTGCTTTTTCACTTCCAAGGTGCTTGATCAA
CATCTCCCTGACAACACAAAACTAGAGCCAGGGGCCTCCGTGAACTCCCAGAGCATGCC
TGATAGAAACTCATTTCTACTGTTCTCTAACTGTGGAGTGAATGGAAATTCCAACTGTA
TGTTCACCCTCTGAAGTGGGTACCCAGTCTCTTAAATCTTTTGTATTTGCTCACAGTGT
TTGAGCAGTGCTGAGCACAAAGCAGACACTCAATAAATGCTAGATTTACACACTCAAAA
AAAAAAAAGCGGCCGC

AGTR2 3’UTR Nucleotide Sequence
CTCGAGTTACGTGAGAGCAAAATGCATGTAATCAACATGGCTACTTGCTTTGAGGCTCA
CCAGAATTATTTTTAAGTGGTTTTAATAAAATAATAAAATTTCCCCTAATCTTTTCTGA
ATCTTCTGAAACCAAATGTAACTATGTTTTATCGTCCAGTGACTTTCAGGAATTGCCCA
TTGTTTTTCTGATATGTTTGTACAAGATTGTCATTAGTGAGACATATTTACAACCTAGA
AGTAACTGGTGATATATCTCAAATTGTAATTAATAATAGATTGTGAATAATGATTTGGG
GATTCAGATTTCTCTTTGAAACATGCTTGTGTTTCTTAGTGGGGTTTTATATCCATTTT
TATCAGGATTTCCTCTTGAACCAGAACCAGTCTTTCAACTCATTGCATCATTTACAAGA
CAACATTGTAAGAGAGATGAGCACTTCTAAGTTGAGTATATTATAATAGATTAGTACTG
GATTATTCAGGCTTTAGGCATATGCTTCTTTAAAAAAGCTATAAATTATATTCCTCTTG
CATTTCACTTGAGTGGAGGTTTATAGTTAATCTATAACTACATATTGAATAGGGCTAGG
AATATAGATTAAATCATACTCCTATGCTTTAGCTTATTTTTACAGTTATAGAAAGCAAG
ATGTACTATAACATAGAATTGCAATCTATAATATTTGTGTGTTCACTAAACTCTGAATA
AGCACTTTTTAAAAAACTTTCTACTCATTTTAATGATTGTTTAAAGGTTTCTATTTTCT
CTGATACTTTTTTGAAATCAGTAAACACTGTGTATTGTTGTAAAATGTAAAGGTCACTT
TTCACATCCTTGACTTTTTAGATGTGCTGCTTTGATATATAGGACATTGATTTGATTTT
TATTATTAATGCTTTGGTTCTGGGTTGTTTCCTAAAATATCTGGGTGGCTTAAAAAAAA
CTCTTTAACTTGTAATAAACCCTTAACTGGCATAGGAAATGGTATCCAGAATGGAATTT
TGCTACATGGGGTCTGGGTGGGGGCAAAGAGACCCAGTCAATTACATGTTTGGTACCAA
GAAAGGAACCTGTCAGGGCAGTACAATGTGACTTTGAAAATATATACCGTGGGGGTAGT
TTTACCCTATATCTATAAACACTGTTTGTTCCAGAATCTGTATGATTCTATGGAGCTAT
TTTAAACCAATTGCAGGTCTAGATACCTCCTTCTCAGCACTATTAAAGCTCCTAAGTTA
GAGGAGTGCCTAAAACTGAGTTACCTAAAGTTTACTTACATTAAAGTATGAATATTAAT
TTTAGAAATTTGAGACTTTATTCTGTACCAGCCCTGTATAATAACAGGTTATCTAGGAC
CTTCCTCTGAGGTAGGTCTAAATACTGATCTCTGAGGCGGAACTAACGTTTTGGGGACT
CAGCATCTCTGCCAGGTTCCAGGATTATAGACAGAAGAGTCCTGTCATACCACTTTCTG
GAAAAGTCCTAATTTCATGTAATCCTTTTATTTTCAATAAAAACAAATAGCTAAATGTA
TAACCAACTATGATGTTATGTTTTCAATAATTTTGTAAAACAGCTCATATAAATAAAAT
TTTTAATTGGAAGAAAAAAAAAGCGGCCGC
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2.2 Cell Culture Maintenance and Transfection
For expression of HA-AT1R and HA-AT2R in mammalian VSMCs, we used the
rat aortic smooth muscle cell (RASMC) line, which was obtained from American Type
Culture Collection (Cat. No. CRL-2018; ATCC, VA, USA). This cell line has been
transformed with the large T antigen of SV40 (SV40-LT), which immortalizes the cell
line and prevents them from dedifferentiating in culture. Importantly, these VSMCs
maintain the characteristics common to primary SMC cultures. RASMCs were grown in
100-mm culture dishes to approximately 40-50% confluency and transfected by
Lipofectamine® Transfection Reagent (Cat. No. 18324; Life Technologies), according to
the manufacturer’s instructions. Briefly, 60 µl of Lipofectamine was added into 1.5 mL
of OPTI-MEM reduced serum media and incubated for 5 min. Twenty-four micrograms
of plasmid DNA (HA-AT1R or HA-AT2R) was added to an additional 1.5 mL of OPTIMEM and the two mixtures were combined and incubated for 20 min at room
temperature. The mixture was then added into the culture medium. Twenty-four hours
following transfection, the medium was removed and medium containing 200 µg/ml of
geneticin was added. Receptor expression was confirmed by Fluorescence Activated Cell
Sorting (FACS) Analysis, which is described in 2.3. The RASMC cell lines stably
expressing HA-AT1R and HA-AT2R were established by geneticin selection (700 µg/ml).

The human embryonic kidney, HEK-293 clonal cell lines stably expressing HAAT1R (5.1 pmol/mg) and HA-AT2R (5 pmol/mg) were established by geneticin selection
(600 µg/ml) as described previously (31). The primary human aortic smooth muscle cells
(HASMC, a gift from A. Majors, Department of Pathobiology, Lerner Research Institute
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(LRI), Cleveland Clinic (CCF)) (Majors et al., 2002) were used between passage number
3 and 6. The AT1R-expressing (0.9 pmol/mg) mouse atrial cardiomyocyte clonal line
(HL-1-AT1R) was established by geneticin selection (800 µg/ml) of HL-1 cells (White et
al., 2004).

For expression of miR-483-3p, we used the RASMC, RASMC-AT1R, and HEK293T cell lines. The HEK-293T cell line is highly transfectable and has been transformed
with the temperature sensitive SV40 T-antigen (Cat. No. CRL-11268; ATCC).
Expression of miR-483-3p was carried out using the Amaxa Nucleofector™ Technology
(Lonza, NJ, USA). The Nucleofector technology is a novel transfection technology
especially designed for the needs of primary cells and difficult-to-transfect cell lines. It is
a non-viral method, which is based on a unique combination of electrical parameters and
cell-type specific solutions to allow DNA to directly enter the nucleus. This procedure
was performed according to the manufacturer’s instructions.

Briefly, cells were

trypsinized and counted using an automated cell counter (Cellometer; Nexcelom, MA,
USA).

Approximately 2 x 106 cells were suspended in Nucleofection Solution L

(RASMCs and RASMCs-AT1R) (Lonza) or 1X phosphate buffered saline (PBS) (HEK293T). Two micrograms of plasmid DNA was added to the suspension and the mixture
was placed into a cuvette. The cuvette was placed into the Nucleofector and the
appropriate program was started (RASMCs – program 33, HEK-293T cells – program
29). Post-nucleofection, 500 µl of medium was added to the cuvette and then pipetted
gently into a 6-well culture dish. Approximately 72 hours post-nucleofection, the cells
were passaged into a 100-mm culture dish, containing culture medium supplemented with
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hygromycin. Clones were picked and expression of miR-483-3p was analyzed by RNA
solution hybridization, which is described in 2.12. For each cell line utilized, a vector
control was also made, which was hygromycin resistant.

A panel of cell lines was used to monitor miR-483-3p expression in various cell
types. These cells included RASMC, RASMC-AT1R, primary rabbit aortic smooth
muscle cells (RASMC, a gift from Edward F. Plow, Department of Molecular
Cardiology, LRI-CCF), rat thoracic aortic smooth muscle cells (A7R5; Cat. No. CRL1444; ATCC), HASMC, rat coronary artery smooth muscle cells (RCASMC), primary
bovine aortic endothelial cells (BAEC, a gift from Paul E. DiCorleto, Department of
Cellular and Molecular Medicine, LRI-CCF), primary human umbilical vein endothelial
cells (HUVEC, a gift from Paul E. DiCorleto, Department of Cellular and Molecular
Medicine, LRI-CCF), breast adenosarcoma epithelial cells (MCF-7; Cat. No. HTB-22;
ATCC), human adrenal carcinoma epithelial cells (NC1-H295R; Cat. No. CRL-2128;
ATCC), mouse myoblast cells (C2C12; Cat. No. CRL-1772; ATCC), rat myocardial
myoblast cells (H9C2; Cat. No. CRL-1446; ATCC), mouse atrial cardiomyocyte cells
(HL-1), HL1-AT1R, pig kidney epithelial cells (LLCPK-1, obtained from the Department
of Molecular Cardiology, LRI-CCF), rat kidney epithelial cells (NRK52E; Cat. No. CRL1571; ATCC), rat liver epithelial cells (WB; obtained from Cell Culture Core, Lerner
Research Institute, Cleveland Clinic). Majority of the cell types were cultured to
approximately 70% confluency in Dulbecco’s Modified Eagle Media (DMEM;
Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS;
Thermo Fisher Scientific, Waltham, MA, USA). HUVECs were cultured in VascuLife
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Basal Medium (Cat. No. LM-0002; Lifeline Cell Technology, MD, USA) supplemented
with Lifeline’s EnGS LifeFactors Kit (Cat. No. LS-1019; containing L-Glutamine, FBS,
rH EGF, Hydrocortisone hemisuccinate, Heparin, and EnGS).

HEK-293T-miR483 and the vector control HEK-293T cells were grown in 6-well
plates to approximately 50-60% confluency and transiently transfected by Attractene
Transfection Reagent (Cat. No. 1051561; QIAGEN) according to the manufacturer’s
instructions. Briefly, 2 µg of plasmid DNA, harboring the 3’-UTR of select genes was
diluted to 100 µl with OPTI-MEM. To the DNA, 4.5 µl of Attractene was added, mixed
by gentle pipetting and incubated for 15 min at room temperature. The mixture was then
added drop-wise to the culture medium and incubated until processing. In experiments
where an antagomir to miR-483-3p was utilized (Cat. No. MIN0002173; QIAGEN),
0.005uM of the antagomir was mixed with the plasmid DNA and diluted to 100 µl with
OPTI-MEM. Attractene was then added and the mixture was incubated for 15 min at
room temperature.

The HEK-293, HEK-293T, HEK-293T-miR483, HEK-AT1R, HEK-AT2R,
RASMC, RASMC-AT1R, RASMC-AT2R, RASMC-miR483, AND HASMC were
cultured in DMEM supplemented with 10% FBS (fetal bovine serum (FBS; Thermo
Fisher Scientific, Waltham, MA, USA) and 100 IU penicillin/streptomycin (SigmaAldrich). HL1-AT1R cells were cultured in Claycomb media supplemented with 10%
FBS and 1% penicillin/streptomycin solution (Sigma-Aldrich). The HEK-293T-miR483
and RASMC-miR483 clonal cell lines stably expressing pre-miR-483 were established by
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hygromycin selection (100 µg/ml and 300 µg/ml, respectively). All cell types were
cultivated at 37°C in a humidified atmosphere containing 5% CO2.

2.3 FACS Analysis
After 48 hours of incubation, HA-AT1R and HA-AT2R transfected cells were
processed for a FACS Analysis. The cells were washed with PBS and treated with cell
dissociation solution for approximately 3-5 min until the cells lifted from the plate. Three
milliliters of PBS was added and the cell solution was centrifuged at 700 RPM for 5
minutes. The cells were resuspended in 500 µl 1X PBS supplemented with 3% FBS.
Twenty microliters of HA-fluorescein (FITC), High Affinity antibody (Cat. No. 1988506;
Roche Molecular Biochemicals, IN, USA) was added to an additional 500 µl of PBS
supplemented with 3% FBS. The cell suspension and HA-FITC solution were combined
and incubated in the dark with end-over-end rocking at 4°C for 30 min. The cells were
centrifuged at 700 RPM for 5 min and washed with 2 mL 1X PBS supplemented with 3%
FBS. The cells were again centrifuged at 700RPM for 5 min and washed an additional
time. The cells were resuspended in 3 mL sorting solution (1X PBS, 25 mmol HEPES),
which had been filter-sterilized, and sorted. Sorted cells, positive for HA-AT1R or HAAT2R were collected in 100-mm culture dishes containing growth medium supplemented
with 700 µg/ml of geneticin for selection. The transfection efficiency of these cells was
low, which is why the sort was necessary. The final population of cells collected
exhibited receptor expression.
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Figure 2.6. FACS analysis of transfected RASMCs. A) HA-AT1R cell sort data. B)
HA-AT2R cell sort data. Black outline around events represents the gate used for sorting.
FSC, forward scattered light; SSC, side scatter detector.
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2.4 Immunocytochemistry
Following FACS analysis, RASMCs expressing HA-AT1R or HA-AT2R was
plated onto fibronectin (Cat. No. 354008, BD Biosciences, CA, USA) coated coverslips
and placed in 6-well culture dishes.

Cells were cultured for 24 hours in DMEM

supplemented with 10% FBS and switched to serum-free DMEM 18 hours before
processing. Cells were washed twice with 1X PBS then fixed with 4% paraformaldehyde
in 1X PBS for 15 min. Cells were washed 3 times with 1X PBS for 10 min each then
permeabilized with 0.3% Triton X – 100 in 1X PBS for 20 min on ice. Cells were
blocked with 5% nonfat dry milk in 1X PBS for 1 hour at room temperature then
incubated overnight with mouse anti-HA monoclonal antibody (1:100) (Cat. No. 2362;
Cell Signaling Technologies, MA, USA) in blocking buffer at 4°C. The following day,
cells were washed and incubated with AlexaFluor 488 anti-mouse antibody (1:2000)
(Cat. No. 2350; Cell Signaling Technologies) for 1 hour at room temperature in the dark.
Cells were then washed and the coverslips were mounted onto glass slides with
Vectashield with DAPI Nucleic Acid Stain (Cat. No. H1200; Vector Laboratories, CA,
USA) for confocal microscopy.
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Figure 2.7. Expression of HA-AT1R and HA-AT2R in RASMCs. A) Confocal image
of HA-AT1R RASMCs (magnification X60). B) Confocal image of HA-AT2R RASMCs
(magnification X60).
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2.5 Ligand Treatment
When ≈70% confluent, cells were subjected to 4-hour starvation in serum-free
DMEM. Then cells were treated with either 1µM [Sar1]AngII or 1µM Losartan or
Candesartan for a 24-hour time period. Untreated controls were kept in serum-free
DMEM. After 24-hour treatment, cells were trypsinized and pelleted by centrifugation
(800 x g). The cell pellets were washed with PBS, flash-frozen in liquid nitrogen and
stored at -80°C until RNA was isolated.

2.6 Samples for miRNA Profiling
Characteristics and treatment conditions for twenty-three samples that were
included in the miRNA profiling study are shown in Table II.II. The samples include a
human embryonic kidney line expressing AT1R or AT2R, an immortalized rat aortic
smooth muscle cell (RASMC) line expressing AT1R or AT2R and a mouse atrial cell line
(HL-1) expressing AT1R (White et al., 2004). Two independent human aortic smooth
muscle cell (HASMC) samples were profiled to reduce potential bias that may result
from the variability in primary cells (passage # 2-3). Hearts were obtained from age and
gender matched transgenic (TG) mice over-expressing the human AT1R under the mouse
α-MHC promoter and corresponding littermate non-transgenic (NT) mouse lines in C3H
and C57BL/6 genetic backgrounds (n = 3 each for TG and NT), which were previously
obtained from Paradis et al (Paradis, 2000). The cardiac hypertrophy and HF phenotype
were assessed by 1) measuring the heart weight to body weight ratio, 2) measuring
ejection fraction and wall thickness by echocardiography (to monitor ejection fraction
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and wall thickness), and 3) expression of BNP as an independent marker of heart failure
as reported previously (Yue et al., 2010).

For primary comparison, correlations were made between the untreated and
ligand treated cells or between NT and TG heart tissue samples. *Biological replicates
control for biological diversity of a response, measure a quantity from different sources
under the same condition and are often more powerful. Biological replicates in this study
are defined as RNA isolated independently from multiple sources, each with a distinct
genome under the same condition, AngII-activation of the AT1R. Technical replicates are
defined as RNA isolated from an AngII-responsive source with same genome under
different treatment conditions.
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Table II.II. Characteristics of biological and technical replicates* utilized in the
microarray analysis.

Sample
ID

Cell/Tissue Type

Experimental
Condition

Measure of
AT1R Activation/Inhibition

SK-1
SK-2

HEK-AT1R
HEK-AT1R

Untreated
AngII

SK-3
SK-4
SK-5
SK-6
SK-7
SK-8
SK-9
SK-10
SK-11
SK-12

HEK-AT2R
HEK-AT2R
HASMC
HASMC
HASMC
HASMC
HASMC
HASMC
HL1-AT1R
HL1-AT1R

Untreated
AngII
Untreated
AngII
Losartan
Untreated
AngII
Losartan
Untreated
AngII

SK-13
SK-14
SK-15
SK-16
SK-17

RASMC
RASMC
RASMC
RASMC-AT1R
RASMC-AT1R

Untreated
AngII
Losartan
Untreated
AngII

SK-18
SK-19
SK-21

RASMC-AT2R
RASMC-AT2R
Whole heart
(C3H NT)
Whole heart
(C3H TG)

Untreated
AngII
Non-transgenic

Control
ERK1/2, JAK, STAT3
phosphorylation
Control
Control
ERK1/2 phosphorylation
ERK1/2 phosphorylation
Control
ERK1/2 phosphorylation
ERK1/2 phosphorylation
Control
ERK1/2, JAK, STAT3
phosphorylation
Control
ERK1/2 phosphorylation
ERK1/2 phosphorylation
Control
ERK1/2, STAT3
phosphorylation
Control
Control

Cardiac-specific
AT1R transgene
overexpression

ERK1/2, JAK, STAT3
phosphorylation, Cardiac
Hypertrophy & HF Phenotype

Non-transgenic

Control

Cardiac-specific
AT1R transgene
overexpression

ERK1/2, JAK, STAT3
phosphorylation, Cardiac
Hypertrophy & HF Phenotype

SK-22

SK-23
SK-24

Whole heart
(C57BL/6 NT)
Whole heart
(C57BL/6 TG)
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2.7 Cardiac Tissue Harvest
The C3H and C57BL/6 transgenic mouse lines over-expressing the human AT1R
under the mouse α-MHC promoter were previously described by Paradis et al (Paradis,
2000). NT and TG mice were cared for in accordance with the Guide for the Care and
Use of Laboratory Animals published by the US National Institute of Health (NIH
publication No. 85-23, revised 1996) in the Biological Resources Unit of Lerner Research
Institute. All experimental protocols described were reviewed and approved by the
Animal Care and Use Committee at the Cleveland Clinic Foundation (CCF).

Parameters of cardiac structure and function in individual mice were determined
by echocardiography and were correlated to expression of HF marker genes as previously
reported (Yue et al., 2010). Briefly, echocardiography was performed on conscious mice
without anesthetic. Doppler images were recorded using a 13 MHz linear transducer
(Vivid 7; GE-Vingmed, Horten, Norway) placed at the left sternal border of the chest and
analyzed by using Prosolv Cardiovascular Analyzer (v 3.5) software. Parameters obtained
were left ventricular (LV) mass, ejection fraction (EF), a measure of left ventricular
function; fractional shortening (FS), a measure of contractility, and wet heart
weight/body weight (HW/BW) (Yue et al., 2010). Whole hearts from C57BL/6 and C3H
mice with cardiac-specific AT1R overexpression (TG) and non-transgenic (NTG) (Yue et
al., 2010) mice were harvested. Upon removal, the heart was perfused in 0.1M KCL.
Hearts were wrapped and flash-frozen in liquid nitrogen then maintained at -80°C until
further analysis was performed.
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2.8 RNA Isolation
Total RNA was isolated from heart tissue (n = 3 each for TG and NT), utilizing
the RNeasy Fibrous Tissue Kit (Cat. No. 74704; QIAGEN) under RNase free conditions,
according to manufacturer’s protocol. Briefly, the heart was homogenized using a Mikro
Dismembrator S (Sartorious Mechatronics Corp., Bohemia, NY, USA) in the RLT buffer
with β-Mercaptoethanol added for 3 minutes at 1200 RPM. Proteinase K was added to
the homogenate and incubated at 55°C for 20 minutes. The mixture was centrifuged at
20-25°C and 5000 x g for 5 minutes. The supernatant was transferred to a clean tube and
100% ethanol was added to each lysate. The sample was transferred to a midi spin
column and centrifuged at 20-25°C and 5000 x g for 5 minutes, washed with the buffer
provided then treated with a DNase I mixture at room temperature for 15 minutes. The
column was washed and dried by centrifugation (at 20-25°C and 5000 x g) before the
RNA was eluted with RNase free water.

Total RNA was isolated from cells using the miRNeasy Mini Kit (Cat. No.
217004; QIAGEN) under RNase free conditions, according to manufacturer’s protocol.
Briefly, the cell pellet was lysed in QIAzol Lysis Reagent at room temperature for 5
minutes. To the homogenate, chloroform was added and incubated for 3 minutes at room
temperature. Following centrifugation for 15 minutes at 12,000 x g at 4°C, the upper
aqueous phase was transferred to a new tube. To this 1.5 volumes of 100% ethanol was
added and mixed and the mixture was pipetted into an RNeasy Mini spin column in a
2mL collection tube and centrifuged at > 8000 x g for 15 seconds at room temperature.
The sample was washed sequentially with buffers RWT and RPE and centrifuged for an
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additional 15 seconds at > 8000 x g each. The column was placed in a new collection
tube and centrifuged at ≥14,000 x g for 1 minute. Finally, the column was transferred to
a new 1.5mL collection tube and the RNA was eluted by centrifugation at 8000 x g in
50ul of RNase-free water.

A spectrophotometer reading was taken for each sample and a small aliquot was
run on a 1% agarose gel to ensure RNA integrity (Figure 2.8). High-quality RNA
preparations (A260/280 ratio >1.8) were submitted to the Genomics Core Facility
(http://www.lerner.ccf.org/services/gc/) for RNA processing.
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Figure 2.8. Agarose gel fractionation of RNA samples for microarray. One
microgram of total RNA was dissolved in H2O in a total volume of 20 µl. Four
microliters of 6X loading dye (Promega) was added. M, 2 µl of 1 Kb Plus DNA ladder
(Life Technologies) mixed with 14 µl of TE buffer and 4 µl of 6X loading dye. Samples
were run on a 1% agarose gel at 90 volts. Both 18S and 28S are visible on the gel for
each RNA sample isolated (1-19).
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2.9 RNA Processing and Profiling
Two separate Mouse v2 MicroRNA Expression BeadChip arrays with UDG (Cat.
No. MI-202–1124; Illumina, San Diego, CA, USA) were used for each sample, according
to the manufacturers recommendations (Illumina MicroRNA Expression Profiling Assay
Guide). This miRNA panel contained 656 assays to cover more than 96% of the miRNAs
described in the miRBase release 12 database (http://www.mirbase.org).

The

chemistry

utilized

by

the

miRNA

BeadArray

http://www.illumina.com/downloads/MicroRNAAssayWorkFlow.pdf.

is

available
Five

at

hundred

nanograms of total RNA was polyadenylated, and then converted into cDNA using a
biotinylated oligo-dT primer with a universal primer-tag sequence at its 5' end. This was
followed by annealing of a miRNA-specific oligonucleotide pool (MSO) which consists
of three parts: a universal PCR priming site at the 5' end, an address sequence
complementary to a capture sequence on the BeadArray, and a microRNA-specific
sequence at the 3' end. Extension of MSO was facilitated by addition of a polymerase, but
only if their 3' bases were complementary to the cognate sequence in the cDNA template.
Common primers were used to amplify the cDNA templates; the primer complimentary
to the BeadArray was fluorescently labeled. The single-stranded PCR product was
hybridized to the Sentrix Array Matrix (SAM), where the labeled strand binds to the bead
on the array containing the complementary address sequence. The SAMs were imaged
using an Illumina iScan Reader, which measures the fluorescence intensity at each
addressed bead location. Intensity files were analyzed using BeadStudio version 3.1.1.
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Expression levels were depicted as an average signal value and was compared with
untreated or NTG samples as baseline.

2.10 Statistical Analysis of miRNA Microarray Data
Raw data were read and preprocessed in BeadStudio and exported for further data
processing and analysis in R (www.r-project.org). Initially, three datasets were generated
for all of the samples: 1) the raw expression dataset exported directly from BeadStudio
(containing 656 genes); 2) the normalized dataset, which was obtained based on the raw
dataset after force-positive background correction, log2 transformation, and quantile
normalization (containing 655 genes); 3) the quality control (QC) filtered dataset, which
was obtained based on the normalized dataset by selecting present probes using the
detection threshold of 0.05 (containing 610 genes).

In BeadStudio, we performed one sample to one sample comparisons using
differential analysis with parameters set up as ‘quantile normalization, subtract
background’. All differential expression was compared with a reference group (Ref
Group) with Illumina custom Error Model. Raw p-values were from the Diff Pval column
of the Differential Expression Genes results. Fdr p-values were obtained by applying
multiple testing corrections using Benjamini and Hochberg False Discovery Rate (a Fdr
p-value of <0.05 was considered statistically significant).

Following quality control analysis, the expression and p-values were read in R for
further graphical representation of the results (e.g., box plot, MA plot, volcano plots,
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scatter plots). Hierarchical clustering was made on the three preprocessed datasets based
on correlation distances in all cases. Comparisons were made for all the sample pairs
(untreated versus treated) and plotted as volcano plots, showing the relationship between
–log10 (p-value) and log2 (fold change) of all the genes in each comparison. Raw pvalues and fold change were calculated.

Genes were categorized as significantly

expressed if their raw p-value was <0.001 and the fold change was > threshold or <
1/threshold. The threshold value of 1.2 – 1.3 cut-off for the threshold was adopted in our
analyses, as recommended by Illumina (Chen et al., 2008).

2.11 RT-qPCR Analysis
The miScript PCR system (Cat. No. 218073, 218060; QIAGEN) was utilized
according to the manufacturer’s protocol for miRNA validation in independent VSMC
samples treated with AngII and Candesartan (Figure 2.9 A).

Two micrograms of

template RNA was mixed with the 5x miScript RT buffer, RNase-free water, and the
miScript reverse transcriptase mix. The reaction was incubated for 60 minutes at 37°C
followed by heating the samples at 95°C for 5 minutes. For the qPCR, a reaction mix
containing 2x QuantiTect SYBR Green PCR master mix, 10x miScript Universal Primer,
10x miRNA specific primer, and RNase-free water was prepared. MiRNA-specific
primers were designed to amplify the mature miRNA (Table II.III.) The cDNA from the
reverse transcription step was dispensed into the individual wells of a 96-well PCR plate
and appropriate volumes of the reaction mix were added.

The plate was briefly

centrifuged at 1000 x g to collect the reaction at the bottom of each well and qPCR was
started using the Applied Biosystems 7500 real-time cycler (Applied Biosystems, CA,

77

USA). The thermal cycling parameters used for the qPCR reaction were an initial
denaturing step of 15 min at 95°C followed by 40 cycles of 94°C for 15 sec, 55°C for 30
sec, and 70°C for 30 sec. CT values recorded were analyzed, following normalization to
RNU6 (Cat. No. MS00033740), an endogenous control, and standardization to the
untreated samples.

The miScript PCR system (QIAGEN) was also utilized for mRNA quantitation in
VSMC-miR-483 and VSMC-vector control samples (Figure 2.9 B). Two micrograms of
template RNA was used for cDNA synthesis as detailed above. For the qPCR, a reaction
mix containing 2x QuantiTect SYBR Green PCR master mix, 10x QuantiTect Primer
Assay, and RNase-free water was prepared. The QuantiTect Primer Assays (QIAGEN)
utilized included forward and reverse primers targeting AGT (Cat. No. QT00177478),
ACE-1 (Cat. No. QT00180439), ACE-2 (Cat. No. QT02480100), AGTR2 (Cat. No.
QT01081864) (Table II.III.)

The cDNA from the reverse transcription step was

dispensed into the individual wells of a 96-well PCR plate and appropriate volumes of the
reaction mix were added. The plate was briefly centrifuged at 1000 x g to collect the
reaction at the bottom of each well and qPCR was started using the Applied Biosystems
7500 real-time cycler (Applied Biosystems). The thermal cycling parameters used for the
qPCR reaction were identical to those used for miRNA quantitation. CT values recorded
were analyzed, following normalization to GAPDH (Cat. No. QT00199633), an
endogenous control.
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The comparative CT method (ΔΔCT) of analysis was utilized to calculate fold
change in expression for all RT-qPCR data. This method involves comparing the CT
values of the samples of interest (i.e., ligand treated sample) with a control (i.e., untreated
sample). The CT values of both the control and the samples of interest are normalized to
an appropriate endogenous housekeeping gene. ΔΔCT = ΔCT sample – ΔCT reference.
Where, ΔCT sample is the CT value for any sample normalized to the endogenous
housekeeping gene and ΔCT reference is the CT value for the control also normalized to
the endogenous housekeeping gene. The fold change in gene expression is determined by
calculating 2-ΔΔCT.

For quantitation of mRNA in RASMC-AT1R, one microgram of total RNA was
used for first-strand cDNA synthesis using the First Strand cDNA Synthesis Kit for RTPCR (AMV+) (Cat. No. 11483188001; Roche Diagnostics, IN, USA). Real-time qPCR
was performed on the Applied Biosystems 7500 real-time cycler (Applied Biosystems)
using QuantiTect SYBR Green PCR kit (QIAGEN), with the primers described below
(Table II.IV.). The thermal cycling parameters used for the qPCR reaction were an initial
denaturing step of 10 min at 95°C followed by 40 cycles of 95°C for 15 sec, 60°C for 1
min. CT values recorded were analyzed, following normalization to GAPDH gene
expression.
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Figure 2.9. miScript principle. A) MiRNAs are polyadenylated by poly (A) polymerase
and subsequently converted into cDNA by reverse transcriptase with oligo-dT priming.
The cDNA is then used for real-time quantification of mature miRNA (using a miRNAspecific primer and the miScript Universal Primer). B) MiRNAs are converted into
cDNA by reverse transcriptase using both oligo-dT and random priming. The cDNA is
used for real-time quantification of mRNA (using a QuantiTect Primer Assay). From the
miScript PCR System Handbook (2nd Ed. 2009).
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Table II.III. MiRNA-specific primers.

Primer

Sequence (5’  3’)

miR-675-5p
miR-343
miR-669C
miR-467b*
miR-218-1*
miR-32
miR-682
miR-1187
miR-297b-3p
miR-188-5p
miR-106a:9.1
miR-466g
miR-325
miR-467a*, -467d*
miR-1198
miR-301b
miR-21*
miR-483-3p
miR-297c
miR-669f
miR-208a
miR-33

TGGTGCGGAAAGGGCCCA
GTCTCCCTTCATGTGCCCA
GGGGATAGTTGTGTGTGGATGT
GGGGATATACATACACACACCA
GGGAAACATGGTTCCGTCAAG
GGGGGTATTGCACATTACTAAGT
GGCTGCAGTCACAGTGAAGT
GGGGTATGTGTGTGTGTATGTG
GGGGTATACATACACACATACC
GCATCCCTTGCATGGTGGA
GGGCAAAGTGCTAACAGTGCA
GGGATACAGACACATGCACAC
GGGGTTTATTGAGCACCTCCTA
GGGGATATACATACACACACC
GTATGTGTTCCTGGCTGGC
GGGCAGTGCAATGGTATTGTC
CAACAGCAGTCGATGGGC
TCACTCCTCCCCTCCCGT
GGGGATGTATGTGTGCATGTAC
GGGGCATATACATACACACACA
GGGGATAAGACGAGCAAAAAGC
GGGGGTGCATTGTAGTTGCATT
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bp
18
19
22
22
21
23
20
22
22
19
21
21
22
21
19
21
18
18
22
22
22
22

%GC
66.67
57.90
50.00
45.46
52.39
43.48
55.01
50.00
45.46
57.90
52.39
52.39
50.00
47.62
57.90
52.39
61.12
66.67
50.00
45.46
50.00
50.00

TM
70.47
62.10
60.93
57.10
63.79
58.42
59.06
58.56
53.43
65.41
63.55
58.88
61.52
54.15
59.11
62.60
61.45
63.07
60.01
58.18
63.33
65.18

Table II.IV. Oligonucleotide primers for mRNA quantitation.

Primer
IGF2 Total
sense
IGF2 Total
antisense
IGF2 P1
sense
IGF2 P1
antisense
IGF2 P2
sense
IGF2 P2
antisense
IGF2 P3’-UTR
sense
IGF2 P3’-UTR
antisense
GAPDH
sense
GAPDH
antisense

Sequence (5’  3’)

bp

% GC

TM

CGCTTCAGTTTGTCTGTTCG

20

50.00

60.00

GCAGCACTCTTCCACGATG

19

58.00

61.00

TTGCCACACAGTTTTCCCATTT

22

41.00

64.00

TCCCAAATCAGACCCTTGTC

20

50.00

60.00

CAAGTGGATTAATTATACGCTTTCTG 26

35.00

60.00

AGAGGCGGGTAGGCTCAC

18

67.00

60.00

GCGTCCCCAGGTTTGCAGCT

20

65.00

69.09

GCGGCAGGCACAGGTGACAT

20

65.00

69.19

AGCCAAAAGGGTCATCATCTCTG

23

47.83

63.86

CATGAGTCCTTCCACGATACCAAA

24

45.84

64.38
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2.12 RNA Solution Hybridization Assay
In addition to RT-qPCR, a RNA solution hybridization assay was used to detect
and visualize miRNA expression. A DNA oligonucleotide template was designed to be
specific for miR-483-3p and contain a T7 promoter sequence at the 3’ end for the action
of RNA polymerase (Figure 2.8 A). The experimental probe was generated using the
miRvana Probe Construction kit (Cat. No. AM1550; Life Technologies) via in vitro
transcription, which resulted in a 33-nucleotide RNA probe with a 25-nucleotide
protected sequence. A positive control probe (for miR-16, provided by Life
Technologies) was generated in parallel and produced a 36-nucleotide RNA probe with a
22-nucleotide protected sequence. According to the manufacturer’s instructions, 2 µl of
T7 promoter primer, 6 µl of DNA hybridization buffer, and 100 µM of the
oligonucleotide template was mixed and heated to 70°C for 5 min. The mixture was then
left at room temperature for 5 minutes to allow hybridization to occur. To the hybridized
oligonucleotides, 2uL of 10X Klenow reaction buffer, 2uLof 10X dNTP mix, 4uL of
nuclease-free water, and 2uL of Exo-Klenow was added. The solution was mixed by
gentle pipetting and incubated at 37°C for 30 min. At room temperature, 1 µl each of the
double-stranded DNA template, 10X transcription buffer, 10 mM ATP, 10 mM GTP, and
10 mM CTP were combined. To that mixture, 10 mM 32P labeled UTP and 2 µl T7 RNA
polymerase were added. The solution was mixed by gently pipetting and incubated at
37°C for 10 min. The template DNA was removed by digesting the transcription reaction
with 1 µl DNase I at 37°C for 10 min.
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Following transcription, an equal amount of Gel Loading Buffer II was added to
the DNase-treated reaction and heated at 98°C for 3 min. The newly synthesized probe
was then gel purified at 25 mAmp. A 12% polyacrylamide gel (13x15cm x0.75mm – 7.2
g Urea, 1.5 mL 10X Tris/Borate/EDTA, 4.5 mL 40% 19 acrylamide:1 bis acrylamide, 11
mL nuclease-free water, 75 µl 10% ammonium persulfate, 15 µl TEMED). After
electrophoresis the gel fragment containing the full-length transcript was excised. One
hundred microliters of probe elution buffer was added to the gel slice and incubated at
37°C for 30 minutes. The probe elution buffer, containing the eluted RNA was
transferred to a clean microfuge tube and the elution step was repeated with an additional
100 µl of probe elution buffer. The elution fractions were pooled and the cpm/µl of the
recovered RNA was determined by scintillation counting.

For hybridization of the miR-483-3p-specific probe in total RNA samples isolated
from cells of interest, we utilized the miRvana miRNA Detection Kit (Cat. No. AM1552;
Life Technologies) according to the manufacturer’s instructions.

A master mix

containing, 10 µl of 2X hybridization buffer, 5 x 104 cpm of labeled RNA probe, 2 µg
sample RNA, enough yeast RNA to make 5 µg total RNA, and nuclease-free water up to
20 µl was prepared.

Two no-target controls were also prepared for each RNA probe.

These consisted of 5 x 104 cpm labeled probe, 5 µg yeast RNA, 10 µl 2X hybridization
buffer, and nuclease-free water up to 20 µl. The experimental and control tubes were
heated at 98°C for 3 min and then incubated at 42°C overnight to allow hybridization to
occur.

84

Excess probe and unhybridized temple RNA was digested with 150 µl RNase
A/T1 (1:100 dilution in RNase digestion buffer) at 37°C for 45 min the following day.
One control (for each RNA probe) was not RNase digested. The RNase was inactivated
with RNase inactivation/PPT solution and the probe and hybridized target were
precipitated with 100% ethanol at -20°C for 1 hour. The samples were centrifuged at 10,
000 x g for 15 min at 4°C and the supernatant was carefully removed. The protected
fragments were air dried for 10 min at room temperature before suspending in gel loading
buffer. For experimental samples and the RNase digested controls, the pellets were
resuspended in 5 µl of buffer. For the undigested control, the pellet was resuspended in
10 µl of buffer and then diluted 1:4 in addition loading buffer. Each tube was vortexed
for 15 sec then incubated at 98°C for 3 min. Each sample was loaded into a pre-run 15%
denaturing polyacrylamide gel. The gel was exposed to an intensifying screen overnight
at room temperature and imaged the following day using a Storm 860 Phosphorimager
(GE Healthcare Life Sciences, PA, USA). Mean band intensity values were determined
using the ImageQuant TL Software (v. 2003.03; GE Healthcare Life Sciences) for all
samples.
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Figure 2.10. Detection of short RNA molecules by solution hybridization. A) The
DNA oligonucleotide template was designed to be specific to miR-483-3p (magenta)
with an 8 base T7 promoter sequence at the 3’ end (green). The stretch of T residues
(blue) will generate an antisense RNA probe with a stretch of As, which can’t be cleaved
by RNase A/T. In vitro transcription generated a probe specific for miR-16 and a probe
specific for miR-483-3p. B) Hybridization of the radiolabeled RNA probes was carried
out in a step-wise fashion, which resulted in detection of miR-483-3p that could be
visualized on a denaturing polyacrylamide gel.
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2.13 Pharmacological Kinase Inhibition
RASMC-AT1R cells subjected to serum starvation were treated with individual
kinase inhibitors for a 1-hour period. Inhibitors to PKC (5µM – 1-O-Hexadecyl-2-Omethyk-rac-glycerol, Santa Cruz Biotechnology, Santa Cruz, CA, USA), MEK1 (10µM –
PD98059, Cell Signaling Technology), JAK (5µM – JAK Inhibitor 1; EMD Chemicals,
Darmstadt, Germany), JNK (1µM SP600125, A.G.Scientific, San Diego, CA, USA), and
p38 (1µM – SB203580; Cell Signaling Technology) were reconstituted in DMSO.
Following kinase inhibition, the cells were treated with 1µM [Sar1]-AngII for 5 minutes
and then harvested (see 3.3 for specific details). For RNA isolation, the cells were treated
for 24-hour with 1µM [Sar1]-AngII.

2.14 Protein Isolation
Cells were placed on ice and washed three times with PBS, scraped from the
plate, and pelleted by centrifugation at 3900 RPM for 5 min at 4°C. Cells were lysed in
1mL 1X PBS, containing 50µl PopCulture Reagent (Cat. No. 71187; Novagen,
Darmstadt, Germany), 100 U of Benzonase Nuclease (Cat. No. 70664; Novagen), 100X
protease inhibitor cocktail (Cat. No. P8340; Sigma-Aldrich), and 100X phosphatase
inhibitor cocktail (Cat. No. 78426; Thermo Scientific, Rockford, IL, USA). The lysates
were incubated on ice for one hour then a standard Bradford Assay for protein estimation
was performed using bovine serum albumin (BSA) as a concentration standard.
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2.15 Analysis of ERK1/2 and STAT3 Phosphorylation
Fifty µg of total protein isolated from RASMC-AT1R cells was used for the
Western blotting assay. Fractions were boiled for 5 minutes and separated by SDS-PAGE
(10%), and transferred onto a nitrocellulose membrane. After blocking in 150 mM of
NaCl buffered with 10 mM of Tris and containing 0.1% Tween 20 and 5% milk powder,
the membrane was incubated overnight in primary antibody specific for phospho-ERK
44/42MAPK (Cat. No. 4370; Cell Signaling Technology) or phospho-STAT3 (Y705) (Cat.
No. 9131; Cell Signaling Technology). The membrane was washed and then incubated in
1:5000 diluted IgG secondary antibody labeled with HRP for 1h. Using ECL Plus
Western Blotting Reagent (GE Healthcare Life Sciences) specific bands were detected.
The same blots were subsequently stripped and re-probed for total ERK 44/42MAPK (Cat.
No. 9102; Cell Signaling Technologies) and total STAT3 (Cat. No. 9139; Cell Signaling
Technology). Densitometry analysis was performed for each experiment. Mean band
intensity values (of phosphorylation activity) were determined using the Kodak 1D
®

Image Analysis Software (Version 3.6.5 K2 – 1B5331010; Eastman Kodak Company,
Rochester, NY, USA). Phospho-ERK1/2 and phospho-STAT3 values were normalized
to the total protein for each and compared to the untreated controls to determine the
percent kinase inhibition.

2.16 MiRNA Target Prediction
MiRNAs represent an important class of small non-coding RNAs that regulate
gene expression by targeting messenger RNAs. Various Internet-based databases exist,
of which 4 were utilized for this study that allow for determining potential mRNA targets
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of known miRNAs. TargetScan is based on conserved seed pairing of miRNAs to their
targets in animals (Lewis et al., 2005). DIANA-microT 3.0 is an algorithm based on
several parameters calculated individually for each microRNA and it combines conserved
and non-conserved microRNA recognition elements into a final prediction score
(Maragkakis et al., 2009). The PITA database incorporates the role of target-site
accessibility, as determined by base-pairing interactions within the mRNA, in microRNA
target recognition (Kertesz et al., 2007). Microcosm Targets uses the miRanda algorithm
to identify potential binding sites for a given miRNA in genomic sequences. The current
version uses dynamic programing alignment to identify highly complementary sites
(Griffiths-Jones et al., 2006).

The

3’-UTR

of

Renin

(ENSG00000143839),

Renin

Receptor

(ENSG00000182220), AGT (ENSG00000135744), ACE-1 (ENSG00000159640), ACE2

(ENSG00000130234),

(ENSG00000144891),

Chymase
AGTR2

1

(CMA1;

ENSG00000092009),

(ENSG00000180772),

AT4

AGTR1
Receptor

(ENSG00000113441), and Ang(1-7) Receptor (ENSG00000130368) was uploaded into
each of the above described databases. The miRNAs that were predicted to bind as well
as the region to which they would bind were recorded.

2.17 Luciferase Reporter Assay
Changes in luciferase gene expression were measured using the Dual-Glo
Luciferase Assay System (Cat. No. E2920; Promega). The principle of luciferase gene
expression is detailed in Figure 2.10. Cells were grown in 6-well culture dishes. Forty-
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eights hours following transfection of the psiCHECK-2-3’-UTR DNA constructs, the
cells were trypsinized, re-suspended in culture medium, and counted using the
Cellometer. The cells were then seeded onto a poly-L-lysine coated 96-well, white, flatbottom culture plate. Approximately 50,000 cells suspended in 50 µl of culture medium
were plated per well and in triplicate. An additional 50 µl of medium was added to the
wells and the cells were allowed to adhere overnight.

The following day, 75 µl of Dual-Glo Luciferase Assay Reagent was added to
each well and incubated with gently rocking for 1 hour at room temperature. Relative
luminescence units (RLUs) for Firefly were read using the FlexStation 3 Multi-Mode
Microplate Reader (Molecular Devices, LLC, CA, USA) at 0.5 sec integration and from
the bottom of the plate. Immediately following completion of the first luminescence
reaction, 75 µl of Dual-Glo Stop and Glo reagent was added to each well. The plate was
incubated with gentle rocking for 1 hour at room temperature. Renilla luminescence was
then read. The ratio of Firefly to Renilla luminescence was calculated for each well. The
ratio of the sample well(s) was normalized to the ratio of the control well(s).

91

Figure 2.11. Principle of luciferase gene expression. A) The psiCHECK-2 vector
facilitates monitoring of changes in expression of a target gene fused to a reporter gene.
Renilla luciferase is used as the primary reporter gene, and the 3’UTR is cloned into a
multiple cloning region located downstream of the Renilla translational stop codon.
Initiation of the RNAi process by synthetic miRNAs results in cleavage and subsequent
degradation of the fused mRNA target. Measuring decreases in Renilla activity provides
a convenient way of monitoring the RNAi effect. A second reporter gene, firefly
luciferase allows normalization of Renilla luciferase expression. From Promega product
resources. B) Biochemistry of firefly and Renilla luciferase expression. Converting the
chemical energy of luciferin oxidation through an electron transition, forming the product
molecule oxyluciferin, produces light. Firefly luciferase, a monomeric 61kDa protein,
catalyzes luciferin oxidation using ATP-Mg2+ as a cosubstrate. Likewise, Renilla
luciferase, a monomeric 36kDa protein, catalyzes coelenterazine oxidation by oxygen to
produce light.
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2.18 Analysis of Endogenous RAS Components
Fifty µg of total protein isolated from RASMC-miR483 cells was used for the
Western blotting assay. Fractions were boiled for 5 minutes and separated by SDS-PAGE
(10%), and transferred onto a nitrocellulose membrane. After blocking in 150 mM of
NaCl buffered with 10 mM of Tris and containing 0.1% Tween 20 and 5% milk powder,
the membrane was incubated overnight in primary antibody specific for AGT (Cat. No.
ab108334; Abcam, MA, USA), ACE-1 (Cat. No. ab134709; Abcam), ACE-2 (Cat.
No.AF933 R & D Systems, MN, USA and Cat. No. ab108252; Abcam) or AGTR2 (Cat.
No. AT21-A and AT22-A; Alpha Diagnostic International, TX, USA). The membrane
was washed and then incubated in 1:5000 diluted IgG secondary antibody labeled with
HRP for 1h.

Using ECL Plus Western Blotting Reagent (Amersham Biosciences)

specific bands were detected. The same blots were subsequently stripped and re-probed
for actin (Cat. No. MAB1501; Millipore, MA, USA). Densitometry analysis was
performed for each experiment. Mean band intensity values were determined using the
Kodak 1D Image Analysis Software (Eastman Kodak Company). Total protein values
®

were normalized to actin and compared to the vector control samples.

2.19 Wound Healing Assay
The wound-healing assay was performed using Ibidi silicone culture inserts (Cat.
No. 80241; Ibidi, LLC, WI, USA) according to the manufacturer’s instructions. The
silicone insert creates a 500 µm cell-free gap (Figure 2.12. A). Following coating with
fibronectin, the wells of a 6-well plate were washed twice with 1X PBS and the insert
was adhered. Cells were trypsinized, counted, and resuspended in growth medium.
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Approximately 7 x 105 cells in 70 µl of medium were seeded into each well of the insert
and allowed to attach overnight.

The following day, the insert was removed with

sterilized forceps and the cells were washed gently with 1X PBS three times. The cells
were cultured in medium supplemented with 0.5% FBS and 1% penicillin/streptomycin,
in addition to 1 µM [Sar1]AngII and/or 1 µM Candesartan.

The progression of wound healing was monitored over a 24-hour period of time
using a Leica DMI6000 inverted microscope (at 10X magnification) equipped with dual
Hamamatsu cameras (ImageEM and Orca-R2) EM-CCD, an environmental chamber
(heat/CO2 incubator), and a motorized stage for capturing multiple time-lapse fields
simultaneously. Images were collected in transmitted light mode every 15 minutes at five
different locations along the wounded area. The area of the wound at time zero and 8
hours compared to the total area was quantified using ImagePro Plus 7.0 (Media
Cybernetics, MD, USA) (Figure 2.12 B). Briefly, the images were processed using the
large spectral filter and converted to grayscale. Additionally, each image was processed
for morphological characteristics to fill the gaps and enlarge protrusions to connect
objects that are close together. The cell-free area and the area containing cells were
measured for each image. The percent wound area was normalized to the total area for
each image.
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Figure 2.12. Wound-healing principle and analysis. A) The Ibidi silicone insert creates
a 500 µm defined cell-free gap that prevents leakage during cultivation and no material
being left behind after the insert’s removal. B) The area of the wound at time zero and 8
hours compared to the total area was quantified for each image (red).
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2.20 Statistical Analysis
All data are expressed as mean ± SEM (n = 3 experiments performed under
identical conditions). Statistical analyses were performed using GraphPad Prism© with an
unpaired Student t-test. A p-value <0.05 was considered statistically significant.
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CHAPTER III
GLOBAL MIRNA EXPRESSION PROFILING

3.1 Introduction
In order to fully understand AT1R-mediated gene expression, the expression
profile of miRNAs in various tissues and disease states must be elucidated.

Of

significant importance is documenting the AngII-regulated miRNA profile for
cardiovascular cells, as a means to enhance our knowledge of AngII biology. This study
was designed for global miRNA expression profiling in biological replicates following
chronic AngII activation.

It is estimated that a single miRNA orchestrates post-transcriptional regulation of
≈100-200 genes in a cell, either by inhibiting the translation or by promoting the
degradation of specific target mRNAs. A comprehensive knowledge of AngII-regulated
miRNAs is therefore exceedingly useful in the context of RAS physiology and pathology.
The miRNA profiles presented here may bridge the gap in our knowledge concerning the
molecular basis of pathogenesis during chronic RAS activation, which increases

angiotensinergic risk associated with morbidity and mortality from cardiovascular
diseases. In many clinical settings, targeting RAS is an important therapeutic paradigm.
Our study provides insights regarding how RAS-targeted therapies may affect miRNAs.

3.2 Distinct AngII-regulated miRNA Expression Profiles
We performed a genome-wide comparative analysis of miRNA expression in 23
small RNA libraries prepared from mice hearts (Yue et al., 2010) and cell types of human
or rodent origins (Table II.II. for sample details). Selection of these samples resulted in
adequate biological and technical replicates for making global comparisons. The
comparisons of the cardiac HL-1 line and heart tissue, HL-1 and VSMCs, VSMCs from
different species (i.e., human and rat), and cell lines from three species (i.e., human, rat
and mouse) served as biological replicates. As indicated in Table II.II, in all of the
biological replicates exposure to AngII led to activation of AT1R-mediated signal
transduction involving the JAK2/STAT3 and the ERK1/2 pathways (Figure 3.1). Samples
not treated with AngII or treated with AT1R-specific inhibitors (Losartan or Candesartan)
and angiotensinergic stimulation through the AT2R are technical replicates included in
the analysis for validating the AT1R-specific regulation of miRNAs. Each library was
constructed from high-quality RNA preparations.

Figure 3.1. Measure of AT1R activation and inhibition. A) The signal transduction
pathway activation of the AT1R by AngII. B) Activation of the receptor was confirmed
by ERK1/2 phosphorylation (pERK1/2) and in some cases, JAK2-mediated STAT3
phosphorylation (pSTAT3), following treatment with 1 µM AngII. In addition, inhibition
of AT1R signaling was monitored in the presence of the AT1R specific antagonist,
losartan or the AT1R specific inverse agonist, candesartan. Total ERK1/2 (tERK1/2) and
total STAT3 (tSTAT3) are shown as loading controls.

Under angiotensinergic stimulation, the miRNA expression profiling microarray
data obtained from these samples was quantile normalized, background corrected, and
log2 transformed (see methods). In addition, quality control measures were taken for
selecting probes, using the detection threshold of p < 0.05. Altogether 655 miRNAs were
detected in our array analysis, of which 610 miRNAs met quality control measures
described in the methods. AngII regulated the expression of 468 miRNAs in all samples.

Most AngII-regulated miRNAs are evolutionarily conserved in related species
and some even show conservation between invertebrates and vertebrates (Pasquinelli et
al., 2000, Lagos-Quintana et al., 2001, Lau et al., 2001, Lee and Ambros, 2001). Our data
provide evidence for AngII-regulated expression of 323 human, 334 mouse, and 109 rat
miRNAs. When orthology relationships for these miRNAs are evaluated, 355 miRNA
genes appear to be AngII-responsive in the mouse and rat genomes. Importantly, 237 of
the AngII-regulated miRNA genes expressed in mouse and rat have human orthologs (as
determined from miRBase 19). Of these, 168 human orthologs are clearly responsive to
AngII in the two human cell types analyzed, demonstrating that genome-wide AngIIregulation of miRNA expression is robust.

Global trends evident in the miRNA expression array data are highlighted in
Figure 3.2. The heat map shown, includes 468 miRNAs, which are significantly altered in
at least one of the 13 experimental comparisons shown. A non-redundant set of 357
miRNAs appeared in two or more models listed in Table II.II and 111 miRNAs are
unique to a cell type or a treatment condition. The comparison showed that 52% of the
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microRNAs were downregulated, while 48% of the microRNAs were upregulated. The
miRNA number observed as a differential response in transgenic mouse hearts [192 and
166], HASMCs [181], and HL-1-AT1R cells [144] is comparable to the response detected
in the engineered HEK- kidney cell line [233]. The number of AngII-responsive miRNAs
in the immortalized RASMC line [60] is lower and is slightly increased [70] upon AT1R
overexpression (Tables III.I. – III.VII.).
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Figure

3.2.

Heat

map

depicting

miRNA

expression across AngII activated samples. Fold
change

in

miRNA

gene

expression

between

untreated and AngII/AT1R samples (columns 1-8). In
addition, comparisons for untreated and Losartan
treated samples (columns 9-11) and untreated and
AngII/AT2R samples (columns 12 and 13) are shown
as controls. A blue color indicates that the miRNA
is downregulated in response to the treatment
condition

(see

Table

1

for

descriptions

of

treatments). A red color indicates that the miRNA is
upregulated. The gradient scale above depicts all
colors within the expression range, +4 to -4 fold
change. The numbers at the bottom of each column
indicates the number of miRNAs differentially
regulated in a specific treatment condition.
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Table III.I. AngII responsive miRNAs in transgenic mouse hearts (C57BL/6).

let-7b*
let-7c-1*
let-7e
let-7g*
let-7i*
miR-106a:9.1
miR-10a
miR-10b*
miR-1186
miR-1191

miR-1192
miR-1198
miR-122
miR-124
miR-125a-3p
miR-125b*
miR-127*
miR-128
miR-128a:9.1
miR-129-3p

miR-130b
miR-130b*
miR-134
miR-141
miR-142-3p
miR-142-5p
miR-144
miR-144:9.1
miR-145*
miR-146a

miR-146b
miR-147
miR-153
miR-154
miR-155
miR-15a*
miR-15b*
miR-16*
miR-181a-2*
miR-181c

miR-181d
miR-185
miR-187
miR-188-5p
miR-18b
miR-191*
miR-193b
miR-194
miR-196a
miR-200b

miR-200c
miR-201
miR-203
miR-206
miR-208b
miR-20a*
miR-21*
miR-214*
miR-218
miR-221

miR-222
miR-224
miR-24-1*
miR-25
miR-26b*
miR-27b*
miR-28*
miR-297a
miR-297c*, a*
miR-299*

miR-29b*
miR-301a
miR-30a*
miR-30b*
miR-30c-1*
miR-30e*
miR-31*
miR-32
miR-320
miR-324-3p

miR-326
miR-33
miR-33*
miR-330
miR-331-3p
miR-335-3p
miR-335-5p
miR-337-3p
miR-337-5p
miR-338-3p

miR-342-5p
miR-343
miR-345-3p
miR-34b-3p
miR-34b-5p
miR-34c
miR-34c*
miR-362-3p
miR-362-5p
miR-365

miR-375
miR-376a
miR-376b
miR-376b*
miR-376c
miR-377
miR-378*
miR-381
miR-409-5p
miR-411

miR-423-3p
miR-423-5p
miR-425*
miR-434-3p
miR-434-5p
miR-450b-3p
miR-455
miR-465c-5p
miR-466a-5p
miR-466c-5p

miR-466d-3p
miR-466f
miR-466g
miR-466h
miR-466i
miR-467a
miR-467a*, d*
miR-467c
miR-467e
miR-467f

miR-467h
miR-489
miR-494
miR-495
miR-497
miR-500
miR-501-3p
miR-501-5p
miR-503
miR-504

miR-505
miR-542-3p
miR-547
miR-574-3p
miR-582-3p
miR-582-5p
miR-592
miR-615-3p
miR-669d
miR-669f

miR-671-3p
miR-674
miR-675-3p
miR-676
miR-676*
miR-677
miR-683
miR-685
miR-689
miR-700

miR-708
miR-709
miR-744
miR-744*
miR-770-5p
miR-7a
miR-7a*
miR-7b
miR-801:9.1
miR-872

miR-874
miR-877*
miR-878-5p
miR-9
miR-9*
miR-93*
solexa-103-3961
solexa-1278-371
solexa-1328-360
solexa-1780-267

solexa-1837-257
solexa-200-2167
solexa-201-2163
solexa-2564-185
solexa-27-9416
solexa-284-1594
solexa-3062-153
solexa-308-1456
solexa-3253-144
solexa-4153-111

solexa-4179-110
solexa-622-718
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Table III.II. AngII responsive miRNAs in transgenic mouse hearts (C3H).

let-7b*
let-7i*
miR-1
miR-101a
miR-101a*
miR-101a:9.1
miR-101b
miR-106a
miR-106b
miR-106b*

miR-107
miR-10b
miR-1187
miR-1198
miR-122
miR-125b-3p
miR-128
miR-128a:9.1
miR-129-5p
miR-133a*

miR-137
miR-138
miR-139-3p
miR-140
miR-142-3p
miR-146a
miR-146b
miR-154
miR-17
miR-181a-1*

miR-181a-2*
miR-181b
miR-181d
miR-182
miR-183
miR-184
miR-18a*
miR-190
miR-191*
miR-193

miR-193*
miR-196a
miR-199a-3p
miR-199a-5p
miR-199b, b,*
miR-19a
miR-200c
miR-201
miR-204
miR-206

miR-208a
miR-20b
miR-21
miR-210
miR-212
miR-214*
miR-215
miR-217
miR-218
miR-221

miR-222
miR-224
miR-26b*
miR-291b-5p
miR-296-5p
miR-297a
miR-29a*
miR-29c
miR-301a
miR-30b*

miR-30c-1*
miR-30c-2*
miR-31
miR-322*
miR-324-5p
miR-330
miR-330*
miR-335-3p
miR-335-5p
miR-337-5p

miR-338-3p
miR-338-5p
miR-340-3p
miR-342-3p
miR-343
miR-345-3p
miR-346
miR-34a
miR-34b-3p
miR-34b-5p

miR-34c
miR-34c*
miR-351
miR-362-5p
miR-409-3p
miR-411*:9.1
miR-421
miR-423-5p
miR-425
miR-433

miR-490
miR-497
miR-501-5p
miR-503
miR-503*
miR-504
miR-505
miR-541
miR-582-3p
miR-582-5p
miR-615-3p
miR-668
miR-669c
miR-669d

miR-669f
miR-672
miR-673-5p
miR-674*
miR-675-3p
miR-689
miR-699
miR-703
miR-708
miR-709
miR-712
miR-715
miR-770-5p
miR-7a

miR-7a*
miR-801:9.1
miR-872*
miR-874
miR-877
miR-877*
miR-92b
miR-93
miR-93*
miR-99b*
solexa-03-3961
solexa-1201-400
solexa-1278-371
solexa-130-3526

miR-434-3p
miR-450a-5p
miR-450b-3p
miR-451
miR-455*
miR-466d-3p
miR-466f
miR-467a*, d*
miR-467c
miR-467h
miR-470
miR-483
miR-483*
miR-485*
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solexa-1328-360
solexa-1837-257
solexa-231-1844
solexa-308-1456
solexa-4153-111
solexa-447-1003
solexa-5306-86
solexa-783-586

Table III.III. AngII responsive miRNAs in primary HASMC culture.

let-7f*
let-7g*
let-7i*
miR-101a
miR-101a*
miR-101b
miR-101b:9.1
miR-106a:9.1
miR-106b*
miR-107

miR-10a*
miR-10b*
miR-1186
miR-1187
miR-1198
miR-1224
miR-125a-3p
miR-125b*
miR-126-3p
miR-129-3p

miR-130b
miR-132
miR-133a
miR-138
miR-141
miR-142-5p
miR-144:9.1
miR-145*
miR-146a
miR-146b

miR-193*
miR-194
miR-195
miR-196a
miR-196b
miR-197
miR-19a
miR-19a*
miR-19b
miR-201

miR-204
miR-206
miR-208a
miR-20b
miR-21*
miR-210
miR-212
miR-214*
miR-219
miR-22*

miR-224
miR-29b
miR-24-1*
miR-29b*
miR-24-2*
miR-29c*
miR-26b*
miR-301b
miR-27a*
miR-30a
miR-27b*
miR-30a*
miR-28*
miR-30b*
miR-293
miR-30c-1*
miR-297a
miR-30c-2*
miR-297c*, a*, b-3pmiR-30d

miR-32
miR-320
miR-324-5p
miR-325
miR-325*
miR-326
miR-33
miR-33*
miR-330
miR-331-3p

miR-331-5p
miR-335-5p
miR-337-5p
miR-339-3p
miR-339-5p
miR-340-3p
miR-340-5p
miR-342-5p
miR-345-3p
miR-345-5p

miR-34a
miR-34b-3p
miR-34b-5p
miR-34c
miR-34c*
miR-362-3p
miR-362-5p
miR-378
miR-384-3p
miR-384-5p

miR-423-3p
miR-423-5p
miR-449a
miR-450b-3p
miR-451
miR-465c-5p
miR-466a-5p
miR-466f
miR-466f-3p
miR-466g

miR-466i
miR-467a
miR-483*
miR-484
miR-489
miR-491
miR-497
miR-499
miR-501-5p
miR-503

miR-503*
miR-532-5p
miR-504
miR-542-5p
miR-509-5p
miR-574-5p
miR-582-5p
miR-592
miR-598
miR-615-5p

miR-652
miR-674
miR-675-5p
miR-676
miR-679
miR-682
miR-685
miR-690
miR-694
miR-703
miR-706

miR-709
miR-718
miR-720
miR-760
miR-7a*
miR-7b
miR-801:9.1
miR-872
miR-874
miR-877*
miR-878-5p

miR-9
miR-92b
miR-93
miR-96
miR-99a
miR-99b
miR-99b*
solexa-103-3961
solexa-1201-400
solexa-1328-360
solexa-173-2522

solexa-1780-267
solexa-1837-257
solexa-200-2167
solexa-2011-236
solexa-231-1844
solexa-239-1823
solexa-2564-185
solexa-27-9416
solexa-3062-153
solexa-308-1456
solexa-3253-144

solexa-403-1161
solexa-4153-111
solexa-4179-110
solexa-447-1003
solexa-622-718
solexa-783-586
solexa-897-515
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miR-146b*
miR-149
miR-150
miR-16*
miR-181a-1*
miR-181b
miR-181c
miR-181d
miR-182
miR-183

miR-185
miR-186
miR-187
miR-188-3p
miR-188-5p
miR-18a*
miR-18b
miR-191*
miR-192
miR-193

Table III.IV. AngII responsive miRNAs in HL-1-AT1R cell line.

let-7f*
let-7i*
miR-1
miR-101a
miR-101a:9.1
miR-107
miR-10a
miR-1187
miR-1191
miR-1196

miR-1198
miR-125a-3p
miR-125b*
miR-125b-3p
miR-126-3p
miR-128
miR-129-3p
miR-130b
miR-133a*
miR-133b

miR-138
miR-139-5p
miR-140*
miR-141
miR-150
miR-15a*
miR-16*
miR-181a-1*
miR-181a-2*
miR-181b

mmu-miR-181c
mmu-miR-183*
mmu-miR-188-3p
mmu-miR-188-5p
mmu-miR-190b
mmu-miR-191*
mmu-miR-192
mmu-miR-194
mmu-miR-196a
mmu-miR-196b

miR-199a-3p:9.1
miR-199b*
miR-19a
miR-19a*
miR-19b
miR-200a
miR-208a
miR-20a*
miR-21*
miR-210

miR-219
miR-22*
miR-24-1*
miR-24-2*
miR-27a*
miR-27b*
miR-28*
miR-29a*
miR-29b
miR-29b*

miR-301a
miR-301b
miR-30b*
miR-32
miR-33
miR-33*
miR-330
miR-331-3p
miR-335-5p
miR-339-3p

miR-339-5p
miR-340-5p
miR-342-5p
miR-343
miR-345-3p
miR-345-5p
miR-34b-5p
miR-34c
miR-362-5p
miR-365

miR-378
miR-421
miR-423-3p
miR-423-5p
miR-425*
miR-450b-5p
miR-463*
miR-465a-3p family
miR-465a-5p
miR-465b-5p

miR-465c-5p
miR-466f-3p
miR-467f
miR-470
miR-471
miR-471:9.1
miR-486
miR-490
miR-491
miR-497

miR-499
miR-500
miR-503
miR-505
miR-542-3p
miR-671-3p
miR-677
miR-684
miR-690
miR-699

miR-709
miR-715
miR-741
miR-742
miR-743b-3p
miR-770-5p
miR-801:9.1
miR-802
miR-871
miR-872

miR-873
miR-878-3p
miR-878-5p
miR-880
miR-9
miR-9*
miR-92b
miR-96
miR-99b*
solexa-103-3961

solexa-1201-400
solexa-1278-371
solexa-130-3526
solexa-173-2522
solexa-1837-257
solexa-201-2163
solexa-231-1844
solexa-2564-185
solexa-4153-111
solexa-447-1003

solexa-5067-90
solexa-622-718
solexa-783-586
solexa-897-515

Table III.V. AngII responsive miRNAs in HEK-AT1R kidney cell line.
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let-7b*
let-7d*
let-7f*
let-7g*
let-7i
let-7i*
miR-101b
miR-106a:9.1
miR-107
miR-10a*

miR-10b*
miR-1186
miR-1187
miR-1192
miR-1197
miR-1224
miR-124
miR-125b*
miR-128
miR-128a:9.1

miR-129-3p
miR-129-5p
miR-132
miR-134
miR-135b
miR-137
miR-138
miR-138*
miR-139-5p
miR-140

miR-141
miR-142-3p
miR-142-5p
miR-143
miR-144
miR-144:9.1
miR-145
miR-146b*
miR-147
miR-150

miR-154
miR-154*
miR-155
miR-16*
miR-17*
miR-183*
miR-184
miR-187
miR-188-3p
miR-18a*

miR-190
miR-190b
miR-191*
miR-192
miR-193
miR-193b
miR-194
miR-195
miR-196a*
miR-199a-5p

miR-19a*
miR-200a
miR-200b
miR-200b*
miR-200c*
miR-203
miR-204
miR-208b
miR-20b
miR-21*

miR-210
miR-211
miR-212
miR-214*
miR-215
miR-216b
miR-217
miR-22*
miR-223
miR-23a

miR-24-1*
miR-24-2*
miR-26b*
miR-27a*
miR-27b*
miR-28*
miR-290-3p
miR-291a-3p
miR-293
miR-295*

miR-296-3p
miR-296-5p
miR-297a
miR-299
miR-299*
miR-29a
miR-29a*
miR-29b*
miR-29c*
miR-302b

miR-30a
miR-30b*
miR-30c-1*
miR-30c-2*
miR-32
miR-323-3p
miR-324-5p
miR-328
miR-33
miR-33*

miR-330
miR-330*
miR-331-3p
miR-335-3p
miR-335-5p
miR-337-5p
miR-338-3p
miR-338-5p
miR-339-3p
miR-341:9.1

miR-342-5p
miR-345-3p
miR-345-5p
miR-34a
miR-34b-3p
miR-34c
miR-362-3p
miR-362-5p
miR-363
miR-369-3p

miR-369-5p
miR-375
miR-376a*
miR-376b
miR-376c
miR-376c*
miR-377
miR-379
miR-381
miR-382

miR-382*
miR-409-3p
miR-409-5p
miR-410
miR-411
miR-411*:9.1
miR-423-5p
miR-449b
miR-450b-3p
miR-451

miR-465c-5p
miR-466a
miR-466f
miR-466h
miR-467a
miR-467h
miR-485*
miR-486
miR-487b
miR-494
miR-495
miR-497
miR-499
miR-501-5p
miR-503
miR-532-3p
miR-539

miR-540-3p
miR-540-5p
miR-542-3p
miR-542-5p
miR-543
miR-551b
miR-551b:9.1
miR-574-5p
miR-582-3p
miR-592
miR-615-3p
miR-615-5p
miR-652
miR-653
miR-654-3p
miR-654-5p
miR-667

miR-668
miR-671-5p
miR-676
miR-679
miR-684
miR-690
miR-692
miR-694
miR-702
miR-703
miR-706
miR-707
miR-708
miR-715
miR-718
miR-719
miR-744*

miR-760
miR-762
miR-7b
miR-801:9.1
miR-872*
miR-873
miR-874
miR-878-3p
miR-878-5p
miR-879
miR-92b
miR-96
miR-98
miR-99a
miR-99b*
solexa-103-3961
solexa-173-2522

solexa-1837-257
solexa-200-2167
solexa-2011-236
solexa-201-2163
solexa-2054-231
solexa-2564-185
solexa-3062-153
solexa-403-1161
solexa-4153-111
solexa-4179-110
solexa-5067-90
solexa-5593.81
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Table III.VI. AngII responsive miRNAs in immortalized RASM cell line.

let-7i*
miR-101a*
miR-107
miR-1198
miR-125a-3p
miR-128
miR-129-3p
miR-138
miR-142-3p
miR-146a
miR-17*
miR-188-5p

miR-19a*
miR-214*
miR-218-1*
miR-24-1*
miR-26b*
miR-32
miR-322*
miR-324-5p
miR-33
miR-330
miR-330*
miR-331-3p

miR-331-5p
miR-345-5p
miR-34a
miR-34b-3p
miR-34b-5p
miR-34c
miR-449a
miR-449b
miR-450b-3p
miR-466h
miR-503*
miR-504
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miR-532-3p
miR-542-5p
miR-551b
miR-551b:9.1
miR-615-5p
miR-652
miR-684
miR-685
miR-706
miR-709
miR-7a*
miR-801:9.1

miR-872
miR-874
miR-99b*
solexa-103-3961
solexa-1837-257
solexa-201-2163
solexa-308-1456
solexa-4153-111
solexa-4179-110
solexa-447-1003

Table III.VII. AngII responsive miRNAs in RASMC-AT1R cell line.

let-7b*
met-7i*
miR-101a*
miR-106a:9.1
miR-10a*
miR-1186
miR-1187
miR-1198
miR-125b*
miR-141
let-7b*
let-7i*
miR-142-5p
miR-149
miR-17*
miR-184
miR-187

miR-188-5p
miR-193
miR-194
miR-196b
miR-20b
miR-142-5p
miR-149
miR-21*
miR-212
miR-217
miR-224
miR-27a*
miR-297c
miR-297c*, a*, b-3p
miR-301b
miR-325
miR-330*

miR-21*
miR-212
miR-335-3p
miR-335-5p
miR-339-3p
miR-345-5p
miR-34a
miR-425*
miR-450b-3p
miR-450b-5p
miR-466f
miR-466f-3p
miR-335-3p
miR-335-5p
miR-466g
miR-466h
miR-466k

110

miR-467a*, d*
miR-467b*
miR-483*
miR-489
miR-500
miR-501-5p
miR-503*
miR-615-5p
miR-669c
miR-669f
miR-685
miR-709
miR-760
miR-872
miR-874
miR-877*
miR-878-5p

miR-92b
miR-99b*
solexa-103-3961
solexa-1201-400
solexa-173-2522
solexa-200-2167
solexa-239-1823
solexa-2564-185
solexa-308-1456
solexa-4179-110

We further observed that AT1R stimulation with AngII affects multiple human
miRNA clusters, defined as regions of the genome harboring two or more miRNAs that
are transcribed from adjacent genes within 10 kb of each other. We observed that 24
known miRNA clusters in the human genome (Zhang et al., 2012, Yu et al., 2006),
located on 14 different chromosomes respond to AT1R stimulation as shown by only one
or a few specific miRNAs expressed from each cluster (Table III.VII.).

In addition to determination of AngII-regulated miRNAs previously determined,
we identified 30 new miRNAs that have only been predicted in the Solexa sequencing
database (www.switchtoi.com) with unclear functional annotation (Table III.VIII.). Only
the mature sequence is known for each miRNA species reported, which was annotated
from the illumina-sequencing chip.
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Table III.VIII. Human miRNA clusters differentially regulated upon AngII
treatment.

Cluster
#

miRNA Cluster

Chromosome

1
2
3
4

miR-29b-2 ~ 29c
miR-200
miR-181b-1-181a-1
miR-466-467-669

1
1
1
2

5
6
7
8

miR-15b ~ 16-2
miR-106b-93-25
miR-29b-1 ~ 29a
miR-290 ~ 293 ~ 295

3
5
6
7

9
10

miR-25 ~ 93 ~ 106
miR-23a ~ 27a ~ 24-2

7
8

11
12
13

let-7a-1 ~ 7f ~7d
miR-8 ~ 141 ~ 200
miR-379 ~ 411 ~ 758

9
12
12

14
15
16

miR-23b-27b-24-1
miR-16-1 ~ 15a
miR-17-19a-92a-1

22
13
13

17

miR-106a-92a-2

14

18
19
20
21
22
23
24

miR-222 ~ 221
miR-98 ~ let-7f-2
miR-181c-181d
miR-99b ~ 125 ~ let-7e
miR-23a ~ 27a ~ 24-2
miR-99a ~ let-7c
let-7a-3 ~ 7b ~ miR-4763

X
X
X
19
19
19
21
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miRNAs Differentially
Regulated in
Untreated v. AngII models
miR-29c
miR-200b, miR-200a
miR-181b-1
miR-466f-1, miR-669d, miR467b*, miR-466c-1, miR-467e,
miR-466a, miR-466d, miR297a
miR-15b, miR-16-2
miR-106a, miR-93, miR-25
miR-29a
miR-290, miR-291a, miR291b, miR-293
miR-25, miR-93, miR-106b
miR-23a, miR-27a*, miR-242*
let-7f*
miR-200c, miR-141
miR-379, miR-329, miR-667,
miR-668, miR-154, miR-410
miR-27b*, miR-24-1
miR-15a
miR-17*, miR-18a, miR-19a,
miR-20a,
miR-92a-1*, miR-106a, miR18b, miR-20b, miR-19b-2*,
miR-92a-2*, miR-363
miR-222, miR-221
miR-98
miR-181c, miR-181d
miR-99b, miR-125, let-7e
miR-24-2, miR-23a, miR-27a
miR-99a, let-7c
let-7b

Table III.IX. Novel miRNAs regulated in response to AT1R activation by AngII.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

miRNA
Solexa-103-3961
Solexa-1201-400
Solexa-1278-371
Solexa-130-3526
Solexa-1328-360
Solexa-173-2522
Solexa-1780-267
Solexa-1837-257
Solexa-200-2167
Solexa-201-2163
Solexa-2011-236
Solexa-2054-231
Solexa-231-1844
Solexa-239-1823
Solexa-2564-185
Solexa-27-9416
Solexa-284-1594
Solexa-3062-153
Solexa-308-1456
Solexa-3253-144
Solexa-403-1161
Solexa-4153-111
Solexa-4179-110
Solexa-447-1003
Solexa-5067-90
Solexa-5306-86
Solexa-5593-81
Solexa-622-718
Solexa-783-586
Solexa-897-515

Mature Sequence
TCCTCGTTAGTATAGTGG
GGTCAAGAGGCGCCTGGGAAC
GTAAAGGCTGGGCTTAGACGTGG
CAAGAAGTAGTTTAATTAGA
ACGCCCTTCCCCCCCTTCTTCA
ACCGTGGCTTTCGATTGTTACT
GAACATCACAGCAAGTCTGTGCT
TATGGAGGTCTCTGTCTGACTT
GTCAGGATGGCCGAGCGGTCTAAG
ACCTTGGCTCTAGACTGCTTACT
AATCAGCAAGTATACTGCCCTA
AGCGAGGTTGCCCTTTGTATATT
ATCTCCATAGTGACCA
CTAGCCCTAGCCCTACA
ACCTGGCATACAATGTAGATTTCTGT
TCCCTGGTGGTCTAGTGGTTAGGATTCGGC
GGCTCGTTGGTCTAGGGGTATGATTC
TGGATATGATGACTGATTACCTGAGA
GCCCGGCTAGCTCAGTCGGTAGA
GGGCTGGAGAGATGGCTCAGCCGTT
GTCTACGGCCATACCACCCTGA
GACCTCGTGGCGCAATGG
CTCACTGAACAATGAATGCAA
GTCAGGATGGCCGAGTGGTCTAAGG
GAAGTTCTGTTATACACTCAGG
ACCCGTCCCGTTCGTCCCCGGA
GCTGGGAAGGCAAAGGGACGT
GGGGATGTAGCTCAGTGGTAGA
GTGCAGTGCTGCATCTC
TTGGAGTTCATGCAAGTTCT
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3.3 AT1R Specificity of miRNA Expression
AngII activation of the AT2R in the human kidney cell line affected only four
miRNAs, out of which the regulation of three miRNAs was antagonistic to regulation by
AT1R (Figure 3.3 A). In contrast, 32 miRNAs were affected by AngII activation of the
AT2R in RASMC. The expression pattern of 18 miRNAs common to AT1R and AT2R
data (Figure 3.3 B) was mostly indicative of the well known antagonistic signaling by
these AngII receptors (de Gasparo et al., 2000). In addition, treatment with the AT1R
blocker, Losartan, altered 90% of the VSMC miRNAs in a manner opposite from that of
AngII treatment. Thus, the AT1R specificity of regulation of miRNAs in our analysis is
clear.

The results discussed in this chapter demonstrate global miRNA expression
profiling in biological replicates following chronic AngII activation. The miRNA
changes in individual comparisons showed a range between 60 and 234 miRNA genes
per sample. This finding is consistent with the miRNA expression profiles characterized
in complex tissues, sorted cells and individual cell lines, which demonstrated that on
average ≈70-150 miRNA genes were expressed per sample (Landgraf et al., 2007,
Chiang et al., 2010). The inclusion of RNA derived from tissue, primary cells and
established cell lines in our analysis demonstrates that this miRNA fingerprint is not
derived from complex heterotypic cell-cell interactions nor influenced by a multitude of
endocrine, paracrine or autocrine and neuronal influences, a common confounding
problem in many analyses.
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Figure 3.3. Venn diagrams of miRNAs altered in response to AngII treatment. A)
AngII activation of the AT2R in the human kidney cell line affected only four miRNAs,
out of which the regulation of three miRNAs was antagonistic in HEK-AT2R compared
to regulation in HEK-AT1R. B) AngII activation of the AT2R in the immortalized
RASMCs affected 32 miRNAs.

Eighteen of those miRNAs are common to the

expression fingerprint observed in the AT1R RASMCs, albeit the manner of expression is
antagonistic. Arrows pointing up () are indicative of an increase in expression while
those pointing down () indicate a decrease in expression. A solid line denotes no
change.
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Demonstrating miRNA specificity is important in elucidating the regulation of
these small RNAs, which is our reasoning for determining the miRNA expression pattern
in response to the AT2R and following treatment of the AT1R with losartan. In both
instances, we showed that expression of miRNAs was antagonized following AT2R
activation by AngII and Losartan blockade of AT1R in both VSMCs and HEK-AT1R
cells, thus displaying that the miRNA profiles generated across each model system with
AngII treatment are AT1R specific.

In addition, several miRNAs mapped to multicopy miRNA genes. Expression of a
specific miRNA or a select few from the cluster suggests stimulus-specificity of
processing of individual miRNAs from polycistronic pri-miRNA transcripts, as
previously observed in human studies (Baskerville and Bartel, 2005). With the global
miRNA profile known, we sought to identify a common set of miRNAs expressed in all
cell types in response to AngII activation of the AT1R.
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CHAPTER IV
ANGII-REGULATED MIRNAS

4.1 Introduction
The tissue and cell-type specific regulation of miRNAs points to the vast role of
these small regulatory RNAs in physiology and in various diseases. As an important RAS
hormone, AngII must play a wider role in regulating the relative abundance and
specificity of expression of miRNAs in order to regulate a variety of physiological and
adaptive tissue remodeling processes. Thus, the miRNA regulation is a critical aspect of
effectiveness of hormones such as AngII in various cells.

Regulation of miRNAs in VSMCs by a local increase in AngII can adversely
affect vessel functions due to the high density of the AT1R on VSMCs. Distinct VSMC
phenotypes accumulate within arteries of individuals with disorders such as systemic and
pulmonary hypertension, atherosclerosis, and asthma. During insult, VSMCs switch to a
proliferative phenotype of poor contractility/excitability, exhibit changes in lipid

metabolism, and have high extracellular matrix production leading to vessel remodeling.
In contrast, the phenotype of healthy adult VSMCs is restricted cellular plasticity, in
which the cells are geared for contraction with a unique repertoire of contractile proteins,
agonist-specific receptors, ion channels, and signaling molecules. Thus VSMCs are an
interesting model system for studying miRNA-modulated mechanisms of cell
maintenance, differentiation, and phenotypic modulation (Rensen et al., 2007, Daugherty
and Cassis, 2004). Regulation of specific miRNAs as contributors to vascular disease
(e.g., miR-155, -143, -145, -21, -126) has been studied (Urbich et al., 2008), but a
comprehensive analysis targeting AngII-regulation of miRNAs in VSMCs and its
associated diseases is lacking.

4.2 MiRNAs Regulated Universally by AngII
Understanding the miRNA expression fingerprint in various cell and tissue types
is an important step in elucidating miRNA function. Two miRNAs, let-7i* and solexa103-3961 were AngII-responsive in all AT1R activated models consisting of six cell lines
and two TG hearts. The AngII-responsive miRNA number increased to six when we
relaxed the cut-off to 7 out of 8 AT1R activated samples. Since regulation of miRNA
expression in a tissue, such as the heart is complex, we evaluated instances of the same
miRNA appearing specifically in the cellular models.

Eighteen miRNAs were differentially altered in 5 out of 6 AT1R activated cell
lines, which represent three mammalian genomes in the context of three different cell
types (Table IV.I). Thirty-two miRNAs are differentially expressed in at least 6 AT1R
activated models including both cell lines and heart tissue from TG mice. These 32
miRNAs are AT1R-specific because all of these were not expressed upon AngII
activation of the AT2R in HEK-293 cells and in VSMCs. In addition, AngII-regulated
pattern of expression of these miRNAs was antagonized by blockade of the AT1R by
Losartan. We designated these 32 miRNAs as a common set of novel endogenous
molecules that regulate in vivo responses to AngII activation of the AT1R, and may also
modulate the effectiveness of AT1R blockade used to treat various pathologies.

Table IV.I. AngII-responsive miRNAs across AT1R overexpressing model systems.

miRNA
let-7i*
miR-330
Solexa-103-3961
Solexa-4153-111
Solexa-1837-257
miR-874
miR-34a
miR-142-5p
miR-345-5p
miR-21*
miR-138
miR-34c
miR-99b*
miR-92b
miR-19a*
miR-709
miR-33
Solexa-308-1456
miR-335-5p
miR-497
miR-801:9.1
miR-345-3p
miR-34b-5p
miR-503
miR-214*
miR-1198
miR-34b-3p
miR-423-5p
Solexa-2564-185
miR-450b-3p
miR-615-5p
miR-27a*

Manner of
Expression
∆‡*◊
∆‡*◊
∆‡*◊
∆‡*◊
∆‡*◊
∆‡*◊
∆*◊
∆*
∆*
∆*
∆*
∆*
∆*
∆*
∆*
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
∆
*
*

Heart
+
+
+
+
+
+ (tissue only)
+ (tissue only)
+ (tissue only)
+
+
+
+
+ (tissue only)
+
+
+
+
+ (tissue only)
+
+
+
+
+
+
+ (tissue only)
+
+
+
+
+
+ (cell line only)
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VSMCs
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ (human only)
+
+ (human only)
+
+ (human only)
+
+
+
+
+
+
+
+

HEK
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

4.3 MiRNA Signature in Human and Rat VSMCs
Relationships between the expression patterns of miRNAs in the biological
replicates in our analysis are shown by pairwise sample comparisons shown in Figure
4.1. The profile of each AngII treated compared to the respective untreated control
showed a strong correlation (>0.95). Comparison of profiles between unrelated replicates
(e.g., SK-1 and SK-24) produced a scatter plot with weak correlation (<0.7).
Interestingly, the miRNA expression in the human and rodent VSMC model systems
(purple box) yielded correlation coefficients >0.95, indicating a unique pattern of
expression. This pattern arises from data consisting of >30 upregulated and >30
downregulated miRNAs in all sixteen possible comparisons, demonstrating a robust
AngII responsive miRNA signature in VSMCs.

Comparison of miRNA expression in the VSMCs to all other samples examined
in this study indicates that 26 miRNAs are highly specific for smooth muscle cells. The
volcano plot de-convoluted the miRNA signature as log2 fold change in expression of
miRNA whose abundance is significantly (p > 0.0001) altered in response to AngII.
Twenty-one miRNAs were significantly down regulated and 5 were significantly
upregulated, following AT1R activation by AngII (Figure 4.2 A). The chromosomal
locations of the 22 VSMC-specific miRNAs are shown. Many of these miRNAs are
encoded within intronic regions in the mouse genome, in which the parent gene is also
known and annotated (Figure 4.2 B).
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Figure 4.1. Pairwise plot of sample comparisons. Differential miRNA expression in
all AngII activated AT1R model systems compared. Each blue bar graph represents the
overall miRNA profile for a given sample (starting with SK-1 in the upper left hand
corner). The corresponding scatter plot shows the general trend of miRNAs altered when
comparing the untreated sample to the AngII treated sample.

The unique miRNA

expression pattern in the human and rodent VSMC model systems, indicated in purple
box. The correlation coefficient is listed for each comparison. In addition, the numbers
of miRNAs that are upregulated (>2) are shown in red and the numbers of miRNAs that
are downregulated (>2) are shown in blue for the VSMC model systems (lower purple
box).
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Figure 4.2. Characteristics of VSMC-specific miRNAs. Profiles of miRNAs pooled
from all VSMCs either treated for 24 hours with 1µM AngII or left untreated. A) The
volcano plot shows the log2 fold change in expression of miRNA whose abundance is
significantly altered in response to AngII.

Twenty-one miRNAs were significantly

downregulated (highlighted in blue) and 5 were significantly upregulated (highlighted in
red), following AngII receptor activation. B) The mouse chromosomal locations of the
twenty-two VSMC-specific miRNAs. Many of the miRNAs are encoded within intronic
regions in the mouse genome, in which the parent gene is also known and annotated in
the corresponding figure legend.
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Conserved expression of several miRNAs observed in three species in our study
was previously unknown (Table IV.I.). The mouse genome is known to contain the
VSMC-specific miRNAs listed; however, the gene assignment for the human equivalent
for 11 of the miRNAs is not yet available by genome BLAST analysis (shown with a
hyphen). However, the expression of miRs-682, -1187, -297c*, -466g, and -1198 were
experimentally detected in the HASMC samples although the genes are not annotated for
these miRNAs. Interestingly, 7 miRNAs are clustered to a single region of the genome,
the miR-466-467-669 cluster (Table III.I).

The results discussed in this chapter importantly demonstrate that thirty-two
miRNAs were AngII regulated in most human and rodent samples, which we deemed as
universally responsive to AngII activation of the AT1R. Expression of these miRNAs
were antagonized following AT2R activation by AngII and Losartan blockade of AT1R in
both VSMCs and HEK-AT1R cells, suggesting that expression of these miRNAs is a
hallmark of AngII action through the AT1R, which is targeted in most clinical settings.
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Table IV.II. Genomic characteristics of VSMC-specific miRNAs.

UGGUGCGGAAAGGGCCCACAGU
UCUCCCUUCAUGUGCCCAGA
AUAGUUGUGUGUGGAUGUGUGU
AUAUACAUACACACACCAACAC
AAACAUGGUUCCGUCAAGCACC
UAUUGCACAUUACUAAGUUGCA
CUGCAGUCACAGUGAAGUCUG
UAUGUGUGUGUGUAUGUGUGUAA

Fold
Change
(VSMCs)
-1.47
-1.33
-1.22
-1.29
1.24
1.86
-1.22
-1.55

Fold
Change
(HEKs)
0.93
0.66
0.82
0.15
0.04
0.45
0.99
0

Chromosome #
for Human
Homologue
11
4
9
-

UAUACAUACACACAUACCCAUA
CAUCCCUUGCAUGGUGGAGGG
CAAAGUGCUAACAGUGCAGGUA
AUACAGACACAUGCACACACA
UUUAUUGAGCACCUCCUAUCAA

-1.92
1.30
-1.29
-1.52
1.28

0.81
0.58
0
0.19
0.99

X
X
X

AUAUACAUACACACACCUACAC
UAUGUGUUCCUGGCUGGCUUGG
CAGUGCAAUGGUAUUGUCAAAGC
CAACAGCAGUCGAUGGGCUGUC
UCACUCCUCCCCUCCCGUCUU
AUGUAUGUGUGCAUGUACAUGU
CAUAUACAUACACACACACGUAU
AUAAGACGAGCAAAAAGCUUGU
GUGCAUUGUAGUUGCAUUGCA

-1.51
-2.23
-1.51
-1.40
-1.48
-1.37
-1.23
-1.29
1.23

1
0.06
0.12
0.35
0.93
0.99
0.99
0.99
0.31

22
17
11
14
22

miRNA

Mature Sequence

miR-675-5p
miR-343
miR-669c
miR-467b*
miR-218-1*
miR-32
miR-682
miR-1187
miR-297c*,
297a*, 297b-3p
miR-188-5p
miR-106a:9.1
miR-466g
miR-325
miR-467a*,
467d*
miR-1198
miR-301b
miR-21*
miR-483-3p
miR-297c
miR-669f
miR-208a
miR-33
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Our analysis of AngII-regulated miRNAs in rat and human VSMC cell lines
(Table IV.III.) indicated for the first time a unique fingerprint consisting of novel
miRNAs and miRNAs with known functions. As shown, a significant number of the
AngII-regulated miRNAs have been implicated in pathogenesis of other organs and
tissues, implying that a systematic study of their role in vasculature is important. Many of
the miRNAs have been previously implicated in various forms of cancer (e.g., miRs-2181, -32, -297b-3p, -106a, -483-3p), while some have been shown to play in a role in
cardiac and vascular disturbances (e.g., miRs-218-1, -188-5p, -208a, -483-3p). Using this
AngII-induced VSMC miRNA profile will allow for enhancement of our understanding
of RAS-mediated vascular abnormalities.
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Table IV.III. Involvement of VSMC-specific miRNAs in various tissues and disease
states.

miRNA

Expression Context (Manner of Alteration)

miR-675
miR-343
miR-669c
miR-467b*

NA
NA
NA
Hepatic steatosis in non-alcoholic fatty liver
disease (downregulated)
Vascular patterning (upregulation), gastric cancer,
oral squamous cell carcinoma (downregulated)
Androgen-regulated prostate cancer (upregulated),
antiviral defense, human myeloid leukemia
(upregulated)
Muscle regeneration (upregulated)
TNFα-mediate hepatic apoptosis (upregulated)
Lymphoma/carcinogenesis (upregulated)
Homocysteine-induced cardiac remodeling
(upregulated)
Malignant bronchial epithelial, human T-cell
leukemia, gastric cancer (upregulation), colon
cancer (downregulation)
NA
Stress-induced suppression of luteinizing hormone
secretion (upregulated)
Stimulates induced pluripotent stem cells
(upregulated)
Growth regulation of mouse embryonic stem cells
(upregulated)
NA
Cardiac hypertrophy/diastolic dysfunction,
electrical conductance, acute myocardial infarction
(upregulated)
Wilms’ tumors, hepatocellular carcinoma,
colorectal cancer, adrenocortical tumours,
pancreatic cancer, proliferation in wounded
epithelial cells (upregulated), myocardium of
obesity-prone rats, melatonin synthesis in pineal
gland (downregulated)
Cholesterol homeostasis in macrophages,
atherosclerosis (upregulated)

miR-218-1
miR-32
miR-682
miR-1187
miR-297b-3p
miR-188-5p
miR-106a
miR-1198
miR-325
miR-301b
miR-467a
miR-669f
miR-208a
miR-483-3p

miR-33
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CHAPTER V
REGULATION OF MIRNAS BY ANGII

5.1 Introduction
Validation of expression patterns is an important aspect of miRNA biology that
must always be considered.

Recapitulating the manner of expression observed by

microarray (i.e., upregulated or downregulated) in independent samples sets is crucial for
teasing out the functional roles of individual miRNAs. In the current study, we have
demonstrated a robust miRNA response following chronic AngII treatment and activation
of the AT1R. Confirming expression of the VSMC-specific miRNAs determined in the
profiling experiment will be useful to determine the important players for regulation of
cellular activities and RAS pathologies where VMSC gene expression is altered.

5.2 Validation of VSMC miRNAs by RT-qPCR
To validate the microarray data and confirm the VSMC-specific miRNA
signature, the stemloop primer-based real-time RT-qPCR analysis was performed on

independent RNA samples. The levels of miR-483-3p, miR-32, miR-669f and miR-1198
compared in untreated samples revealed that basal levels of these miRNAs changed in
RASMC-AT1R compared to RASMC (Figure 5.1. A). The change in the level of these
four miRNAs in AngII treated samples followed similar pattern in RASMC-AT1R
compared to RASMC, suggesting that the AngII dependent effects are not altered due to
AT1R over expression in the RASMC-AT1R.

Figure 5.1 B shows ligand-dependent changes in the levels of 20 VSMC-specific
miRNAs, following treatment with either AngII or Candesartan for 24 hours (n = 3).
Since basal levels of miRNAs were altered in the RASMC-AT1R cells due to mere
overexpression of the AT1R, the inverse agonist, Candesartan was used to inhibit the
basal AT1R-specific effect. The result was then compared to the AngII-induced effect in
each case. Of the VSMC candidate miRNAs that were identified from the microarray, 17
showed the same trend in expression (i.e., upregulated or downregulated) in the
independent samples in response to AngII. In addition, Candesartan treatment produced
distinct response for these miRNAs. Either the miRNA expression was reversed or
miRNA expression was less diminished compared to treatment with AngII (Figure 5.1
B). Both types of responses suggest that these miRNAs do respond to AngII activation of
the AT1R, however, the variability in the type of response may point to additional
regulatory events downstream of the receptor. Taken together, our data demonstrate that
AngII activation of AT1R in VSMCs produces a specific miRNA signature that is
validated independently.

Figure 5.1. RT-qPCR validation of VSMC miRNAs. A) Relationship of AT1R cellular
levels and miRNA expression analyzed by the stem-loop primer-based real-time RTqPCR. Expression of 4 representative miRNAs was monitored in RASMCs and RASMCAT1R cells (n = 3). Data are presented as fold over U6 RNA internal control following
normalization. B) MiRNA expression modulated by AT1R-specific ligands. Change of
expression of 20 miRNA in the AT1R RASMCs following 1uM AngII or Candesartan
treatment for 24 hours (n = 3). Data are presented following normalization to U6 RNA,
the cellular levels of which did not vary under different experimental conditions and
standardization to an untreated control.
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5.3 Modulation of the AngII-regulated VMSC miRNA Pool
Transcriptional regulation of miRNA genes and posttranscriptional processing of
pri-miRNA could be affected by AT1R-regulated kinases. Therefore, we blocked PKCζ,
MEK1, JAK2, JNK, and p38 cascades during AngII activation of the AT1R and measured
the effects on cellular miRNA levels. Inhibitors of PKCζ, JNK, and p38 did not interfere
with AngII-mediated miRNA regulation, but inhibitors of JAK2 and MEK1 had a
significant effect.

To examine whether the AT1R-activated MEK1 and JAK2 pathways regulate the
miRNA pool globally or if miRNAs are regulated individually, the RASMC-AT1R cells
were pretreated with inhibitors of MEK1 or JAK2 and were then treated with AngII and
processed. As shown in Figure 5.2 A and B, the effect of MEK1 inhibition (iMEK1) was
monitored by a decrease in ERK1/2 phosphorylation and the effect of JAK2 inhibition
(iJAK) was monitored by a decrease in phosphorylation of STAT3. Under conditions of
inhibition, both blockers had an effect that was of equal strength or exceeded the
inhibition of the AT1R caused by Candesartan. We observed no significant change in the
expression of the endogenous U6 control RNA under the same experimental conditions.
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Figure 5.2. Inhibition of AngII-mediated ERK1/2 and STAT3 phosphorylation. A)
Activation of phospho-ERK1/2 and phospho-STAT3 (Y705) in AT1R RASMCs samples
untreated (lane 1), treated with 1µM AngII (lane 2), 1µM Candesartan +0.1µM AngII
(lane 3), 30µM MEK1 inhibitor +1µM AngII (lane 4), and 5µM JAK inhibitor +1µM
AngII (lane 5) was visualized. B) Densitometry quantification of iMEK1 and iJAK
effects on phosphorylation of ERK1/2 and STAT3.

The MEK1 inhibitor (iMEK1)

completely inhibited ERK1/2 phosphorylation and the JAK inhibitor (iJAK) inhibited
approximately 98% of STAT3 phosphorylation (n = 3, p < 0.01).
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The RT-PCR data in Figure 5.3 shows that levels of miR-483-3p, miR-33 and
miR-301b increased, but the levels of miR-188-5p and miR-208a were not significantly
altered by MEK1 blockade. In contrast, inhibition of JAK2 had the opposite effect. When
JAK2 was blocked, the levels of miR-188-5p and miR-208a increased while the levels of
miR-483-3p, miR-33, and miR-301b did not significantly change.

Combined iMEK1 and iJAK2 impacted all five miRNAs, demonstrating that
MEK1 and JAK2 are essential for the AngII-mediated modulation of distinct miRNAs.
Furthermore, loss of any individual protein kinase function is not compensated by the
remaining cellular kinases, which suggests a parallel, non-overlapping effect of different
signaling circuits on miRNA regulation. Our data identifies non-redundant roles played
by MEK1 and JAK2, emphasizing non-canonical pathways.
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Figure 5.3. Effect of kinase inhibition, iMEK1 and iJAK2, on miRNA levels. Levels
of miRNA in AT1R RASMCs monitored by qRT-PCR after inhibition of the AngIIspecific kinases, MEK1 and JAK. The 5 candidate miRNAs tested exhibited a distinct
changes, for instance changes in miR-483-3p (p < 0.0001), miR-188-5p (p = 0.0005), and
miR-301b (p < 0.0001) expression observed under iMEK1 and changes in miR-33 (p =
0.0002) and miR-208a (p = 0.004) expression observed under iJAK2 condition (n = 3).
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Kim et al showed that the proteins involved in miRNA biogenesis (e.g., Drosha,
TRBP, Dicer, Ago 2) could be phosphorylated by protein kinases. Accordingly, AngIIactivated kinases may potentially target Drosha, TRBP, Dicer, or Ago 2 to regulate
biogenesis or degradation of miRNAs (Kim et al., 2010) (Figure 5.4 A). As a means to
understand the mechanism of AngII-induced miRNA regulation, we looked at AngIImediated signaling molecules that could alter expression of miRNA biogenesis proteins
and thereby alter the expression of the miRNAs.

In RASMC-AT1R samples, we

analyzed total protein levels of Drosha, TRBP, and Ago2 by western immunoblotting to
determine if these miRNA maturation proteins were affected by inhibition of MEK1 and
JAK2. We observed that upon inhibition of these kinases, there was no change in total
protein levels of Drosha, TRBP, or Ago2 when compared to AngII treated samples
(Figure 5.4 B). This suggests that post-translational modification of these biogenesis
proteins is the driving force behind altering the miRNA pool or that other components all
together are participating in altering the AngII/AT1R induced expression of miRNAs.
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Figure 5.4. Mechanism of AngII-induced miRNA regulation. A) Pri-miRNAs are
processed by a number of proteins within the nucleus and cytoplasm to yield the mature
miRNA. A recent review reported that protein factors, which are involved in the miRNA
biogenesis pathway, can be subjected to various posttranslational modifications (Kim et
al., 2010). B) Total protein levels for Drosha, TRBP, and Ago2 in RASMC-AT1R
samples untreated (lane 1), treated with 1µM AngII (lane 2), 1µM Candesartan +0.1µM
AngII (lane 3), 30µM MEK1 inhibitor +1µM AngII (lane 4), and 5µM JAK inhibitor
+1µM AngII (lane 5) was visualized. The corresponding plots show densitometry values
for each protein normalized to actin. There is no change in total levels of these three
proteins (n = 1).
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The results presented in this chapter display evidence of unconventional
regulation of miRNA levels in VSMCs through AT1R signaling. Our data indicate that
AT1R signaling through JAK2 and MEK1 regulate two completely independent miRNA
pools. Both MEK1 and JAK2 inhibitors inhibited ERK1/2 activation, but these inhibitors
affected distinct miRNAs, suggesting that the AngII-activated JAK2 and MEK1 signaling
alters non-canonical and perhaps miRNA-specific regulatory steps.
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CHAPTER VI
MIR-483-3P: A NOVEL ANGII-REGULATED MIRNA

6.1 Introduction
The genome-wide miRNA expression profiling provided us with a subset of
AngII-responsive miRNAs across various model systems. For this study, we focused our
efforts on a single VSMC-specific miRNA, miR-483-3p, which until now had an
unknown functional role in SMC biology.

The role of miR-483-3p in SMC physiology and pathology is unknown. Since
2010 several groups have reported a functional role for miR-483-3p in various in vitro
and in vivo systems, which gives us confidence that this miRNA could also possess an
important function in our model system. Veronese and colleagues observed that miR483-3p was overexpressed in 100% of Wilms’ tumors and highly expressed in 30% of the
cases of colon, breast, and liver cancers (Veronese et al., 2010). Coregulation with IGF2
mRNA was detected in some, but not all tumors, suggesting that the miRNA can act

concomitantly or autonomously as an oncogene. MiR-483-3p was observed to regulate
the proapoptotic protein PUMA, acting as an antiapoptotic oncogene. The same group
reported that miR-483 expression could be induced independently of IGF2 by the
oncogene beta-catenin. They also show that beta-catenin is a target of miR-483-3p,
triggering a negative feedback loop that becomes ineffective in cells harboring a betacatenin mutation (Veronese et al., 2011).

It has been reported that miR-483-3p is

strongly enhanced in pancreatic cancer and that Smad4 is a direct target of miR-483-3p,
promoting cell proliferation and colony formation in vitro (Hao et al., 2011). In a noncancerous disease state, miR-483-3p was implicated in regulating melatonin synthesis
and expression in adipose tissue of diabetics (Ferland-McCollough et al., 2012). Most
recently, miR-483-3p was observed to target CDC25A and contribute to cell-cycle arrest
(Bertero et al., 2013).

Important for our purposes, researchers demonstrated that miR-483-3p is
upregulated in 2 distinct epithelial models of wound healing (scratch and wounded skin).
They show that 483-3p expression peaks at the final stage of wound closure (Bertero et
al., 2011).

In addition, the study determined that miR-483-3p inhibits keratinocyte

migration and proliferation and use of an antagomir rescues this observation. Kinase
MK2, proliferation marker MK167, and transcription factor YAP1 were confirmed to be
direct targets of miR-483-3p in this study. Finally, it has been observed that Igf2 derived
miR-483 can induce proliferation in hepatocellular carcinoma cells (Ma et al., 2012).
The group showed that suppressor of cytokine signaling 3 (Socs3) is a target of miR-483.

What has yet to be determined regarding miR-483-3p is its role as an AngII
responsive miRNA in VSMC behavior. In this chapter we describe the logic behind
choosing miR-483-3p for in-depth analysis and the importance that this miRNA could
have in terms of AngII biology.

6.2 Selection of miR-483-3p for Analysis
We performed extensive bioinformatic analyses on each of the 26 VSMC-specific
miRNA that we obtained from our genome-wide miRNA expression profiling
experiment. We completed miRNA target prediction analyses using Target Scan,
DIANA, PITA, and MicroCosm databases. Additionally, we utilized Ingenuity Pathway
Analysis (IPA) to construct functional networks of the miRNAs with their predicted
targets. We eliminated miRNA candidates that had already been extensively studied and
focused on those VSMC-specific miRNAs that would have some role in SMC
physiology. Of the 21 downregulated miRNAs and 5 upregulated miRNAs, we chose
miR-483-3p, which is significantly downregulated in response to chronic AngII treatment
(Figure 6.1).

Figure 6.1. Volcano plot of VSMC-specific miRNAs. The volcano plot shows the log2
fold change in expression of miRNAs whose abundance is significantly altered in
response to AngII. MiR-483-3p was observed to be significantly downregulating in
response to AngII receptor activation (depicted with a solid arrow).
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Tissue RAS activation is known to be a major cause of SMC disease. Therefore,
we sought to explore the involvement of miRNAs in potentially targeting components of
RAS. We examined the 3’-UTRs of each RAS component (e.g., Renin, Renin Receptor,
AGT, ACE-1, ACE-2, AGTR1, AGTR2, AT4 receptor, Ang(1-7) Receptor) to see which
of the VSMC-specific miRNAs could potentially target these genes. We observed that
miR-33 could potentially target the AT1R. MiR-33, an intronic miRNA located within the
gene encoding sterol-regulatory element-binding factor-2 (SREBF-2), has been
extensively studied and has been shown to be a regulator of cholesterol metabolism. The
miRNA targets the adenosine triphosphate-binding cassette transporter, thereby
attenuating cholesterol efflux to apolipoprotein A1. In mouse macrophages, miR-33 also
targets ABCG1, reducing cholesterol efflux to nascent high-density lipoprotein (Rayner
et al., 2010). In addition, we observed that miR-188-5p could potentially target ACE-2.
This miRNA was previously implicated in homocysteine-induced cardiac remodeling
during heart failure, wherein the miRNA is downregulated, which upregulates MMP-2, -9
and TIMP-1, and -3 (Mishra et al., 2009).

MiR-483-3p is one of the 26 VSMC-specific miRNAs that was predicted to
potentially target 4 key components of the RAS; thereby, regulating the whole pathway.
The seed sequence of miR-483-3p is complementary to regions within the 3’-UTR of
AGT, ACE-1, ACE-2, and AGTR2 (Figure 6.1). In addition, complementary regions for
miR-483-3p exist within the coding regions of AGT and ACE-1, suggesting that this
miRNA could act most potently in vivo on these genes.
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Figure 6.1. MiR-483-3p target prediction. Using multiple target prediction databases,
miR-483-3p was predicted to target the 3’-UTR of AGT, ACE-1, ACE-2, and AGTR2
with near complete complementarity. The regions of potential miRNA (red) binding to
the 3’-UTR (black) of each gene is shown below.
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During our bioinformatic analysis, we also determined that miR-483-3p does not target
any of the components of the ANF system, which is a counter-regulatory system to RAS
with similar complexity. Taken together, this suggests that miR-483-3p could be a
selective mechanism for regulating tissue RAS.

In addition to miR-483-3p being predicted to target multiple components of tissue
RAS, it is also known that the gene for miR-483 is encoded within intron 2 of Insulin-like
growth factor 2 (IGF2). IGF2 is an imprinted gene with expression resulting favorably
from the paternally inherited allele. It has growth-regulating, insulin-like and mitogenic
activities. IGF2 is believed to be a major growth factor during gestation, as it promotes
development of fetal pancreatic islet cells (Bergman et al., 2012).

Perhaps most

importantly, IGF2 is a signaling molecule that is known to interact with AngII signaling.
Studies have shown that an increase in Igf2 expression in the left ventricle corresponds to
blood pressure increase (Kadlecova et al., 2008) and that AngII-induced IGF2 gene
expression has been positively correlated with cardiomyoblast apoptosis in animals with
hypertension (Lee et al., 2006). In addition, targeted expression of Igf2 transgene in
SMCs shortens life span, leading to bradycardia and hypotension (Zaina et al., 2003). We
have observed that in response to chronic AngII treatment, the transcript levels of IGF2
are enhanced in RASMC-AT1R cells (Figure 6.2).

148

Figure 6.2. IGF2 abundance in VSMCs after AngII treatment. Transcript levels of
IGF2 were quantitated by RT-qPCR, following treatment of RASMC-AT1R cells with 1
µM AngII for 24 hours (n = 3). Data are presented following normalization to GAPDH,
the cellular levels of which did not vary under different experimental conditions and
standardization to an untreated control. IGF2 is synergistically enhanced, following
treatment with AngII.
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Upon transcription of IGF2 in the 3’ direction, 11 transcripts are produced, all of
which contain intron 2 and the coding region for miR-483 (Figure 6.3). The pri-miRNA
is independently produced from intron 2 and is processed in the nucleus to yield a
precursor-miRNA stem-loop structure. This pre-miR is exported into the cytoplasm
where it is cleaved to form a double-stranded miRNA duplex of miR-483-5p and miR483-3p. The guide strand of this duplex, which is miR-483-3p (or the antisense strand) in
our case, is loaded into RISC and carries out its function by binding to target mRNAs,
resulting in translational repression.

Additional observations were made during our bioinformatic analyses of miR483-3p, which suggested that this miRNA is favored over its hairpin counterpart, miR483-5p. First and foremost, the AngII stimulated miRNA profile showed only miR-4833p as being significantly altered in the VSMC model systems.

RNA sequencing

databases also consistently show that miR-483-3p is the most frequently expressed and
conserved miRNA across a range of species (Figure 6.4). Finally, by looking at the
sequence of the miRNA itself, we see that miR-483-3p is very AU-rich, which makes it a
perfect candidate for seed recognition by Ago2 and loading into RISC for translational
silencing.

The results described in this chapter provide the logic and reasoning for selection
of the novel AngII-regulated miR-483-3p from the 26 VSMC-specific miRNAs. Due to
the ability of this miRNA to potentially target and regulate multiple components of the
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RAS and its location within the genome, miR-483-3p is a prime candidate for
understanding the functional role of AngII-responsive miRNAs in SMC biology.
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Figure 6.3. MiR-483 encoded in intron 2 of IGF2. Pri-miR-483 is encoded in and
produced from intron 2 of IGF2. Following processing by canonical miRNA biogenesis
proteins, pre-miR-483 is exported into the cytoplasm where it is further processed to
yield the mature miR-483-3p, which has a functional role.
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Figure 6.4. MiR-483-3p expression is favored over miR-483-5p expression. Deep
sequencing efforts by miRBase have shown IGF2 encoded miR-483-3p to be expressed
by all species, but miR-483-5p has only been shown to be experimentally expressed in
human and mouse.
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CHAPTER VII
EXPRESSION AND FUNCTIONAL ROLE OF MIR-483-3P

7.1 Introduction
Characterization of individual miRNAs is important in order to fully understand
the biological role that these small, non-coding RNAs possess. Therefore, it is imperative
to examine both the expression pattern of the miRNA of interest and also to determine its
functionality, in terms of ability to translationally suppress predicted target genes. In this
chapter we describe both of these aspects for miR-483-3p as a means to understand its
role in regulating tissue RAS.

7.2 Validation of miR-483-3p
Using two independent assays, we were able to validate miR-483-3p expression in
RASMC-AT1R samples treated with AngII. In the RNA solution hybridization assay, we
detected and visualized miR-483-3p expression using a
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P labeled antisense probe

specific for miR-483-3p. Following time-course treatment with AngII, total RNA was

isolated and hybridized to the miR-483-3p probe. Recovered hybrids were analyzed on a
denaturing polyacrylamide gel (Figure 7.1. A). The densitometry for miR-483-3p and
miR-16 (control) for a single experiment (upper panel) and the calculated fold change in
expression of miR-483-3p compared to miR-16 is shown in triplicate (lower panel) in
Figure 7.1 B.

We have also detected this miRNA by RT-qPCR using a miR-483-3p specific
primer. Following treatment with either AngII or Candesartan, levels of miR-483-3p
were quantified in RASMC-AT1R cells (Figure 7.2). We observed a decrease in miR483-3p expression upon treatment with AngII and an increase in expression upon
treatment with Candesartan.

In both assays, miR-483-3p showed the same trend in expression (i.e.,
downregulated) in the independent samples in response to AngII as we observed in the
profiling experiment. In addition, Candesartan treatment produced a distinct response, in
which miR-483-3p expression was reversed. Validation of this miRNA in independent
VSMC samples gives us confidence that miR-483-3p is robustly regulated by AngII
receptor activation.

Figure 7.1. Detection of miR-483-3p by solution hybridization. A) Following
treatment with 1µM AngII at various time points, total RNA from RASMC-AT1R cells
was hybridized to a miR-483-3p radiolabeled probe and analyzed by denaturing
polyacrylamide gel electrophoresis (lanes 6-10, red box). The miR-16 probe was utilized
as a control and detected in mouse kidney RNA (lane 3). Each probe was loaded without
(lanes 1 and 4) and with (lanes 2 and 5) RNase digestion. B) The corresponding plots
show the densitometry analysis of miR-483-3p (closed bar) and miR-16 (open bar) for a
single experiment (upper panel) and the calculated fold change for miR-483-3p
normalized to miR-16 (n = 3; ** p = 0.0005, *** p = 0.0001) (lower panel).

Figure 7.2. Quantitation of miR-483-3p by RT-qPCR. MiRNA expression modulated
by AT1R-specific ligands. Change of expression of miR-483-3p in the AT1R RASMCs
following 1uM AngII or Candesartan treatment for 24 hours (n = 3). Data are presented
following normalization to U6 RNA, the cellular levels of which did not vary under
different experimental conditions and standardization to an untreated control.
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7.3 Muscle Cell Lineage Expression of miR-483-3p
We demonstrated that miR-483-3p is selectively expressed in various human and
rodent VSMCs and validated its expression by two distinct methods. As a means to
determine its expression across a broad range of cell types, we utilized the solution
hybridization technique to detect miR-483-3p. Interestingly, we have found miR-483-3p
to be present at basal levels in cardiac (HL-1, H9C2), kidney (NRK52E), and carcinoma
cell lines (MCF-7, NC1-H295R) (Figure 7.3). Each of the cell types in which miR-4833p is present at basal levels are important in tissue RAS, suggesting that miR-483-3p may
be an important regulator of the RAS in these cell types.

Importantly, we do not detect miR-483-3p in HEK 293 or HEK-AT1R cells after
treatment with AngII via solution hybridization (Figure 7.4). This observation, along
with selective expression of miR-483-3p in VSMCs and cardiomyocytes (HL-1) allows
us to be further confident in classifying this miRNA as a muscle cell lineage specific
miRNA.
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Figure 7.3. Basal miR-483-3p expression across various cell lines. A) Solution
hybridization of total RNA from multiple cell lines shown below to a radiolabeled probe
specific to miR-483-3p was performed. B) Densitometry analysis in provided in the
corresponding plot for each sample. Expression in the RASMC line was considered basal
expression for our purposes. Anything at or above that level was important.
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Figure 7.4. MiR-483-3p is undetectable in HEK-AT1R cells. Using RASMC-AT1R
cells for comparison, we performed solution hybridization of total RNA from HEK-AT1R
cells to miR-483-3p specific probe, following treatment with 1 µM AngII at various time
points (lanes 6-15). miR-16 probe was used as a control and detected in mouse kidney
RNA (lane 3). Each probe was loaded without (lanes 1 and 4) and with (lanes 2 and 5)
RNase digestion. miR-483-3p was undetectable in the HEK cell line.
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7.4 Functionality of miR-483-3p
To determine the functionality of miR-483-3p in vitro we constructed 3
independent cell lines using the miR-483 expression cassette. HEK-293T, RASMC, and
RASMC-AT1R cells were nucleofected with pRNA U6.1-miR483. Cells were cultured
in selection medium containing hygromycin and clones were screened for miR-483-3p
expression by solution hybridization. We chose clones with the highest detectable level
of miR-483-3p for use in our functional assay. Clone #5 in HEK-293T cells (Figure 7.5),
clone #3 in RASMC, and clone #10 in RASMC AT1R cells (Figure 7.6) was chosen as
the highest expressing clone and used for further analyses. Control cell lines were also
constructed with the pRNA U6.1 empty expression vector and exposed to hygromycin
selection.

The HEK-293T-miR483 cells were primarily used for analysis of miR-483-3p
targets in a functional luciferase assay. We cloned the 3’UTRs of AGT, ACE-1, ACE-2,
and AGTR2 into a dual luciferase expression vector. Following transfection of the HEK293T-miR483 cells with the 3’-UTR constructs, the cells were subjected to a luciferase
substrate and firefly luciferase activity was measured.

The cell lysates were then

subjected to a second luciferase substrate and Renilla luciferase activity was measured.
The Renilla luciferase expression was then normalized to firefly luciferase activity.
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Figure 7.5. Stably expressing miR-483-3p in HEK-293T cells. Of the 10 clones that
were picked for HEK-293T cells, we chose clone #5 as having the highest level of miR483-3p expression, which was determined by solution hybridization. Phase-contrast
images (15X) of live cells in culture are shown for both the vector control and miR-483
lines.
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Figure 7.6. Stably expressing miR-483-3p in RASMC and RASMC-AT1R cells. Of
the 10 clones that were picked for both RASMC and RASMC-AT1R cells, we chose
clone #3 and clone #10, respectively as having the highest level of miR-483-3p
expression as determined by solution hybridization. Phase-contrast images (15X) of live
cells in culture are shown for both the vector control and miR-483 lines.
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In our vector system, Renilla luciferase expression is stabilized by the presence of
the 3’UTR, and activity decreases in each case in the presence of miR-483-3p.

In

addition, in the presence of an antagomiR specific to miR-483-3p, we are able to rescue
the luciferase expression in each 3’-UTR example (Figure 7.7). Thus, miR-483-3p can
effectively initiate the RNAi process on the target 3’-UTR, suggesting that this miRNA
could be a global regulator of tissue RAS.

In addition to the functional readout for the luciferase assay, we also monitored
levels of endogenous AGT and ACE-1 by western immunoblotting in the RASMC-AT1R
cells stably expressing miR-483-3p. We demonstrated that in the presence of the miRNA
protein levels of AGT and ACE-1 decreased, which can be rescued with the antagomir
for miR-483-3p (Figure 7.8). The suppression of ACE-1 levels was not as dramatic as the
effect of miR-483-3p on AGT, suggesting that miR-483-3p more strongly regulates AGT
endogenously. Unfortunately the AGTR2 and ACE-2 primary antibodies utilized were
not functional. We also looked at mRNA levels of the 4 targets and observed no change
in AGT, ACE-1, ACE-2, or AGTR2 transcripts in the presence of miR-483-3p. Thereby
suggesting that miR-483-3p is acting post-transcriptionally on these target genes.
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Figure 7.7. MiR-483-3p targets components of tissue RAS. HEK-293T-miR483 cells
were transfected with a 3’-UTR construct and both firefly and Renilla activity were
measured. In each 3’-UTR target assay, Renilla luciferase activity decreased in the
presence of miR-483-3p. When a miR-483-3p specific antagomir was introduced into the
system, the dampened luciferase activity was rescued to basal levels.
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Figure 7.8. MiR-483-3p alters expression of endogenous AGT and ACE-1. A)
Western immunoblotting for endogenous AGT and ACE-1 in RASMC-pRNA (lane 1),
RASMC-miR483 (lane 2), and RASMC-miR483 + antagomir (lane 3) was visualized. B)
Densitometry quantification of AGT and ACE-1 levels. Transfection of an antagomir
specific for miR-483-3p significantly reduced the levels of AGT, but had a lesser effect
on ACE-1 levels (n = 3; *p < 0.05).

166

We have demonstrated that upon stimulation with AngII, the AT1R is activated,
leading to a decrease in miR-483-3p expression, which would ultimately result in an
increase in the RAS targets of this miRNA. In our initial efforts of understanding the
mechanism by which the VSMC-specific miRNAs are regulated by AngII, we utilized
MEK1 and JAK2 inhibitors and monitored miRNA expression. We observed that upon
inhibition of MEK1 only, miR-483-3p expression increased. An increase in miR-483-3p
expression would lead to a decrease in RAS target expression (Figure 7.9 A). Following
inhibition with MEK1 and JAK2, we monitored levels of AGT and ACE-1 by western
immunoblotting. We determined that MEK1 inhibition causes a decrease in endogenous
AGT, but we don’t see the effect with ACE-1 (Figure 7.9 B).

This result further

solidifies the idea that miR-483-3p acts most potently on AGT.

The results presented in this chapter provide significant insight into the expression
pattern and functional role of miR-483-3p in targeting and regulating tissue RAS. We
have demonstrated expression of this miRNA in multiple cell types of muscle cell
lineage, which is important for cardiovascular biology and for fully understanding the
effects that AngII has on those tissues. Additionally, we have shown that miR-483-3p,
which is in part regulated by the AngII-mediated kinase MEK1, functions biologically to
inhibit multiple components of the RAS. From our studies, endogenous AGT appears to
be most altered in response to miR-483-3p expression. Demonstrating that this VSMCspecific miRNA has a functional role prompted us to determine whether miR-483-3p
could affect VSMC behavior and phenotype.

167

Figure 7.9. Effect of MEK1 inhibition on endogenous AGT and ACE-1. A) AngII
stimulation of the AT1R causes activation of the AngII-mediated kinase MEK1, which
leads to a decrease in miR-483-3p expression and a subsequent increase in RAS target
genes. Conversely, inhibition of MEK1 leads to an increase in miR-483-3p, which
should lead to a decrease in RAS target genes. B) Following kinase inhibition of
RASMC-AT1R-miR483 cells, we detected a decrease in AGT, but not ACE-1 by western
immunoblotting (lane 4, n = 1).
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CHAPTER VIII
MODULATING VSMC PHENOTYPE

8.1 Introduction
To further characterize the function of miR-483-3p, we have observed its effects
on VSMC phenotype. It is well known that various stimuli, including AngII, can cause
VSMCs to switch between contractile and proliferative states due to global gene
expression changes, which play a central role in cell motility and diverse vascular
diseases. Understanding the extent to which miR-483-3p plays a role in this phenomenon
will reveal if this miRNA acts as a critical regulator of cellular phenotype as a potential
player in various vascular pathologies (Figure 8.1).

Figure 8.1. Effect of miR-483-3p on VSMC phenotypic switching. Due to the high
density of AT1 receptors on VSMCs, AngII is able to induce VSMCs to switch from a
contractile to the synthetic state, which can ultimately lead to increased cell motility and
vascular abnormalities.

8.2 Effects of miR-483-3p on VSMC Migration
To determine the involvement of miR-483-3p in VSMC in vitro migration we
utilized the RASMC-AT1R cells, stably expressing miR-483-3p.

Using a standard

wound-healing assay, we monitored cell movement into a wounded or cleared area for a
period of 24 hours. We performed this experiment in the presence of 1 µM AngII and
Candesartan to understand the effects that AT1R-specific ligands would have on this
phenomenon.

In cells that were left untreated, there was no significant difference in the
wounded area when comparing presence and absence of miR-483-3p. We observed that
by 8 hours, miR-483-3p action significantly decreased AngII-mediated VSMC migration
when compared to conditions where the miRNA was absent (Figure 8.2 A). This same
effect was observed under treatment with Candesartan.

The area of the wound was

determined, in relation to the total area, for each well and the percent wound area was
calculated (Figure 8.2 B).

The results discussed in this chapter examine a novel role of miR--483-3p in
mediating VSMC phenotype. In response to AngII, VSMCs enter into the synthetic and
migratory phenotype, giving rise to vascular pathologies. MiR-483-3p functions to slow
the rate of AngII-mediated VSMC migration in culture, thereby suggesting that when this
miRNA is downregulated in response to AngII molecules involved in cellular movement
would be independently and adversely increased. This effect could ultimately give rise to
vascular abnormalities in vivo.
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Figure 8.2. MiR-483-3p decreases AngII-mediated cell migration. A) Wound healing
was observed in RASMC-miR483 and RASMC-pRNA untreated (panel 1), treated with 1
µM AngII (panel 2), or 1 µM Candesartan (panel 3) for a period of 24 hours. By 8 hours,
RAMSC-miR483 cells exhibited a decrease in AngII-mediated migration (red box). In
addition, in cells containing miR-483-3p and treated with Candesartan, the cell migration
was decreased. B) The corresponding plot shows the quantitation of the results using
ImagePro Plus software. The area of the wound and the total area at time 0h and 8h were
determined for 2 different positions in each well (n = 3; ns, not significant, *** p =
0.0003, ** p = 0.0045).
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CHAPTER IX
FUTURE DIRECTIONS

9.1 Comprehensive Description of miR-483-3p
As a means to fully characterize the function of miR-483-3p, we will turn to
monitoring the effects of miR-483-3p on additional phenotypic phenomena, including
adhesion and proliferation via thymidine (DNA) or leucine (protein) incorporation.
Additionally, we aim to determine the ability of this miRNA to regulate the cell cycle.
We have performed one cell cycle analysis and observed that miR-483-3p has the ability
to alter the number of cells in the G2 phase; however, additional experiments need to be
performed in order to wholly demonstrate the effect of miR-483-3p on cell cycle control.
A critical aspect of our study is to understand the mechanism by which miR-483-3p
effects AngII-mediated VSMC migration. In so doing, we will determine changes in
contractile proteins (e.g., α-actin, myosin) and possible secretion of SMC-specific ECM
components (e.g., collagen, fibronectin, laminin, tenascin) that would be important in
regulating phenotypic alterations. Further, we will determine if miR-483-3p affects the

secretion of AngII-specific cytokines (e.g., MCP-1, IL-1, IL-6, TNF-α) and chemokines
(e.g., RANTES, IP-10, CyPB) and accumulation of reactive oxygen species, all of which
have been previously shown to play a role in VSMC physiology and pathology. Taken
together, these future studies will allow us to determine the full capacity of the AngIIregulated miR-483-3p on vascular biology.

Ultimately, our goal is to see if the effect miR-483-3p has in the cellular system
(i.e., inhibition of RAS components and ability to decrease VSMC migration) is also a
phenomenon that can bee seen in vivo. We would expect that expression of the miRNA
would protect the vessels against activation of tissue RAS, creating an overall beneficial
effect. Thereby, preventing VSMCs from entering into the synthetic migratory
phenotype. Using a lentiviral system, we will first recapitulate the effect of miR-483-3p
in VSMCs infected with the lentivirus produced from a viral vector (Figure 9.1). The
BLOCK-IT™ technology from Life Technologies is designed to express artificial
miRNAs. Using this system, a double-stranded DNA oligonucleotide encoding miR-483
would be cloned into one of the BLOCK-iT™ entry expression vectors and the miRNA
cassette would be transferred into the lentiviral destination vector by Gateway®
recombination. The vectors would be transfected into the viral producer cells to produce
viral stocks, which can be used immediately or stored at –80°C. The viral supernatants
would be harvested and the viral titer determined. Finally, the lentiviral stocks could be
transduced to any cell type, specifically VSMCs.

We will then monitor the effect of miR-483-3p in a hypertensive mouse model by
injecting the virus into the tail vein (Figure 9.2). One mouse model utilized in hypertensive
research consists of crossbreeding a transgenic mouse containing the human renin gene (hRN
8-12; 10 copies of a 15 kbp human DNA fragment containing the renin gene) with a
transgenic mouse for human angiotensinogen (hAG 2-5; 100 copies of a 14 kbp human DNA
fragment containing the angiotensinogen gene). This results in a mouse with high blood
pressure.

By monitoring the phenotype of these animals, through either determining that this
miRNA could prevent or reduce development of hypertension (by measuring blood pressure)
and vascular changes (by examining vessel wall thinning), we would be able to determine if
tmiR-483-3p has the capability of regulating a physiological phenomenon in vivo, such as the
RAS.

Overall, observing the full effect of miR-483-3p in vitro and in vivo will allow us to
understand its capacity as a regulatory molecule. Most importantly, we will be able to
discern its involvement in RAS pathologies within the cardiovascular system.

Figure 9.1. Lentiviral expression system. Viral delivery of RNAi vectors is a powerful
alternative to transfection for primary cell types as well as for in vivo applications. The
procedure for creating a lentiviral expression system consists of cloning the double-stranded
DNA oligonucleotide encoding a miR RNAi into one of the BLOCK-iT™ entry expression
vectors. The RNAi cassette is transferred into the lentiviral destination vector by Gateway®
recombination and transfected into the viral producer cells to produce viral stocks, Viral
supernatants are harvested and titers are determined. Finally, the lentiviral stocks can be
transduced into any cell type of used in vivo (From Life Technologies).

Figure 9.2. Genetic murine models constructed to exhibit increased blood pressure.
Through manipulation by overexpression (yellow) or knockout (orange) of various
components of the RAS, hypertensive mouse models exist and are useful for understanding
biological functions in vivo From (Lerman et al., 2005).
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CHAPTER X
DISCUSSION

10.1 The Implications of Genome-wide MiRNA Profiling in Response to AngII
It has become increasingly apparent over time that the complexity of RAS is
immense. Securing AngII through its interaction with the AT1R as a powerful regulator
of gene expression has given much insight into the potent role for this vasoactive
hormone in cardiac biology and disease. Intracellular signaling mediated through AT1R
activation by AngII has a prominent place in vascular and endothelial physiology and
dysfunction.

The unbiased miRNA profiles presented here may bridge the gap in our
knowledge concerning the molecular basis of pathogenesis during chronic RAS
activation, which increases angiotensinergic risk associated with morbidity and mortality
from cardiovascular diseases. In many clinical settings, targeting RAS is an important
therapeutic paradigm. Our study provides insights regarding how RAS-targeted therapies
may affect miRNAs. This study was designed for global miRNA expression profiling in
biological replicates following chronic AngII activation. Thirty-two miRNAs were AngII

regulated in most human and rodent samples. Expression of these miRNAs were
antagonized following AT2R activation by AngII and Losartan blockade of AT1R in both
VSMCs and HEK-AT1R cells, suggesting that expression of these miRNAs is a hallmark
of AngII action through the AT1R, which is targeted in most clinical settings. The
inclusion of RNA derived from tissue, primary cells and established cell lines in our
analysis demonstrates that this miRNA fingerprint is not derived from complex
heterotypic cell-cell interactions nor influenced by a multitude of endocrine, paracrine or
autocrine and neuronal influences, a common confounding problem in many analyses.

The identified miRNA profile discussed in this study reflects common AngII-regulated
changes in humans and rodents, a miRNA fingerprint of RAS action through the AT1R.
Though we did not determine how alterations in these miRNAs functionally affect the in
vivo response to AngII, we propose that these miRNAs play a significant role in AngII
mediated physiology and pathogenesis. If the miRNAs we identified can be shown to
play a role in RAS function in vivo, they may represent new biomarkers of injury caused
by RAS and should serve as useful prognostic markers during RAS targeted therapy.

10.2 Specificity of MiRNA Expression
Demonstrating miRNA specificity is important in elucidating the regulation of
these small RNAs. Inclusion of losartan treated AT1R as well as AngII treated AT2R
expressing control samples demonstrated specificity of the AngII effect through the
AT1R in our profiling experiments. The miRNA changes in individual comparisons
showed a range between 60 and 234 miRNA genes per sample (Fig. 3.2 & 3.3).

This finding is consistent with the miRNA expression profiles characterized in complex
tissues, sorted cells and individual cell lines, which demonstrated that on average ≈70150 miRNA genes were expressed per sample (Landgraf et al., 2007, Chiang et al.,
2010). Our finding of ≈30 miRNAs (Table IV.I) ubiquitously expressed in cell lines and
tissue samples from rodents and human is also consistent with the observation in model
studies for basic mechanisms of stem cell maintenance, hormonal differentiation, and
malignant transformation to organ systems, in which the authors estimated ≈30-40
ubiquitously expressed miRNAs per sample (Chiang et al., 2010, Landgraf et al., 2007).

In addition, several miRNAs mapped to multicopy miRNA genes (Table III.VIII).
Expression of a specific miRNA or a select few from the cluster suggests stimulusspecificity of processing of individual miRNAs from polycistronic pri-miRNA
transcripts, as previously observed in human studies (Baskerville and Bartel, 2005). A
third of the remaining miRNAs were expressed with a high degree of cell specificity
(e.g., miRs-365, -699, -490, -434-3p, -675-3p are cardiomyocyte-specific).

Additionally, the expression of some miRNAs was only altered under one
treatment condition (e.g., miRs-546, -100, -92a are strictly Losartan modulated) or only
altered in one cell type (e.g., miRs- 376a*, -487b, -154*, -539, -376c* are expressed in
HEK-AT1R cells only). Tissue-specific factors might be essential for biogenesis of
tissue-specific miRNAs, and therefore might be sensitive to the potential absence of such
factors in some cells and tissues. Taken together, these findings are consistent with the

tissue and cell-type specific regulation of miRNAs in response to AngII and the potential
role of these miRNAs in physiology and in various diseases.

As an important RAS hormone, AngII must play a wider role in regulating the
relative abundance and specificity of expression of miRNAs in order to regulate a variety
of physiological and adaptive tissue remodeling processes. Thus, the miRNA regulation
is a critical aspect of effectiveness of hormones such as AngII in various cells.

10.3 A SMC-specific MiRNA Signature
Regulation of miRNAs in VSMCs by a local increase in AngII can adversely
affect vessel functions due to the high density of the AT1R on VSMCs. Distinct VSMC
phenotypes accumulate within arteries of individuals with disorders such as systemic and
pulmonary hypertension, atherosclerosis, and asthma. During insult, VSMCs switch to a
proliferative phenotype of poor contractility/excitability, exhibit changes in lipid
metabolism, and have high extracellular matrix production leading to vessel remodeling.
In contrast, the phenotype of healthy adult VSMCs is restricted cellular plasticity, in
which the cells are geared for contraction with a unique repertoire of contractile proteins,
agonist-specific receptors, ion channels, and signaling molecules. Thus VSMCs are an
interesting model system for studying miRNA-modulated mechanisms of cell
maintenance, differentiation, and phenotypic modulation (Rensen et al., 2007, Daugherty
and Cassis, 2004).
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Regulation of specific miRNAs as contributors to vascular disease (e.g., miR-155,
-143, -145, -21, -126) has been studied (Urbich et al., 2008), but a comprehensive
analysis targeting AngII-regulation of miRNAs in VSMCs and its associated diseases is
lacking. Our analysis of AngII-regulated miRNAs in rat and human VSMC cell lines
(Table IV.III) indicated for the first time a unique fingerprint consisting of novel
miRNAs and miRNAs with known functions. As shown in Table IV.III, a significant
number of the AngII-regulated miRNAs have been implicated in pathogenesis of other
organs and tissues, implying that a systematic study of their role in vasculature is
important. Confirmation of the VSMC candidates identified miRNAs that were both up
and downregulated by AngII signaling through the AT1R.

10.4 Regulation of the AngII-induced MiRNA Pool
Our data indicate that AT1R signaling through JAK2 and MEK1 regulate two
completely independent miRNA pools (Figures 5.2 & 5.3). The amount of a specific
miRNA that exists within a cell is determined by its biogenesis and decay. The
biogenesis of miRNAs is critically regulated at the level of transcription similar to those
of protein-coding genes. Regulation of miRNA expression through the MEK/ERK1/2
interaction with PEA-15 cascade is known. PEA-15 sequesters ERK1/2 in the cytoplasm,
thereby inhibiting the ability of ERK1/2 to localize to the nucleus and modulate miRNA
gene transcription (Romano et al., 2012). Many miRNA genes are transcribed by a
transcription factor binding to upstream promoters. However, transcriptional regulation
of miRNA pools by AngII appears unlikely to us for two reasons: (i) transcription of
miR-483 and IGF2 (the gene that harbors miR-483) were not altered by AngII activation
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of the RASMC-AT1R cells (data not shown); and (ii) ERK1/2 phosphorylation leads to
translocation into the nucleus, where gene transcription and pri-miRNA processing are
regulated.

In our study, both MEK1 and JAK2 inhibitors inhibited ERK1/2 activation, but
these inhibitors affected distinct miRNAs, suggesting that the AngII-activated JAK2 and
MEK signaling alters non-canonical and perhaps miRNA-specific regulatory steps. PrimiRNA sequence-specific recruitment of Smad proteins (Smad-1 and -5) to the p68–
DROSHA complex in pulmonary artery smooth muscle cells has been reported (Davis et
al., 2010, Davis-Dusenbery and Hata, 2011). The association between Smads and primiRNAs is primarily controlled by Smad nuclear localization upon TGF-β activation.
This non-canonical pathway relies on the interaction of the Smad amino-terminus MH1
domain with R-SBE. R-SBE contains a consensus RNA binding sequence (5’ – CAGAC
– 3’), which is present in the stem region of miR-21, miR-100, miR-199a-5p, and miR27a (Davis et al., 2010).

AngII regulation of distinct miRNAs may involve novel non-canonical pathways.
Our results suggest a novel Tyr-kinase pathway in miRNA regulation. Kim et al showed
that the proteins involved in miRNA biogenesis (e.g., Drosha, TRBP, Dicer, Ago 2)
could be phosphorylated by protein kinases. Accordingly AngII-activated kinases may
potentially target Drosha, TRBP, Dicer, or Ago 2 to regulate biogenesis or degradation of
miRNAs (Kim et al., 2010). However, this type of regulation would be expected to alter
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the miRNA pool in a cell not individual miRNAs, hence this may not be the mechanism
in our model system.

10.5 MiR-483-3p is a Novel AngII-regulated MiRNA
In our unbiased genome-wide screen of miRNAs modulated by AngII, we
identified a subset of 22 miRNAs differentially regulated in VSMCs by AngII activation
of the AT1R, including one whose predicted gene targets are involved in RAS
homeostasis.

Identifying miR-483-3p as a novel AngII-regulated miRNA has given us some
insight into the complexity of miRNA biology. Not only can many miRNA genes be
expressed in any given cell type, but they also can regulate a multitude of cellular
processes within a cell type (Bartel, 2004). Sequence alignment revealed that one of the
VSMC candidate miRNAs, miR-483-3p, is encoded within intron 2 of IGF2, a gene that
encodes a key mitogenic factor (Figure 6.3). Furthermore, the pri-miRNA is highly
conserved in mammals (Figure 6.4), prompting us to select miR-483-3p for further
characterization of its role in altering global gene networks, cellular metabolism, and
VSMC phenotype.

We found that in VSMCs, miR-483-3p is downregulated, whereas, IGF2
expression is upregulated, suggesting that miR-483-3p is independently regulated by
AngII signaling (Figure 6.2). Furthermore, VSMCs treated with the AT1R-specific
inverse agonist, Candesartan showed upregulation of miR-483-3p. Analysis of the
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kinetics of miR-483-3p induction revealed that upon acute treatment with AngII (0.5 h),
the miRNA levels increase, however with chronic AngII treatment (24 h), miR-483-3p
levels are significantly decreased (Figure 7.1), pointing toward a role for this miRNA in
tissue RAS, which is substantially involved in AngII-mediated vascular pathologies. We
next determined whether miR-483-3p was expressed in any other cell types that are
commonly and adversely affected by local action of AngII. Our observations
demonstrated that miR-483-3p is expressed in various cell types of muscle cell lineage, in
addition to a kidney and multiple carcinoma cells types (Figure 7.3), and to a lesser
extent in epithelial cells (Figure 7.4). Taken together these data reveal that miR-483-3p
could have a distinct role in mediating vascular abnormalities that arise as a result of
tissue RAS activation.

10.6 Regulation of the RAS by miR-483-3p
To gain insight into the function of miR-483-3p, we analyzed its potential gene
targets, using several miRNA target prediction algorithms (Brennecke et al., 2005). We
identified putative binding sites for miR-483-3p in the 3′UTR of several genes involved
in the RAS, including AGT, ACE-1, ACE-2 and the type II receptor, AGTR2, suggesting
that miR-483-3p coordinates RAS homeostasis (Figure 6.1). To test this hypothesis, we
determined the effect of miR-483-3p on the expression of AGT, ACE-1, ACE-2 and
AGTR2 in HEK-293T cells and RASMCs. To assess the effects of miR-483-3p on the 3’UTR of human AGT, ACE-1, ACE-2, and AGTR2, we used luciferase reporter
constructs. Transfection of HEK-293T-miR483 cells with 3’-UTR constructs for the
RAS target genes repressed luciferase activity of all 4 targets. These effects of miR-483-
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3p were reversible by co-transfection with an antisense inhibitor of miR-483-3p (antimiR-483) (Figure 7.7). MiR-483-3p also repressed AGT and to a lesser extent ACE-1
protein in RASMCs, indicating that its effects are robust on endogenous protein levels as
well. Inhibition of miR-483-3p by anti-miR-483 increased the expression of AGT and
ACE-1 in RASMCs (Figure 7.8), which is consistent with the hypothesis that miR-4833p has a physiological role in regulating the expression of these components of the RAS.

Determining the molecular mechanism by which AngII, through receptor
activation, can lead to a change in miR-483-3p expression was of importance in this
study. We showed that miR-483-3p is regulated in part by the AngII-specific kinase
MEK1. Levels of miR-483-3p were upregulated upon inhibition of MEK1, which was
the opposite response seen with AngII stimulation (Figure 5.3). Additionally, under
pharmacological inhibition of MEK1, the miR-483-3p target AGT was increased (Figure
7.9). Together, these results give us confidence that AGT is a direct target of miR-483-3p
and that the regulation of this miRNA is in fact through MEK1 activation.

The ability of miR-483-3p to target multiple components of the RAS is profound.
Most importantly, the effect of miR-483-3p on AGT is the most convincing and points to
a third portion of the RAS that could be a potential therapeutic target. Both ACE-1
inhibitors and ARBs are utilized to date to effectively treat hypertension and related
abnormalities caused by over activity of tissue RAS (Ritter, 2011); however, targeting
AGT has not been shown until now. Suppressing angiotensinogen would ultimately
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block production of AngII, similar to ACE-1 inhibitors, but may have fewer side effects.
Without in vivo studies, however, we will not know the true capacity of targeting AGT.

10.7 Modulation of VSMC Phenotype
The RAS is known to be highly active during vascular insult. Specifically, AngII
when over active plays a significant role in inducing a synthetic phenotype in adult
VSMCs (Bader et al., 2001). In this state, cells synthesize growth factors and other
proteins that enhance their proliferative and migratory potential. A critical aspect of this
study was to determine the extent to which miR-483-3p could alter VSMC phenotype and
thereby modify migration of VSMCs in the presence of AngII. Using a wound-healing
assay, we demonstrated that RASMCs overexpressing miR-483-3p had the capability of
suppressing AngII-mediated cell migration (Figure 8.2). In the presence of Candesartan
the effect of miR-483-3p is maintained and cell migration is also slowed.

A single miRNA has the potential to orchestrate post-transcriptional regulation of
approximately 100-200 genes in a cells, either by translational inhibition or degradation
of the target mRNA (Bartel, 2009). We postulate that miR-483-3p targets VSMCspecific cytoskeletal proteins involved in cellular movement, thereby causing suppression
of cell migration even in the presence of AngII.

Characterizing miR-483-3p, as a

causative agent in VSMC phenotypic switching is a significant aspect of AngII biology
that will aid in understanding tissue RAS further.

10.8 Final Remarks
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The results of the current work have shown that AT1R activation by AngII
produces signals that regulate specific miRNA expression. A distinct AngII-regulated
miRNA signature emerged in VSMCs, which was validated in independent samples.
Further insight into how miRNAs modulate phenotype of cells in different tissues will be
valuable for a greater understanding of AngII biology, as well as in determining the
intrinsic regulatory influence of RAS on cardiovascular disease.

Following our previous profiling study in human heart failure (Naga Prasad and
Karnik, 2010, Naga Prasad et al., 2009) it was increasingly apparent that understanding
the complex network involving miRNAs and their targets, which leads to a coordinated
pattern of gene expression, will undoubtedly provide important tools to develop novel
therapeutic strategies.

This will enhance knowledge of physiological regulation,

dysregulated vascular remodeling, and mechanism for atherosclerotic disease
progression. In addition, selective regulation of particular miRNAs targeting vascular
diseases is a promising prospect for future therapy. Much work remains to be
accomplished to advance our knowledge of the involvement of miRNAs in RAS
pathogenesis of cardiovascular disease and to develop therapeutic strategies to ultimately
affect morbidity and mortality.

Although the pathways regulating the RAS are well characterized, AngII-induced
miRNAs and the molecular mechanisms of their expression remain poorly defined.
Having focused our efforts on understanding the functional role and mechanism by which
miR-483-3p is regulated is only one example of an AngII-responsive miRNA having a
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substantial impact. As we move forward with this work, we will be able to distinguish
additional RAS regulated miRNA that could have an important function in cardiovascular
biology.

Our work identifies miR-483-3p as a potential regulator of tissue RAS

homeostasis, which has an important impact on VSMC biology. Because tissue RAS is
highly active in vascular disease, there has been intense interest in therapeutically
targeting the RAS (Paul et al., 2006). Our study suggests that modulating endogenous
levels of miR-483-3p may be a useful therapeutic strategy for regulating RAS and
controlling VSMC phenotypic switching.
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CHAPTER XI
FUTURE DIRECTIONS

11.1 Introduction
The results presented in this dissertation have shown a class of 32 miRNAs that
are universally responsive to AngII in humans and rodents, a fingerprint of miRNA
expression in VSMCs regulated by AngII, and evidence of unconventional regulation of
miRNA levels in VSMCs through AT1R signaling. This study as a whole has allowed us
to appreciate the capacity of AngII signaling through the AT1R in mediating the
transcriptome and the miRNome. Further in-depth analyses of the AngII-responsive
miRNAs will answer questions regarding the function of these miRNAs in modulating
phenotype in other cell systems.

We also present our initial efforts of characterizing the biological function of a
single AngII-regulated miRNA in VSMCs, as a means to understand its role in vascular
physiology and progression of AngII-mediated pathologies.

In addition to fully

characterizing miR-483-3p, in future studies we will examine whether additional
miRNAs identified as differentially regulated in the genome-wide analysis are able to
modulate VSMC phenotypes, such as vascular inflammation and remodeling in response
to AngII.

11.2 Complete Transcriptional Characterization
With the more recent advent of techniques for direct sequencing of the
transcriptional output of the genome, we can now begin to think about a complete
transcriptional characterization of all the cells of an organism, following AngII
stimulation. RNA sequencing (RNA-Seq) is direct high-throughput sequencing that
enables researchers to examine transcriptome fine structure. Transcript sequences are
mapped back to a reference genome and then counted to assess the level of gene
expression, the number of mapped reads being the measure of expression level for that
gene or genomic region (Malone and Oliver, 2011). Because RNA-Seq provides direct
access to the sequence, junctions between exons can be assayed without prior knowledge
of the gene structure, RNA editing events can be detected, and knowledge of
polymorphisms can provide direct measurements of allele-specific expression (Malone
and Oliver, 2011).

Since the completion of the Human Genome Project, our perception of our
genome has dramatically shifted. That is, the number of protein-coding genes in our
genome has been revised down, whereas the number of non-protein coding transcripts
has significantly increased. Long non-coding RNAs (lncRNAs) are one group of non-

protein coding transcripts that were generally considered transcriptional ‘noise’ until the
advent of RNA-Seq technologies. These RNAs are longer than 200 nucleotides, making
them distinguishable from small regulatory RNAs such as miRNAs. The function and
activity of these lncRNAs remain poorly understood; therefore, future studies must seek
to examine their role within our genome. What is known is that these RNAs are involved
in a variety of biological processes as regulatory molecules (Moran et al., 2012, Yan and
Wang, 2012). Much like miRNAs, lncRNA expression profiles are altered in human
disease states, including several types of cancer (Brunner et al., 2012). Deciphering the
role of AngII in mediating expression of lncRNAs would be beneficial in elucidating the
complete effect of AngII stimulation and AT1R activation on regulating the cellular
transcriptome.

The ability of the peptide hormone AngII to induce transcription by signaling
through the AT1R is an area of research that is constantly being expanded. Elucidating
the full capacity of AngII as a cellular agonist in inducing gene expression of additional
non-coding RNAs will likely provide further insight into the tissue-selective modulation
of AngII effects in disease states.

194

BIBLIOGRAPHY

APLIN, M., CHRISTENSEN, G. L. & HANSEN, J. L. 2008. Pharmacologic perspectives
of functional selectivity by the angiotensin II type 1 receptor. Trends Cardiovasc Med,
18, 305-12.
BADER, M. & GANTEN, D. 2008. Update on tissue renin-angiotensin systems. J Mol
Med (Berl), 86, 615-21.
BADER, M., PETERS, J., BALTATU, O., MULLER, D. N., LUFT, F. C. & GANTEN,
D. 2001. Tissue renin-angiotensin systems: new insights from experimental animal
models in hypertension research. J Mol Med (Berl), 79, 76-102.
BARTEL, D. P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell, 116, 281-97.
BARTEL, D. P. 2009. MicroRNAs: target recognition and regulatory functions. Cell,
136, 215-33.
BASKERVILLE, S. & BARTEL, D. P. 2005. Microarray profiling of microRNAs
reveals frequent coexpression with neighboring miRNAs and host genes. RNA, 11, 241-7.
BELL, L. & MADRI, J. A. 1990. Influence of the angiotensin system on endothelial and
smooth muscle cell migration. Am J Pathol, 137, 7-12.
BERGMAN, D., HALJE, M., NORDIN, M. & ENGSTROM, W. 2012. Insulin-Like
Growth Factor 2 in Development and Disease: A Mini-Review. Gerontology.
BERK, B. C. 2003. Angiotensin type 2 receptor (AT2R): a challenging twin. Sci STKE,
2003, PE16.

BERTERO, T., GASTALDI, C., BOURGET-PONZIO, I., IMBERT, V., LOUBAT, A.,
SELVA, E., BUSCA, R., MARI, B., HOFMAN, P., BARBRY, P., MENEGUZZI, G.,
PONZIO, G. & REZZONICO, R. 2011. miR-483-3p controls proliferation in wounded
epithelial cells. FASEB J, 25, 3092-105.
BERTERO, T., GASTALDI, C., BOURGET-PONZIO, I., MARI, B., MENEGUZZI, G.,
BARBRY, P., PONZIO, G. & REZZONICO, R. 2013. CDC25A targeting by miR-4833p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death
Differ.
BHATNAGAR, A., UNAL, H., JAGANNATHAN, R., KAVETI, S., DUAN, Z. H.,
YONG, S., VASANJI, A., KINTER, M., DESNOYER, R. & KARNIK, S. S. 2013.
Interaction of G-Protein betagamma Complex with Chromatin Modulates GPCRDependent Gene Regulation. PLoS One, 8, e52689.
BHATT, K., MI, Q. S. & DONG, Z. 2011. microRNAs in kidneys: biogenesis,
regulation, and pathophysiological roles. Am J Physiol Renal Physiol, 300, F602-10.
BILLET, S., BARDIN, S., VERP, S., BAUDRIE, V., MICHAUD, A., CONCHON, S.,
MUFFAT-JOLY, M., ESCOUBET, B., SOUIL, E., HAMARD, G., BERNSTEIN, K. E.,
GASC, J. M., ELGHOZI, J. L., CORVOL, P. & CLAUSER, E. 2007. Gain-of-function
mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular
fibrosis in mice. J Clin Invest, 117, 1914-25.
BLUME, A., KASCHINA, E. & UNGER, T. 2001. Angiotensin II type 2 receptors:
signalling and pathophysiological role. Curr Opin Nephrol Hypertens, 10, 239-46.

196

BOETTGER, T., BEETZ, N., KOSTIN, S., SCHNEIDER, J., KRUGER, M., HEIN, L. &
BRAUN, T. 2009. Acquisition of the contractile phenotype by murine arterial smooth
muscle cells depends on the Mir143/145 gene cluster. J Clin Invest, 119, 2634-47.
BOOZ, G. W. & BAKER, K. M. 1996. Role of type 1 and type 2 angiotensin receptors in
angiotensin II-induced cardiomyocyte hypertrophy. Hypertension, 28, 635-40.
BRENNECKE, J., STARK, A., RUSSELL, R. B. & COHEN, S. M. 2005. Principles of
microRNA-target recognition. PLoS Biol, 3, e85.
BRODERICK, J. A. & ZAMORE, P. D. 2011. MicroRNA therapeutics. Gene Ther, 18,
1104-10.
BRUNNER, A. L., BECK, A. H., EDRIS, B., SWEENEY, R. T., ZHU, S. X., LI, R.,
MONTGOMERY, K., VARMA, S., GILKS, T., GUO, X., FOLEY, J. W., WITTEN, D.
M., GIACOMINI, C. P., FLYNN, R. A., POLLACK, J. R., TIBSHIRANI, R., CHANG,
H. Y., VAN DE RIJN, M. & WEST, R. B. 2012. Transcriptional profiling of long noncoding RNAs and novel transcribed regions across a diverse panel of archived human
cancers. Genome Biol, 13, R75.
BUCHAN, J. R. & PARKER, R. 2007. Molecular biology. The two faces of miRNA.
Science, 318, 1877-8.
BURNIER, M. 2001. Angiotensin II type 1 receptor blockers. Circulation, 103, 904-12.
CHEN, J., LOZACH, J., GARCIA, E. W., BARNES, B., LUO, S., MIKOULITCH, I.,
ZHOU, L., SCHROTH, G. & FAN, J. B. 2008. Highly sensitive and specific microRNA
expression profiling using BeadArray technology. Nucleic Acids Res, 36, e87.
CHIANG, H. R., SCHOENFELD, L. W., RUBY, J. G., AUYEUNG, V. C., SPIES, N.,
BAEK, D., JOHNSTON, W. K., RUSS, C., LUO, S., BABIARZ, J. E., BLELLOCH, R.,

197

SCHROTH, G. P., NUSBAUM, C. & BARTEL, D. P. 2010. Mammalian microRNAs:
experimental evaluation of novel and previously annotated genes. Genes Dev, 24, 9921009.
DAUGHERTY, A. & CASSIS, L. 2004. Angiotensin II-mediated development of
vascular diseases. Trends Cardiovasc Med, 14, 117-20.
DAVIS, B. N., HILYARD, A. C., NGUYEN, P. H., LAGNA, G. & HATA, A. 2010.
Smad proteins bind a conserved RNA sequence to promote microRNA maturation by
Drosha. Mol Cell, 39, 373-84.
DAVIS-DUSENBERY, B. N. & HATA, A. 2011. Smad-mediated miRNA processing: a
critical role for a conserved RNA sequence. RNA Biol, 8, 71-6.
DE GASPARO, M., CATT, K. J., INAGAMI, T., WRIGHT, J. W. & UNGER, T. 2000.
International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol
Rev, 52, 415-72.
DINH, D. T., FRAUMAN, A. G., JOHNSTON, C. I. & FABIANI, M. E. 2001.
Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond), 100, 481-92.
DORN, G. W., 2ND 2011. MicroRNAs in cardiac disease. Transl Res, 157, 226-35.
DOULTON, T. W., HE, F. J. & MACGREGOR, G. A. 2005. Systematic review of
combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in
hypertension. Hypertension, 45, 880-6.
ELIA, L., QUINTAVALLE, M., ZHANG, J., CONTU, R., COSSU, L., LATRONICO,
M. V., PETERSON, K. L., INDOLFI, C., CATALUCCI, D., CHEN, J.,
COURTNEIDGE, S. A. & CONDORELLI, G. 2009. The knockout of miR-143 and -145

198

alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with
human disease. Cell Death Differ, 16, 1590-8.
ELTON, T. S. & MARTIN, M. M. 2007. Angiotensin II type 1 receptor gene regulation:
transcriptional and posttranscriptional mechanisms. Hypertension, 49, 953-61.
ELTON, T. S., SANSOM, S. E. & MARTIN, M. M. 2010. Cardiovascular Disease,
Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a
MicroRNA Connection? Int J Hypertens, 2010.
ELTON, T. S. K., D. E.; MALANA, G. E.; MARTIN, M. M.; NUOVO, G. J.;
PLEISTER, A. P.; FELDMAN, D. S. 2008. MiR-132 Regulates Angiotensin II Type 1
Receptor Expressiong Through a Protein Coding Region Binding Site. Circulation. 118:
S_513.
ESQUELA-KERSCHER, A. & SLACK, F. J. 2006. Oncomirs - microRNAs with a role
in cancer. Nat Rev Cancer, 6, 259-69.
FABIAN, M. R., SONENBERG, N. & FILIPOWICZ, W. 2010. Regulation of mRNA
translation and stability by microRNAs. Annu Rev Biochem, 79, 351-79.
FAZI, F. & NERVI, C. 2008. MicroRNA: basic mechanisms and transcriptional
regulatory networks for cell fate determination. Cardiovasc Res, 79, 553-61.
FERLAND-MCCOLLOUGH, D., FERNANDEZ-TWINN, D. S., CANNELL, I. G.,
DAVID, H., WARNER, M., VAAG, A. A., BORK-JENSEN, J., BRONS, C., GANT, T.
W., WILLIS, A. E., SIDDLE, K., BUSHELL, M. & OZANNE, S. E. 2012. Programming
of adipose tissue miR-483-3p and GDF-3 expression by maternal diet in type 2 diabetes.
Cell Death Differ, 19, 1003-12.

199

FERNANDES, T., HASHIMOTO, N. Y., MAGALHAES, F. C., FERNANDES, F. B.,
CASARINI, D. E., CARMONA, A. K., KRIEGER, J. E., PHILLIPS, M. I. &
OLIVEIRA, E. M. 2011. Aerobic exercise training-induced left ventricular hypertrophy
involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin
ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7).
Hypertension, 58, 182-9.
FICHTLSCHERER, S., DE ROSA, S., FOX, H., SCHWIETZ, T., FISCHER, A.,
LIEBETRAU, C., WEBER, M., HAMM, C. W., ROXE, T., MULLER-ARDOGAN, M.,
BONAUER, A., ZEIHER, A. M. & DIMMELER, S. 2010. Circulating microRNAs in
patients with coronary artery disease. Circ Res, 107, 677-84.
FIRE, A., XU, S., MONTGOMERY, M. K., KOSTAS, S. A., DRIVER, S. E. &
MELLO, C. C. 1998. Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature, 391, 806-11.
FORBES, J. M. C., M. E. 2011. The Renin Angiotensin System. In: AL., T. M. E. (ed.)
Studies on Renal Disorders, Oxidative Stress in Applied Basic Research and Clinical
Practice. Springer Science.
FRIDDLE, C. J., KOGA, T., RUBIN, E. M. & BRISTOW, J. 2000. Expression profiling
reveals distinct sets of genes altered during induction and regression of cardiac
hypertrophy. Proc Natl Acad Sci U S A, 97, 6745-50.
GABBIANI, G., SCHMID, E., WINTER, S., CHAPONNIER, C., DE CKHASTONAY,
C., VANDEKERCKHOVE, J., WEBER, K. & FRANKE, W. W. 1981. Vascular smooth
muscle cells differ from other smooth muscle cells: predominance of vimentin filaments
and a specific alpha-type actin. Proc Natl Acad Sci U S A, 78, 298-302.

200

GALLINAT, S., BUSCHE, S., RAIZADA, M. K. & SUMNERS, C. 2000. The
angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol
Endocrinol Metab, 278, E357-74.
GRIFFITHS-JONES, S., GROCOCK, R. J., VAN DONGEN, S., BATEMAN, A. &
ENRIGHT, A. J. 2006. miRBase: microRNA sequences, targets and gene nomenclature.
Nucleic Acids Res, 34, D140-4.
HAO, J., ZHANG, S., ZHOU, Y., HU, X. & SHAO, C. 2011. MicroRNA 483-3p
suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett, 585, 207-13.
HARRISON, D. G., CAI, H., LANDMESSER, U. & GRIENDLING, K. K. 2003.
Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular
disease. J Renin Angiotensin Aldosterone Syst, 4, 51-61.
HUNYADY, L. & CATT, K. J. 2006. Pleiotropic AT1 receptor signaling pathways
mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol, 20,
953-70.
HUTVAGNER, G. & ZAMORE, P. D. 2002. A microRNA in a multiple-turnover RNAi
enzyme complex. Science, 297, 2056-60.
IKEDA, S. & PU, W. T. 2010. Expression and function of microRNAs in heart disease.
Curr Drug Targets, 11, 913-25.
IRANI, K. 2000. Oxidant signaling in vascular cell growth, death, and survival : a review
of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic
and apoptotic signaling. Circ Res, 87, 179-83.
JEPPESEN, P. L., CHRISTENSEN, G. L., SCHNEIDER, M., NOSSENT, A. Y.,
JENSEN, H. B., ANDERSEN, D. C., ESKILDSEN, T., GAMMELTOFT, S., HANSEN,

201

J. L. & SHEIKH, S. P. 2011. Angiotensin II type 1 receptor signalling regulates
microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol, 164, 394404.
KADLECOVA, M., DOBESOVA, Z., ZICHA, J. & KUNES, J. 2008. Abnormal Igf2
gene in Prague hereditary hypertriglyceridemic rats: its relation to blood pressure and
plasma lipids. Mol Cell Biochem, 314, 37-43.
KARNIK, S. S., GOGONEA, C., PATIL, S., SAAD, Y. & TAKEZAKO, T. 2003.
Activation of G-protein-coupled receptors: a common molecular mechanism. Trends
Endocrinol Metab, 14, 431-7.
KERTESZ, M., IOVINO, N., UNNERSTALL, U., GAUL, U. & SEGAL, E. 2007. The
role of site accessibility in microRNA target recognition. Nat Genet, 39, 1278-84.
KIM, S. & IWAO, H. 2000. Molecular and cellular mechanisms of angiotensin IImediated cardiovascular and renal diseases. Pharmacol Rev, 52, 11-34.
KIM, Y. K., HEO, I. & KIM, V. N. 2010. Modifications of small RNAs and their
associated proteins. Cell, 143, 703-9.
KOBILKA, B. K. 2007. G protein coupled receptor structure and activation. Biochim
Biophys Acta, 1768, 794-807.
LAGOS-QUINTANA, M., RAUHUT, R., LENDECKEL, W. & TUSCHL, T. 2001.
Identification of novel genes coding for small expressed RNAs. Science, 294, 853-8.
LAGOS-QUINTANA, M., RAUHUT, R., YALCIN, A., MEYER, J., LENDECKEL, W.
& TUSCHL, T. 2002. Identification of tissue-specific microRNAs from mouse. Curr
Biol, 12, 735-9.

202

LANDGRAF, P., RUSU, M., SHERIDAN, R., SEWER, A., IOVINO, N., ARAVIN, A.,
PFEFFER, S., RICE, A., KAMPHORST, A. O., LANDTHALER, M., LIN, C., SOCCI,
N. D., HERMIDA, L., FULCI, V., CHIARETTI, S., FOA, R., SCHLIWKA, J., FUCHS,
U., NOVOSEL, A., MULLER, R. U., SCHERMER, B., BISSELS, U., INMAN, J.,
PHAN, Q., CHIEN, M., WEIR, D. B., CHOKSI, R., DE VITA, G., FREZZETTI, D.,
TROMPETER, H. I., HORNUNG, V., TENG, G., HARTMANN, G., PALKOVITS, M.,
DI LAURO, R., WERNET, P., MACINO, G., ROGLER, C. E., NAGLE, J. W., JU, J.,
PAPAVASILIOU, F. N., BENZING, T., LICHTER, P., TAM, W., BROWNSTEIN, M.
J., BOSIO, A., BORKHARDT, A., RUSSO, J. J., SANDER, C., ZAVOLAN, M. &
TUSCHL, T. 2007. A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell, 129, 1401-14.
LAU, N. C., LIM, L. P., WEINSTEIN, E. G. & BARTEL, D. P. 2001. An abundant class
of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294,
858-62.
LAVOIE, J. L. & SIGMUND, C. D. 2003. Minireview: overview of the reninangiotensin system--an endocrine and paracrine system. Endocrinology, 144, 2179-83.
LEE, R. C. & AMBROS, V. 2001. An extensive class of small RNAs in Caenorhabditis
elegans. Science, 294, 862-4.
LEE, R. C., FEINBAUM, R. L. & AMBROS, V. 1993. The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 84354.
LEE, S. D., CHU, C. H., HUANG, E. J., LU, M. C., LIU, J. Y., LIU, C. J., HSU, H. H.,
LIN, J. A., KUO, W. W. & HUANG, C. Y. 2006. Roles of insulin-like growth factor II in

203

cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am
J Physiol Endocrinol Metab, 291, E306-14.
LEMARIE, C. A. & SCHIFFRIN, E. L. 2010. The angiotensin II type 2 receptor in
cardiovascular disease. J Renin Angiotensin Aldosterone Syst, 11, 19-31.
LERMAN, L. O., CHADE, A. R., SICA, V. & NAPOLI, C. 2005. Animal models of
hypertension: an overview. J Lab Clin Med, 146, 160-73.
LEWIS, B. P., BURGE, C. B. & BARTEL, D. P. 2005. Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human genes are microRNA targets.
Cell, 120, 15-20.
LI, J. Y., YONG, T. Y., MICHAEL, M. Z. & GLEADLE, J. M. 2010. Review: The role
of microRNAs in kidney disease. Nephrology (Carlton), 15, 599-608.
LIJNEN, P. & PETROV, V. 1999. Renin-angiotensin system, hypertrophy and gene
expression in cardiac myocytes. J Mol Cell Cardiol, 31, 949-70.
LIU, X., SEMPERE, L. F., GUO, Y., KORC, M., KAUPPINEN, S., FREEMANTLE, S.
J. & DMITROVSKY, E. 2011. Involvement of microRNAs in lung cancer biology and
therapy. Transl Res, 157, 200-8.
MA, N., LI, F., LI, D., HUI, Y., WANG, X., QIAO, Y., ZHANG, Y., XIANG, Y.,
ZHOU, J., ZHOU, L., ZHENG, X. & GAO, X. 2012. Igf2-derived intronic miR-483
promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem, 361, 33743.
MAJORS, A. K., SENGUPTA, S., WILLARD, B., KINTER, M. T., PYERITZ, R. E. &
JACOBSEN, D. W. 2002. Homocysteine binds to human plasma fibronectin and inhibits
its interaction with fibrin. Arterioscler Thromb Vasc Biol, 22, 1354-9.

204

MALONE, J. H. & OLIVER, B. 2011. Microarrays, deep sequencing and the true
measure of the transcriptome. BMC Biol, 9, 34.
MARAGKAKIS, M., ALEXIOU, P., PAPADOPOULOS, G. L., RECZKO, M.,
DALAMAGAS, T., GIANNOPOULOS, G., GOUMAS, G., KOUKIS, E., KOURTIS,
K., SIMOSSIS, V. A., SETHUPATHY, P., VERGOULIS, T., KOZIRIS, N., SELLIS, T.,
TSANAKAS, P. & HATZIGEORGIOU, A. G. 2009. Accurate microRNA target
prediction correlates with protein repression levels. BMC Bioinformatics, 10, 295.
MARGULIES, K. B., BEDNARIK, D. P. & DRIES, D. L. 2009. Genomics,
transcriptional profiling, and heart failure. J Am Coll Cardiol, 53, 1752-9.
MARTIN, M. M., BUCKENBERGER, J. A., JIANG, J., MALANA, G. E., KNOELL, D.
L., FELDMAN, D. S. & ELTON, T. S. 2007a. TGF-beta1 stimulates human AT1
receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK,
and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol, 293, L790-9.
MARTIN, M. M., BUCKENBERGER, J. A., JIANG, J., MALANA, G. E., NUOVO, G.
J., CHOTANI, M., FELDMAN, D. S., SCHMITTGEN, T. D. & ELTON, T. S. 2007b.
The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna155 binding. J Biol Chem, 282, 24262-9.
MATSUBARA, H. 1998. Pathophysiological role of angiotensin II type 2 receptor in
cardiovascular and renal diseases. Circ Res, 83, 1182-91.
MEHTA, P. K. & GRIENDLING, K. K. 2007. Angiotensin II cell signaling:
physiological and pathological effects in the cardiovascular system. Am J Physiol Cell
Physiol, 292, C82-97.

205

MISHRA, P. K., TYAGI, N., KUNDU, S. & TYAGI, S. C. 2009. MicroRNAs are
involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys, 55, 15362.
MISRA, S., FU, A. A., MISRA, K. D., SHERGILL, U. M., LEOF, E. B. &
MUKHOPADHYAY, D. 2010. Hypoxia-induced phenotypic switch of fibroblasts to
myofibroblasts

through

a

matrix

metalloproteinase

2/tissue

inhibitor

of

metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in
hemodialysis access. J Vasc Interv Radiol, 21, 896-902.
MIURA, S. & KARNIK, S. S. 1999. Angiotensin II type 1 and type 2 receptors bind
angiotensin II through different types of epitope recognition. J Hypertens, 17, 397-404.
MIURA, S. & KARNIK, S. S. 2000. Ligand-independent signals from angiotensin II type
2 receptor induce apoptosis. EMBO J, 19, 4026-35.
MIURA, S., KARNIK, S. S. & SAKU, K. 2011. Review: angiotensin II type 1 receptor
blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst, 12,
1-7.
MIURA, S., MATSUO, Y., KIYA, Y., KARNIK, S. S. & SAKU, K. 2010. Molecular
mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem
Biophys Res Commun, 391, 85-90.
MIURA, S., ZHANG, J., MATSUO, Y., SAKU, K. & KARNIK, S. S. 2004. Activation
of extracellular signal-activated kinase by angiotensin II-induced Gq-independent
epidermal growth factor receptor transactivation. Hypertens Res, 27, 765-70.

206

MORAN, V. A., PERERA, R. J. & KHALIL, A. M. 2012. Emerging functional and
mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res, 40,
6391-400.
NAGA PRASAD, S. V., DUAN, Z. H., GUPTA, M. K., SURAMPUDI, V. S.,
VOLINIA, S., CALIN, G. A., LIU, C. G., KOTWAL, A., MORAVEC, C. S.,
STARLING, R. C., PEREZ, D. M., SEN, S., WU, Q., PLOW, E. F., CROCE, C. M. &
KARNIK, S. 2009. Unique microRNA profile in end-stage heart failure indicates
alterations in specific cardiovascular signaling networks. J Biol Chem, 284, 27487-99.
NAGA PRASAD, S. V. & KARNIK, S. S. 2010. MicroRNAs--regulators of signaling
networks in dilated cardiomyopathy. J Cardiovasc Transl Res, 3, 225-34.
NAKASHIMA, H., SUZUKI, H., OHTSU, H., CHAO, J. Y., UTSUNOMIYA, H.,
FRANK, G. D. & EGUCHI, S. 2006. Angiotensin II regulates vascular and endothelial
dysfunction: recent topics of Angiotensin II type-1 receptor signaling in the vasculature.
Curr Vasc Pharmacol, 4, 67-78.
NANA-SINKAM, S. P. & CROCE, C. M. 2011. MicroRNAs as therapeutic targets in
cancer. Transl Res, 157, 216-25.
OHTSU, H., SUZUKI, H., NAKASHIMA, H., DHOBALE, S., FRANK, G. D.,
MOTLEY, E. D. & EGUCHI, S. 2006. Angiotensin II signal transduction through small
GTP-binding proteins: mechanism and significance in vascular smooth muscle cells.
Hypertension, 48, 534-40.
OLIVERIO, M. I., KIM, H. S., ITO, M., LE, T., AUDOLY, L., BEST, C. F., HILLER,
S., KLUCKMAN, K., MAEDA, N., SMITHIES, O. & COFFMAN, T. M. 1998. Reduced
growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated

207

blood pressure regulation in mice lacking both AT1A and AT1B receptors for
angiotensin II. Proc Natl Acad Sci U S A, 95, 15496-501.
PANDIT, K. V., MILOSEVIC, J. & KAMINSKI, N. 2011. MicroRNAs in idiopathic
pulmonary fibrosis. Transl Res, 157, 191-9.
PARADIS, P. 2000. Overexpression of angiotensin II type I receptor in cardiomyocytes
induces cardiac hypertrophy and remodeling. Proceedings of the National Academy of
Sciences, 97, 931-936.
PASQUINELLI, A. E., REINHART, B. J., SLACK, F., MARTINDALE, M. Q.,
KURODA, M. I., MALLER, B., HAYWARD, D. C., BALL, E. E., DEGNAN, B.,
MULLER, P., SPRING, J., SRINIVASAN, A., FISHMAN, M., FINNERTY, J.,
CORBO, J., LEVINE, M., LEAHY, P., DAVIDSON, E. & RUVKUN, G. 2000.
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory
RNA. Nature, 408, 86-9.
PAUL, M., POYAN MEHR, A. & KREUTZ, R. 2006. Physiology of local reninangiotensin systems. Physiol Rev, 86, 747-803.
PIERCE, K. L., PREMONT, R. T. & LEFKOWITZ, R. J. 2002. Seven-transmembrane
receptors. Nat Rev Mol Cell Biol, 3, 639-50.
PONTREMOLI, R., RAVERA, M., VIAZZI, F., NICOLELLA, C., BERRUTI, V.,
LEONCINI, G., GIACOPELLI, F., BEZANTE, G. P., SACCHI, G., RAVAZZOLO, R.
& DEFERRARI, G. 2000. Genetic polymorphism of the renin-angiotensin system and
organ damage in essential hypertension. Kidney Int, 57, 561-9.
RAMCHANDRAN, R., TAKEZAKO, T., SAAD, Y., STULL, L., FINK, B., YAMADA,
H., DIKALOV, S., HARRISON, D. G., MORAVEC, C. & KARNIK, S. S. 2006.

208

Angiotensinergic stimulation of vascular endothelium in mice causes hypotension,
bradycardia, and attenuated angiotensin response. Proc Natl Acad Sci U S A, 103, 1908792.
RAYNER, K. J., SUAREZ, Y., DAVALOS, A., PARATHATH, S., FITZGERALD, M.
L., TAMEHIRO, N., FISHER, E. A., MOORE, K. J. & FERNANDEZ-HERNANDO, C.
2010. MiR-33 contributes to the regulation of cholesterol homeostasis. Science, 328,
1570-3.
REINHART, B. J., SLACK, F. J., BASSON, M., PASQUINELLI, A. E., BETTINGER,
J. C., ROUGVIE, A. E., HORVITZ, H. R. & RUVKUN, G. 2000. The 21-nucleotide let7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 403, 901-6.
RENSEN, S. S., DOEVENDANS, P. A. & VAN EYS, G. J. 2007. Regulation and
characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J, 15,
100-8.
RITTER, J. M. 2011. Dual blockade of the renin-angiotensin system with angiotensin
converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Br J Clin
Pharmacol, 71, 313-5.
ROMANO, G., ACUNZO, M., GAROFALO, M., DI LEVA, G., CASCIONE, L.,
ZANCA, C., BOLON, B., CONDORELLI, G. & CROCE, C. M. 2012. MiR-494 is
regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung
cancer through BIM down-regulation. Proc Natl Acad Sci U S A, 109, 16570-5.
ROSENBAUM, D. M., RASMUSSEN, S. G. & KOBILKA, B. K. 2009. The structure
and function of G-protein-coupled receptors. Nature, 459, 356-63.

209

ROSSI, G. P., SACCHETTO, A., CESARI, M. & PESSINA, A. C. 1999. Interactions
between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res, 43,
300-7.
RUIZ-ORTEGA, M., LORENZO, O., RUPEREZ, M., ESTEBAN, V., SUZUKI, Y.,
MEZZANO, S., PLAZA, J. J. & EGIDO, J. 2001. Role of the renin-angiotensin system in
vascular diseases: expanding the field. Hypertension, 38, 1382-7.
SAITO, Y. & BERK, B. C. 2002. Angiotensin II-mediated signal transduction pathways.
Curr Hypertens Rep, 4, 167-71.
SANSOM, S. E., NUOVO, G. J., MARTIN, M. M., KOTHA, S. R., PARINANDI, N. L.
& ELTON, T. S. 2010. miR-802 regulates human angiotensin II type 1 receptor
expression in intestinal epithelial C2BBe1 cells. Am J Physiol Gastrointest Liver Physiol,
299, G632-42.
SANTOS, R. A., SIMOES E SILVA, A. C., MARIC, C., SILVA, D. M., MACHADO, R.
P., DE BUHR, I., HERINGER-WALTHER, S., PINHEIRO, S. V., LOPES, M. T.,
BADER, M., MENDES, E. P., LEMOS, V. S., CAMPAGNOLE-SANTOS, M. J.,
SCHULTHEISS, H. P., SPETH, R. & WALTHER, T. 2003. Angiotensin-(1-7) is an
endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A,
100, 8258-63.
SCALBERT, E. & BRIL, A. 2008. Implication of microRNAs in the cardiovascular
system. Curr Opin Pharmacol, 8, 181-8.
SHUKLA, G. C., SINGH, J. & BARIK, S. 2011. MicroRNAs: Processing, Maturation,
Target Recognition and Regulatory Functions. Mol Cell Pharmacol, 3, 83-92.

210

SILVERSTEIN, R. L. & RAM, C. V. 2005. Angiotensin-receptor blockers: benefits
beyond lowering blood pressure. Cleve Clin J Med, 72, 825-32.
SMALL, E. M. & OLSON, E. N. 2011. Pervasive roles of microRNAs in cardiovascular
biology. Nature, 469, 336-42.
STAESSEN, J. A., LI, Y. & RICHART, T. 2006. Oral renin inhibitors. Lancet, 368,
1449-56.
TAUBMAN, M. B. 2003. Angiotensin II: a vasoactive hormone with ever-increasing
biological roles. Circ Res, 92, 9-11.
TEERLINK, J. R. 1996. Neurohumoral mechanisms in heart failure: a central role for the
renin-angiotensin system. J Cardiovasc Pharmacol, 27 Suppl 2, S1-8.
TOUYZ, R. M. & SCHIFFRIN, E. L. 2000. Signal transduction mechanisms mediating
the physiological and pathophysiological actions of angiotensin II in vascular smooth
muscle cells. Pharmacol Rev, 52, 639-72.
URBICH, C., KUEHBACHER, A. & DIMMELER, S. 2008. Role of microRNAs in
vascular diseases, inflammation, and angiogenesis. Cardiovasc Res, 79, 581-8.
VAN ROOIJ, E., MARSHALL, W. S. & OLSON, E. N. 2008. Toward microRNA-based
therapeutics for heart disease: the sense in antisense. Circ Res, 103, 919-28.
VAN ROOIJ, E., PURCELL, A. L. & LEVIN, A. A. 2012. Developing microRNA
therapeutics. Circ Res, 110, 496-507.
VASUDEVAN, S., TONG, Y. & STEITZ, J. A. 2007. Switching from repression to
activation: microRNAs can up-regulate translation. Science, 318, 1931-4.
VERDONK, K., DANSER, A. H. & VAN ESCH, J. H. 2012. Angiotensin II type 2
receptor agonists: where should they be applied? Expert Opin Investig Drugs, 21, 501-13.

211

VERONESE, A., LUPINI, L., CONSIGLIO, J., VISONE, R., FERRACIN, M.,
FORNARI, F., ZANESI, N., ALDER, H., D'ELIA, G., GRAMANTIERI, L., BOLONDI,
L., LANZA, G., QUERZOLI, P., ANGIONI, A., CROCE, C. M. & NEGRINI, M. 2010.
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res, 70, 3140-9.
VERONESE, A., VISONE, R., CONSIGLIO, J., ACUNZO, M., LUPINI, L., KIM, T.,
FERRACIN, M., LOVAT, F., MIOTTO, E., BALATTI, V., D'ABUNDO, L.,
GRAMANTIERI, L., BOLONDI, L., PEKARSKY, Y., PERROTTI, D., NEGRINI, M. &
CROCE, C. M. 2011. Mutated beta-catenin evades a microRNA-dependent regulatory
loop. Proc Natl Acad Sci U S A, 108, 4840-5.
WANG, W. C., JUAN, A. H., PANEBRA, A. & LIGGETT, S. B. 2011. MicroRNA let-7
establishes expression of beta2-adrenergic receptors and dynamically down-regulates
agonist-promoted down-regulation. Proc Natl Acad Sci U S A, 108, 6246-51.
WHITE, S. M., CONSTANTIN, P. E. & CLAYCOMB, W. C. 2004. Cardiac physiology
at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle
cell structure and function. Am J Physiol Heart Circ Physiol, 286, H823-9.
WINTER, J., JUNG, S., KELLER, S., GREGORY, R. I. & DIEDERICHS, S. 2009.
Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell
Biol, 11, 228-34.
YAN, B. & WANG, Z. 2012. Long noncoding RNA: its physiological and pathological
roles. DNA Cell Biol, 31 Suppl 1, S34-41.
YIN, G., YAN, C. & BERK, B. C. 2003. Angiotensin II signaling pathways mediated by
tyrosine kinases. Int J Biochem Cell Biol, 35, 780-3.

212

YU, J., WANG, F., YANG, G. H., WANG, F. L., MA, Y. N., DU, Z. W. & ZHANG, J.
W. 2006. Human microRNA clusters: genomic organization and expression profile in
leukemia cell lines. Biochem Biophys Res Commun, 349, 59-68.
YUE, H., LI, W., DESNOYER, R. & KARNIK, S. S. 2010. Role of nuclear
unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy.
Cardiovasc Res, 85, 90-9.
ZAINA, S., PETTERSSON, L., THOMSEN, A. B., CHAI, C. M., QI, Z., THYBERG, J.
& NILSSON, J. 2003. Shortened life span, bradycardia, and hypotension in mice with
targeted expression of an Igf2 transgene in smooth muscle cells. Endocrinology, 144,
2695-703.
ZHANG, F., HU, Y., XU, Q. & YE, S. 2010. Different effects of angiotensin II and
angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One,
5, e12323.
ZHANG, X., AZHAR, G. & WEI, J. Y. 2012. The expression of microRNA and
microRNA clusters in the aging heart. PLoS One, 7, e34688.

213

